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Summary 
 
Isoprenoids comprise an extremely large and diverse group of natural compounds with more than 
40,000 described examples. Isoprenoids are involved in numerous biological and ecological roles 
in the native organisms. From an industrial point of view, isoprenoids are becoming industrially 
important compounds because of their potent applications as anticancer, antitumor, antiviral, 
antibiotic, nutraceuticals, feed supplements as well as their characteristic flavors and aromas. 
Although the current large-scale processes for the production of isoprenoids rely mainly on 
extraction from plant sources or chemical synthesis these methods in many cases cannot support 
a viable industrial production. Heterologous microbial production of isoprenoids is therefore 
considered as a suitable alternative to extraction from plants or chemical synthesis.   
The aim of this PhD study was to establish the yeast Saccharomyces cerevisiae as a platform for 
production of sesquiterpenes (a group of isoprenoids). S. cerevisiae exhibits several advantages 
as an isoprenoid producer platform including availability of its genome sequence, well 
established techniques required for cultivation and genetic manipulation, and its public 
acceptance as a GRAS (Generally Regarded As Safe) organism. Expression of three different 
plant sesquiterpene genes namely valencene synthase, cubebol synthase and patchoulol synthase 
resulted in the accumulation of the corresponding sesquiterpenes in the medium culture. 
However, a substantial amount of excreted sesquiterpenes were lost through the off-gas. 
Therefore a two-phase fermentation using dodecane as the secondary phase was developed for 
characterization of the engineered sesquiterpene producing yeast strains in batch fermentations.  
In the next step, the mevalonate pathway of yeast strains was deregulated to augment the 
intracellular pool of the farnesyl diphosphate (FPP) which is the precursor for sesquiterpene 
biosynthesis. Deregulation of the yeast mevalonate pathway was performed through altered 
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expression of two main regulatory genes in the pathway namely ERG9 and HMG1.  Attenuated 
expression of ERG9 by replacing the native ERG9 promoter with a regulatable MET3 promoter 
in the presence of methionine led to reduced ergosterol content of cells, accumulation of 
sesquiterpenes and also formation of farnesol as an FPP derived by-product. Overproduction of 
the catalytic domain of HMG-CoA reductase encoded by tHMG1 also resulted in accumulation 
of squalene and higher titer of cubebol.  
In a further attempt, in silico metabolic engineering approach was used to identify new target 
genes whose deletions could improve sesquiterpene biosynthesis in yeast. Deletion of NADPH-
dependent glutamate dehydrogenase encoded by GDH1 identified by this method led to 
significantly higher cubebol production.  
Finally, heterologous production of lycopene in S. cerevisiae by expression of codon optimized 
crtE, crtB, and crtI genes from the bacterium Erwinia herbicola was investigated. Expression of 
the three carotenogenic genes led to accumulation of lycopene in the yeast strains. The effects of 
ERG9 down-regulation and tHMG1 overexpression on lycopene accumulation were also 
examined.  
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Dansk Sammenfatning 
 
Isoprenoider er navnet på en kemisk stofgruppe og består af en diverse samling af naturligt 
forekomne forbindelser. De udfylder en lang række af biologiske og økologiske funktioner, og 
mere end 40,000 eksempler er beskrevet i litteraturen. Industrielt er isoprenioder i stigende grad 
blevet en interessent stofgruppe grundet deres virksomme egenskaber i forbindelse med 
behandling af kræft og virusinfektioner, men også i forbindelse med helseprodukter, og som 
smags og duft tilsætningsmiddel har isoprenoider fundet anvendelse. Den traditionelle 
fremstilling af isoprenoider har hidtil primært været baseret på ekstraktion fra planter eller 
gennem kemisk synthese, men disse metoder er resource krævene og problematiske set fra en 
økonomisk synsvinkel. Produktion af isoprenoider med hjælp fra rekombinante mikroorganismer 
synes derfor som et godt alternativ til de traditionelle metoder. Målet med dette Ph.D. studie har 
været at etablere en produktionsplatform i bagegær, Saccharomyces cerevisiae, for en 
undergruppe af Isoprenioder kaldet sesquiterpener. Valget af S. cerevisiae, som 
produktionsplatform, er udover kendskab til den fulde genomsekvens, baseret på en lang række 
af de fordele som knytter sig til denne organisme, eksempelvis et godt kendskab til 
dyrkningsmetoder og teknikker til genetisk modifikation samt den generelle accept af bagegær 
som en uskadelig organisme (GRAS). Ekspression af tre forskellige sesquiterpen gener fra 
planter, valencene synthase, cubebol synthase samt pathchoulol synthase, resulterede i 
akkumulering af de forventede sesquiterpener i vækstmediet, men det blev samtidig konstateret 
at en stor del af disse forbindelser grundet deres flygtige egenskaber blev tabt via afgangsgassen 
under dyrkningsprocessen. Dette dannede grundlag for udviklingen af en to-fase gæringsproces 
hvori dodecane bliver anvendt som anden fase, og denne teknik blev efterfølgende anvendt til 
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karakterisering af de udviklede sesquiterpene producerende gærstammer under de i projektet 
udførte gæringsforsøg. I det næste udviklingstrin blev regulering af mevalonate stofskiftet 
afkoblet i et forsøg på at ændre den intercellulære koncentration af farnesyl diphosphat (FPP), 
der udgør udgangspunktet for sesquiterpene biosynthesen. Denne afkobling blev gennemført ved 
ændring af udtrykket af to af de mest betydningsfulde regulatoriske gener i mevalonate 
stofskiftet, kaldet ERG9 og HMG1. For at opnå reduceret udtryk af genet ERG9 blev den 
oprindelige promoter udskiftet med den svagere og inducerbare MET3 promoter, og i nærvær af 
aminosyren methionin blev et reduceret indhold af stoffet ergosterol målt i cellerne. Desuden 
blev der målt akkumulering af sesquiterpener og farnesol som er et biproduct af FPP. Overudtryk 
af det katalytiske domæne af HMG-CoA reduktase, der kodes af genet tHMG1, resulterede også i 
akkumulering af squalener og højere koncentrationer af cubebol.  
Videre undersøgelser baseret på anvendelse af in silico metoder (metabolic engineering) 
identicerede to nye gener, hvis fjernelse kunne forbedre biosyntesen af sesquiterpener i gær. 
Fjernelsen af genet GDH1, der koder for det NAPDH-afhængige enzym glutamat 
dehydrogenase, der blev identificeret via den tidligere beskrevne fremgangsmåde, resulterede i et 
betydeligt højere udbytte af cubebol.   
Afslutningsvis blev rekombinant produktion af lycopene i S. cerevisiae undersøgt gennem udtryk 
af de kodon-optimerede gener crtE, crtB og crtI fra bakterien Erwinia herbicola, og udtryk af de 
tre karoten-gener medførte akkumulering af lycopener. Effekten af nedregulering af ERG9 og 
overudtryk af tHMG1 i forbindelse med produktionen af lycopene blev ligeledes undersøgt. 
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Outline of the thesis 
 
The current thesis is divided into the following sections: 
 
Chapter 1 introduces isoprenoids, the metabolic pathways for the biosynthesis of isoprenoid 
precursors in different organisms, genes involved in each pathway, regulation of pathways, and a 
summary of metabolic engineering studies for the heterologous production of various 
isoprenoids in microbial hosts. This chapter is mainly based on the publication: Maury J, 
Asadollahi MA, Møller K, Clark A, Nielsen J. 2005. Microbial isoprenoid production: An 
example of green chemistry through metabolic engineering. Adv Biochem Eng Biotechnol 
100:19-51. 
 
Chapter 2 is dedicated to the development of a two-phase fermentation strategy for in situ 
separation of sesquiterpenes. The developed two-phase fermentation was further used for 
characterization of all sesquiterpene producing strains in batch fermentations throughout the 
project.  
 
Chapter 3 deals with the effect of ERG9 down-regulation on the ergosterol content of yeast 
cells, improvement of the intracellular pool of FPP and enhanced production of sesquiterpenes. 
A number of yeast strains producing valencene, cubebol or patchoulol were characterized in 
batch fermenters and effect of ERG9 down-regulation, promoter and also carbon source on 
sesquiterpene production was studied. The results from this chapter were based on the 
publication: Asadollahi MA, Maury J, Møller K, Nielsen KF, Schalk M, Clark A, Nielsen J. 
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2008. Production of plant sesquiterpenes in Saccharomyces cerevisiae: Effect of ERG9 
repression on sesquiterpene biosynthesis. Biotechnol Bioeng 99:666-677. 
 
Chapter 4 demonstrates how the flux towards FPP can be increased by overproduction of the 
catalytic domain of HMG-CoA reductase (encoded by tHMG1) which catalyzes the main flux 
controlling step in the mevalonate pathway. Influence of overexpression of tHMG1 and its 
combination with ERG9 down-regulation on cubebol biosynthesis and squalene and ergosterol 
content of yeast cells is discussed.  
 
Chapter 5 illustrates how in silico metabolic engineering using the genome-scale reconstructed 
metabolic network of S. cerevisiae can be used for the identification of new target genes to 
improve sesquiterpene production in the yeast strains. Manipulation of the ammonium 
assimilation pathway by deletion of NADPH-dependent glutamate dehydrogenase encoded by 
GDH1 that was identified by in silico metabolic engineering approach enhanced significantly 
cubebol production. Overexpression of NADH-dependent glutamate dehydrogenase encoded by 
GDH2 restored the assimilation of ammonium and the specific growth rate of the yeast strains.  
 
Chapter 6 explains construction of lycopene accumulating yeast strains by expression of crtE, 
crtB, and crtI genes from the bacterium E. herbicola. Expression of these genes in yeast led to 
accumulation of lycopene and appearance of a reddish color in the yeast strains. Effects of 
tHMG1 overexpression and ERG9 down-regulation on lycopene accumulation were studied. All 
strains were characterized in 5 L batch fermenters.  
 
Chapter 7 concludes the thesis by summarizing the obtained results. This chapter also proposes 
strategies for further improvement of isoprenoid producing yeast strains.  
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Chapter 1 
Introduction   
 
1.1 Isoprenoids 
Isoprenoids (also referred to as terpenoids) are a diverse group of natural compounds with more 
than 40,000 identified compounds (Withers and Keasling, 2007); most of them are found in 
plants as constituents of essential oils (McCaskill and Croteau, 1997). Isoprenoids are derived 
from five-carbon isoprene units (2-methyl-1,3-butadiene) and the combination of isoprene units 
leads to the formation of different isoprenoids. Based on the ‘isoprene rule’ that was first 
recognized in 1887 by Wallach (1887) and later, in 1953, was extended to the ‘biogenetic 
isoprene rule’ by Ruzicka (1953), isoprenoids can be divided into different groups depending on 
the number of isoprene units in their carbon skeleton (Table 1.1). 
Table 1.1. Classification of isoprenoids based on the number of isoprene units 
 
Class Isoprene 
units 
Carbon 
atoms Formula 
Monoterpenoids 2 10 C10H16 
Sesquiterpenoids 3 15 C15H24 
Diterpenoids 4 20 C20H32 
Sesterterpenoids 5 25 C25H40 
Triterpenoids 6 30 C30H48 
Tetraterpenoids 8 40 C40H64 
Polyterpenoids > 8 > 40 (C5H8)n 
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The universal biological precursor for all isoprenoids is isopentenyl diphosphate (IPP) (Figure 
1.1). Since the 1960s, when Bloch and Lynen discovered the mevalonate pathway for cholesterol 
synthesis (Katsuki and Bloch, 1967; Lynen, 1967) and until recently, IPP was assumed to be 
synthesized through the mevalonate-dependent pathway in all living organisms. However, in the 
1990s, the existence of an alternative pathway, called the 2-methylerythritol 4-phosphate (MEP) 
pathway, was demonstrated in bacteria, green algae, and higher plants (Rohmer et al., 1993; 
Rohmer, 1999; Broers, 1994; Schwarz, 1994). 
 
Figure 1.1. The different classes of isoprenoids and their precursors 
DMAPP: dimethylallyl diphosphate, IPP: isopentenyl diphosphate, GPP: geranyl diphosphate, 
FPP: farnesyl diphosphate, GGPP: geranylgeranyl diphosphate. 
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Isoprenoids are functionally important in many different parts of cell metabolism such as 
photosynthesis (carotenoids, chlorophylls, plastoquinone), respiration (ubiquinone), hormonal 
regulation of metabolism (sterols), regulation of growth and development (giberellic acid, 
abscisic acid, brassinosteroids, cytokinins, prenylated proteins), defense against pathogen attack, 
intracellular signal transduction (Ras proteins), vesicular transport within the cell (Rab proteins) 
as well as defining membrane structures (sterols, dolichols, carotenoids) (Sacchettini and Poulter, 
1997; Bach et al., 1999). Many isoprenoids also have considerable medical and commercial 
interest as flavors, fragrances (e.g. limonene, menthol, camphor), food colorants (carotenoids) or 
pharmaceuticals (e.g. bisabolol, artemisinin, lycopene, Taxol). In Table 1.2, some examples of 
isoprenoids and their corresponding biological functions or commercial applications are listed. 
Isoprenoids are widely present in plant tissues and extraction from plants has been the traditional 
option for the large-scale production of these compounds. However, in many cases this method is 
neither feasible nor economical. Among the drawbacks in using plants as a source for isoprenoid 
production are influence of geographical location and weather on the composition and 
concentration of isoprenoids in the plant tissues, low concentration and poor yields for recovery 
of isoprenoids from plants and high costs associated with extraction and purification. Taxol, 
known as the most important anti-cancer drug introduced in the last fifteen years (Kingston, 
2001), was originally extracted from the bark of the Pacific yew (Taxus brevifolia) through an 
extensive isolation and purification process. However, extraction of enough Taxol to treat one 
cancer patient requires six 100-year-old Pacific yew tree (Horwitz, 1994).  
Chemical synthesis of isoprenoids has also been reported (Mukaiyama et al., 1999; Danishefsky 
et al., 1996; Miyaoka et al., 2002) and currently most of the industrially interesting carotenoids 
are produced via chemical synthesis (Sandmann et al., 1999). Nevertheless, because of the 
complex structure of isoprenoids, chemical synthesis, involving many steps, is difficult. Side 
reactions, unwanted side products, and low yield are other disadvantages. In vitro enzymatic 
production of isoprenoids through the act of plant isoprenoid synthases is also not practical 
because of dependency on the expensive precursors as well as poor in vitro conversion. 
Microbial production of chemicals is an accepted environmentally friendly method that may lead 
to the production of large amounts of high-value isoprenoids from simple and cheap carbon 
sources. Engineered microorganisms would also enable production of unusual and novel 
isoprenoids with excellent biological and commercial applications.  
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Table 1.2. Biological activities or commercial applications of typical isoprenoids 
   
 Class Biological 
activitiesa 
Commercial applicationsa Examples 
   
 
Monoterpenoids Signal molecules, 
e.g. as defense 
mechanism against 
pathogens 
Flavors, fragrances, 
cleaning products, 
anticancer agents, 
antimicrobial agents 
Limonene, menthol, 
camphor 
 
   
Sesquiterpenoids Antibiotic, 
antitumor, antiviral, 
immunosuppressive, 
and hormonal 
activities 
Flavors, fragrances, 
potential pharmaceuticals 
Juvenile hormone, 
nootkatone, artemisinin 
 
   
Diterpenoids Hormonal activities, 
antitumor properties 
Anticancer agents Gibberellins, phytol, 
Taxol 
 
   
Sesterterpenoids Cytostatic activities None as yet Haslenes 
 
   
Triterpenoids Membrane 
components 
Biological markers Sterols, hopanoids 
 
   
Tetraterpenoids Antioxidants, 
photosynthetic 
components, 
pigments, and 
nutritional elements 
Food additives (colorants, 
antioxidants), anticancer 
agents 
Lycopene, β-carotene 
 
   
Polyterpenoids N-linked protein 
glycosylation, side 
chains of 
ubiquinones 
Rubber Dolichols, 
prenols/quinones 
rubber 
a
 Biological functions and commercial applications are selected examples. 
CHAPTER 1                                                                                                                   Introduction 
 5 
Directed manipulation of cell factories using genetic engineering techniques requires detailed 
information about the metabolic pathways and enzymes involved in the biosynthesis of the 
desired product(s) and also an understanding of the mechanisms by which the flux through the 
pathway is controlled. One of the major obstacles for the commercial production of isoprenoids 
by cell factories is the limited supply of precursors. Replenishing the intracellular pool of 
precursors will need deregulation of pathways in order to improve the flux towards the 
biosynthesis of isoprenoid precursors. Therefore, before dealing with the investigations 
conducted in order to construct enhanced strains capable of isoprenoid production, the metabolic 
pathways for isoprenoid biosynthesis, their enzymes and genes and also the regulatory network 
of pathways are discussed. 
 
1.2 The mevalonate pathway of Saccharomyces cerevisiae 
Due to the involvement of isoprenoids in a variety of physiologically and medically important 
processes, the sterol biosynthetic pathway or mevalonate pathway has been intensively studied in 
eukaryotes. Principal end products of the mevalonate pathway are sterols, e.g. cholesterol in 
animal cells and ergosterol in fungi, which are important regulators of membrane permeability 
and fluidity (Daum et al., 1998; Veen and Lang, 2004). In addition to sterols, the mevalonate 
pathway provides intermediates for the synthesis of a number of other essential cellular 
constituents like hemes, quinones, dolichols or isoprenylated proteins which are all derived from 
the early part of the pathway (Lees et al., 1999). Thus, the mevalonate pathway can be 
considered to consist of two distinct parts: an early isoprenoid portion of the pathway, common 
to many branches and ending with the formation of farnesyl diphosphate (FPP), and a late part of 
the pathway mainly dedicated to ergosterol biosynthesis in S. cerevisiae (Figure 1.2). This 
partition of the pathway is also reflected by the oxygen requirement of some enzymatic steps in 
the second part of the pathway while this constraint does not exist for the first part of the 
pathway (Figure 1.2). As the early steps of the mevalonate pathway generate precursors for 
isoprenoid production, the next paragraphs will focus on the enzymes catalyzing these steps with 
emphasis on the key regulatory points of the pathway. 
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Figure 1.2. The mevalonate pathway of S. cerevisiae 
1: acetyl-CoA, 2: acetoacetyl-CoA, 3: 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA), 4: 
mevalonate, 5: phosphomevalonate, 6: diphosphomevalonate, 7: IPP, 8: DMAPP, 9: GPP, 10: 
FPP. Gray boxes specify the general precursors for the different classes of isoprenoids. 
ERG10: acetoacetyl-CoA thiolase, ERG13: HMG-CoA synthase, HMG1, HMG2: HMG-CoA 
reductases, ERG12: mevalonate kinase, ERG8: phosphomevalonate kinase, ERG19: 
diphosphomevalonate decarboxylase, IDI1: IPP:DMAPP isomerase, ERG20: FPP synthase. 
 
The first reaction of the mevalonate pathway is the synthesis of acetoacetyl-CoA from two 
molecules of acetyl-CoA, catalyzed by the acetoacetyl-CoA thiolase which is encoded by ERG10 
(Figure 1.2). S. cerevisiae contains two forms of the enzyme, which have different subcellular 
locations (the cytosol and the mitochondrion). In S. cerevisiae, the reaction step is subject to 
regulation by the intracellular levels of sterols, by transcriptional regulation mediated by late 
intermediate(s) or product(s) of the pathway (Trocha and Sprinson, 1976; Servouse and Karst, 
1986; Dimster-Denk and Rine, 1996; Dixon et al., 1997; Dimster-Denk et al., 1999). However, 
overexpression of ERG10 did not increase the radio-labeled acetate incorporation on total sterol, 
suggesting other enzyme(s) of the sterol biosynthetic pathway to be flux controlling (Dimster-
Denk and Rine, 1996). 
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The condensation of acetyl-CoA with acetoacetyl-CoA to yield 3-hydroxy-3-methylglutaryl-CoA 
(HMG-CoA) is catalyzed by the ERG13 gene product, HMG-CoA synthase. This enzymatic step 
is subject to regulatory control (Trocha and Sprinson, 1976; Servouse and Karst, 1986). The 
details of the regulatory mechanism involved remain uncharacterized (Daum et al., 1998). 
However, the first crystal structure of an HMG-CoA synthase from an organism, Staphylococcus 
aureus, was recently described (Campobasso et al., 2004). Although the staphylococcal and 
streptococcal enzymes exhibit little identity (20%) with the eukaryotic counterparts, the amino 
acid residues involved in the acetylation and condensation reactions are conserved among 
bacterial and eukaryotic HMG-CoA synthases (Campobasso et al., 2004).  
The third enzyme in the pathway, HMG-CoA reductase, responsible for the conversion of HMG-
CoA into mevalonate, is the most studied enzyme of the mevalonate pathway. Unlike humans, S. 
cerevisiae has two copies of the gene encoding HMG-CoA reductase: HMG1 and HMG2, but 
Hmg1p was shown to be responsible for more than 83% of the enzyme activity in wild type cells 
(Basson et al., 1986). Disruption of both genes is lethal for cell, as predicted. This enzymatic step 
is highly regulated at different levels and appears to be a key regulatory point in the mevalonate 
pathway. 
Mevalonate kinase, encoded by ERG12, phosphorylates mevalonate at the C-5 position using 
ATP. It has been shown that FPP and geranyl diphosphate (GPP) exert an inhibitory effect on the 
enzyme (Dorsey and Porter, 1968). The next step catalyzed by the phosphomevalonate kinase, 
the gene product of ERG8, is not subject to feedback regulation by ergosterol (Daum et al., 
1998). Overexpression of ERG8 using the strong GAL1 promoter led to largely unchanged 
ergosterol levels, suggesting that this enzyme is not flux controlling for ergosterol production 
(Lees et al., 1999). 
The next two steps in the mevalonate pathway involve the ERG19 gene product (mevalonate 
diphosphate decarboxylase) which converts mevalonate diphosphate to IPP. The IDI1 gene 
product (isopentenyl diphosphate:dimethylallyl diphosphate isomerase) can then convert IPP into 
dimethylallyl diphosphate (DMAPP). IPP isomerase catalyzes an essential activation step in 
isoprenoid metabolism in the conversion of IPP to DMAPP by enhancing the electrophilicity of 
the isoprene unit by at least a billion-fold (Anderson et al., 1989). Two different classes of IPP 
isomerases have been reported: the type I enzyme, first characterized in the late 1950s, is widely 
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distributed in eukaryota and eubacteria, while the type II enzyme was recently discovered in 
Streptomyces sp. strain CL190 and in the archaeon Methanothermobacter thermautotrophicus 
(Barkley et al., 2004; Kaneda et al., 2001). The type I and type II isomerases have different 
structures and different cofactor requirements, suggesting that they catalyze isomerizations by 
different chemical mechanisms (Barkley et al., 2004). The properties of mevalonate diphosphate 
decarboxylase and of IPP isomerase are largely uncharacterized. However, reduced sterol 
content observed after overexpression of ERG19 was attributed to the accumulation of 
diphosphate intermediates leading to feedback inhibitions. Hence, ERG19 could encode a flux 
controlling step of the mevalonate pathway (Bergès et al., 1997). 
The final step in the early portion of the pathway is the conversion of DMAPP into geranyl and 
farnesyl diphosphates (GPP and FPP, respectively). Farnesyl (geranyl) diphosphate synthase, the 
product of the ERG20 gene, catalyzes this reaction. The enzyme combines first DMAPP and IPP 
to form GPP, and then GPP is extended by combination with a second IPP to form FPP. FPP 
synthase is a well characterized prenyltransferase. The enzyme has been purified to homogeneity 
from several eukaryotic sources including S. cerevisiae (Eberhardt and Rilling, 1975), avian liver 
(Reed and Rilling, 1975), porcine liver (Bernard et al., 1978; Yeh and Rilling, 1977) or human 
liver (Bernard and Popjak, 1981). FPP is a pivotal molecule situated at the branch point of 
several important metabolic pathways leading to sterols, heme, dolichol or quinone biosynthesis 
and prenylation of proteins and also involved in several key regulations of the mevalonate 
pathway. Furthermore, overexpression of ERG20 has been shown to result in increased levels of 
enzyme activity and ergosterol production, indicating that FPP synthase exerts some flux control 
in the pathway (Daum et al., 1998). 
The regulation of the isoprenoid biosynthetic pathway is known to be complex in all eukaryotic 
organisms examined, including the budding yeast S. cerevisiae (Goldstein and Brown, 1990; 
Hampton et al., 1996; Hampton, 1998). The overriding principle for the regulation of this 
pathway is multiple levels of feedback inhibition (Figure 1.3). This feedback regulation involves 
several intermediates and appears to act both at different steps of the pathway and at different 
levels of regulation as it involves changes in gene transcription, mRNA translation, enzyme 
activity and protein stability. The emerging picture is that the isoprenoid pathway has a number 
of points of regulation that act to control the overall flux through the pathway as well as the 
relative flux through the various branches of the pathway (Dimster-Denk et al., 1999). From 
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these complex multilevel regulations, two distinct but interconnected major sites of regulation 
are evident: one is the HMG-CoA reductase, the other is due to enzymes competing for FPP. 
The yeast HMG-CoA reductase is subject to complex regulation by a number of factors and 
conditions, at different levels. At the transcriptional level, HMG1 expression is stimulated by 
heme via the transcriptional regulator Hap1p while HMG2 expression is inhibited, indicating a 
relationship between heme and sterol biosynthesis (Thorsness et al., 1989). Hmg1p was shown to 
be transcriptionally repressed by a non-sterol product of the pathway (Dimster-Denk et al., 
1994). In a different study, the same group reported the induction of HMG1 reporter gene after 
inhibition of squalene synthase or lanosterol demethylase suggesting that HMG1 responded to 
the levels of sterol products of the pathway (Dimster-Denk et al., 1999). The two yeast isozymes 
have also distinctly different posttranslational fates: Hmglp was shown to be extremely stable 
while Hmg2p was subject to rapid regulated degradation depending on the flux through the 
mevalonate pathway (Hampton and Rine, 1994). The stability of each isozyme is determined by 
its non-catalytic amino-terminal domain. Hmg2p was demonstrated to undergo ERAD 
(endoplasmic reticulum associated degradation), similar to its mammalian ortholog, dependent 
on ubiquitination (Hampton and Rine, 1994; Nakanishi et al., 1988; Shearer and Hampton, 2004; 
Hampton and Bhakta, 1997). FPP was demonstrated as the source of the regulatory signal 
controlling and coupling ubiquitination/degradation of Hmg2p with the flux in the mevalonate 
pathway (Hampton and Rine, 1994; Hampton and Bhakta, 1997; Gardner and Hampton, 1999). 
In addition to the FPP signal, an oxysterol derived signal positively regulates Hmg2p degradation 
in yeast, but in contrast with mammals it is not an absolute requirement for degradation in yeast 
(Gardner et al., 2001).  
To summarize, the different regulations of HMG-CoA reductase can be grouped as 1) feedback 
inhibition, i.e. regulation of HMG-CoA reductase activity in response to intermediates or 
products from the mevalonate pathway, and 2) cross-regulation, i.e. regulation by processes 
independent of the mevalonate pathway (Hampton et al., 1996). As a consequence, in aerobic 
conditions Hmg1p is actively synthesized and extremely stable consistent with the constant need 
of sterols, while in anaerobic conditions the enzyme with a high turn-over, i.e. Hmg2p, is 
dominant to allow rapid adjustment of the balance between cellular demand and the potential 
accumulation of toxic compounds (Hampton et al., 1996). HMG1 and HMG2 are also expressed 
differently as a function of the growth phase (Thorsness et al., 1989; Casey et al., 1992). 
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FPP, the product of FPP synthase (Erg20p), is a pivotal intermediate in the mevalonate pathway 
leading to the synthesis of several critical end products (Daum et al., 1998). In addition, the 
farnesyl units and the related geranyl and geranylgeranyl species are important elements for the 
posttranslational modification of proteins that require hydrophobic membrane anchors for proper 
placement and function. Furthermore, farnesol, a metabolite causing apoptotic cell death in 
human acute leukaemia, a molecule involved in quorum sensing in Candida albicans (Hornby et 
al., 2001; Grabińska and Palamarczyk, 2002) and causing growth inhibition in S. cerevisiae, is 
endogenously generated in the cells by enzymatic dephosphorylation of FPP (Haug et al., 1994; 
Melnykovych et al., 1992; Machida et al., 1998). To ensure a constant production of the multiple 
isoprenoid compounds at all stages of growth whilst preventing accumulation of potentially toxic 
intermediates, cells must precisely regulate the level of activity of enzymes of the mevalonate 
pathway (Brown and Goldstein, 1980). A number of experimental data show that biosynthesis of 
dolichols and ubiquinones, as well as isoprenylated proteins, is being regulated by enzymes 
distal to HMG-CoA reductase (Szkopińska et al., 2000; Grabowska et al., 1998). This is 
illustrated on one hand by recent data on the effects of modulating FPP pools on dolichol 
biosynthesis and on the other hand by effects of increased tRNA prenylation on FPP synthase 
levels. 
In aerobic conditions, a strain with ERG20 on a multicopy plasmid was characterized by an 
almost 6-fold higher FPP synthase activity than a control wild-type strain. Simultaneously, the 
HMG-CoA reductase activity was changed by about 20%, which is consistent with the known 
regulations of HMG-CoA reductase activity (Szkopińska et al., 2000). Such an immense increase 
in FPP synthase activity correlated with a significant elevation in dolichol and ergosterol 
synthesis (about 80% and 32% higher, respectively). These results suggested that FPP synthase, 
independently of HMG-CoA reductase, is responsible for the partition of FPP, the substrate for 
squalene synthase and cis-prenyltransferase, between the syntheses of both groups of compounds 
acting as a flux controlling enzyme (Szkopińska et al., 2000). An intricate correlation between 
FPP synthase activity, ergosterol level and physiology of the cells has also been observed (Karst 
et al., 2004). Nevertheless, the disruption of the squalene synthase gene (when the strain deleted 
of ERG9 was cultivated in the presence of ergosterol) resulted in concurrently diminished 
activities of both FPP synthase and HMG-CoA reductase (78 and 83% repression, respectively). 
This strongly indicated the implication of squalene synthase in determining the intermediate flow 
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rates in the mevalonate pathway i.e. when the early intermediates of the pathway cannot be 
converted to ergosterol and its esters, and synthesis of dolichols is unable to assimilate the bulk 
of FPP, both FPP synthase and HMG-CoA reductase are repressed (Szkopińska et al., 2000). 
Moreover, changing an erg9 deleted strain from a medium containing ergosterol to a medium 
deprived of ergosterol resulted in a more than 10-fold increase in FPP synthase activity while 
HMG-CoA reductase activity was increased by 1.4-fold. Therefore, evidence is given that earlier 
literature data indicating strictly coordinated regulation of the mevalonate pathway enzymes, i.e. 
HMG-CoA reductase, FPP synthase, and squalene synthase with HMG-CoA reductase as the 
main regulatory enzyme in sterol biosynthesis, does not find full confirmation. FPP synthase, 
independently of HMG-CoA reductase and to a certain degree of squalene synthase, responds the 
most to changes in internal and external environmental conditions (Szkopińska et al., 2000). This 
is perhaps not surprising if one considers the diversified cell functions in which its product, FPP, 
directly participates (Szkopińska et al., 2000). 
DMAPP, the substrate of FPP synthase, forms a branch point of the isoprenoid pathway because 
it is also a substrate of Mod5p, tRNA isopentenyltransferase (Gillman et al., 1991). As a 
consequence, tRNA and the isoprenoid biosynthetic pathway compete for DMAPP as a common 
substrate. It has been shown that overexpression of ERG20 causes a decrease of i6A modification 
of tRNA, i.e. tRNA processing is dependent upon changes in the level of FPP synthase 
(Kamińska et al., 2002). Moreover, in a strain defective in Maf1p (a negative regulator of tRNA 
transcription) an excessive amount of DMAPP is dedicated to tRNA modification and, 
consequently, a lower amount of DMAPP is accessible for FPP synthase. As a consequence, the 
maf1-1 strain is characterized by elevated levels of Erg20p and decreased ergosterol content. In 
this case, regulation of Erg20p levels is both due to transcriptional as well as post-translational 
regulations (Kamińska et al., 2002). Therefore, in yeast, tRNA levels appear to contribute to the 
complex regulation of FPP synthase and of the mevalonate pathway. 
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Figure 1.3. Principal regulations of the mevalonate pathway 
Solid lines: regulations at gene expression level, dashed lines: regulations at protein synthesis 
level, : regulation of protein stability. 
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1.3 The MEP pathway 
Since the discovery of the mevalonate pathway, it was largely accepted that IPP and DMAPP 
originated exclusively from this pathway in all living organisms. However, inconsistency of 
several results, mainly involving labeling experiments, with the sole operation of the mevalonate 
pathway was reported (Zhou and White, 1991; Cane et al., 1979; Cane et al., 1981; Flesch and 
Rohmer, 1988). The existence of a second pathway was discovered relatively recently by the 
research groups of Rohmer and Arigoni using stable isotope incorporation in various eubacteria 
and plants (Rohmer et al., 1993; Schwarz, 1994). These data suggested that pyruvate and a triose 
phosphate could serve as precursors for the formation of IPP and DMAPP (Rohmer et al., 1993). 
The gene encoding the first reaction step of the alternative non-mevalonate pathway was 
identified and cloned from E. coli and the plant Mentha piperita (Sprenger et al., 1997; Lois et 
al., 1998; Lange et al., 1998) (Figure 1.4). It now seems obvious that most Gram negative 
bacteria and Bacillus subtilis use the MEP pathway for isoprenoid biosynthesis, whereas 
staphylococci, streptococci, enterococci, fungi and archae use the mevalonate pathway (Wilding 
et al., 2000; Hedl et al., 2002; Bochar et al., 1999; Doolittle and Logsdon, 1998). Although most 
Streptomyces strains are equipped with the MEP pathway, some of them have been reported to 
possess the mevalonate pathway in addition to the MEP pathway to produce terpenoid antibiotics 
(Takagi et al., 2000a; Hamano et al., 2001; Hamano et al., 2002; Kawasaki et al., 2003). Listeria 
monocytogenes was reported as the only pathogenic bacterium known to contain both pathways 
concurrently (Begley et al., 2004). Plants use the MEP pathway in plastids and the mevalonate 
pathway in their cytosol. Elucidation of the MEP pathway has been achieved through 
multidisciplinary approaches including organic chemistry, microbial genetics, biochemistry, 
molecular biology, and bioinformatics. The impressive fast increase in available information 
about the MEP pathway is a good example of integration of genomics with more traditional 
approaches to identify whole metabolic pathways in distant organisms (Rodríguez-Concepción 
and Boronat, 2002). 
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Figure 1.4. The E. coli MEP pathway for the synthesis of IPP and DMAPP. 
1: D-glyceraldehyde 3-phosphate, 2: pyruvate, 3: 1-deoxy-D-xylulose 5-phosphate, 4: 2-C-
methyl-D-erythritol 4-phosphate, 5: 4-diphosphocytidyl-2-C-methyl-D-erythritol, 6: 2-phospho-
4-diphosphocytidyl-2-C-methyl-D-erythritol, 7: 2-C-methyl-D-erythritol 2,4-cyclodiphosphate, 
8: 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate, 9: isopentenyl diphosphate, 10: 
dimethylallyl diphosphate. 
The enzymes encoded by the different genes are: dxs: DXP synthase, dxr: DXP 
isomeroreductase, ispD: MEP cytidylyltransferase, ispE: CDP-ME kinase, ispF: MECDP 
synthase, gcpE: MECDP reductase, lytB: HMBPP reductase. 
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In the first step of the MEP pathway, 1-deoxy-D-xylulose 5-phosphate synthase, also named 
DXP synthase or Dxs, catalyzes the condensation of the two precursors from the central 
metabolism, D-glyceraldehyde 3-phosphate (GAP) and pyruvate, to form DXP. However, DXP 
synthase is not the first specific enzymatic step of the MEP pathway as, in addition to IPP and 
DMAPP, DXP is the precursor for the biosynthesis of vitamins B1 (thiamine) and B6 (pyridoxal) 
in E. coli (Sprenger et al., 1997). DXP synthase activity, which is relatively high compared to the 
other enzymes of the pathway, requires both thiamine and a divalent cation (Mg2+ or Mn2+) 
(Eisenreich et al., 2004). DXP synthases represent a new class of TPP dependent enzymes 
combining the characteristics of decarboxylases and transketolases (Eubanks and Poulter, 2003). 
As DXP is the precursor for different kinds of compounds, the committed step of the pathway is 
catalyzed by DXP isomeroreductase (Dxr) and leads to the formation of 2-C-methyl-D-erythritol 
4-phosphate (MEP), hence its name: “MEP pathway”. yaeM gene from E. coli was shown to be 
responsible for the rearrangement and reduction of DXP in a single step (Takahashi et al., 1998)  
and was therefore renamed dxr. The catalytic activity of DXP isomeroreductase is substantially 
lower (12 µmol mg-1 min-1) than DXP synthase (Eisenreich et al., 2004). The reaction catalyzed 
by DXP isomeroreductase is reversible although the equilibrium is largely displaced in favor of 
the formation of MEP (Hoeffler et al., 2002a). Due to the wide distribution of DXP 
isomeroreductase in plants and many eubacteria, including pathogenic bacteria, and its absence 
in mammalian cells, this enzyme has been studied as a target for herbicides and antibacterial 
drugs. Fosmidomycin, an antibacterial agent active against most Gram negative and some Gram 
positive bacteria, has been shown to be a strong specific and competitive inhibitor of DXP 
isomeroreductase activity (Takahashi et al., 1998).  
In order to study the MEP pathway, E. coli strains were engineered to allow the study of 
mutations in otherwise essential genes. For this purpose, in addition to the MEP pathway, E. coli 
was transformed with the genes encoding yeast mevalonate kinase, phosphomevalonate kinase 
and diphosphomevalonate decarboxylase in one operon. This allowed the study of mutants of the 
MEP pathway which would have led to lethality of wild type cells (Kuzuyama, 2002; Campos et 
al., 2001a). Mutants with a defect in the synthesis of IPP from MEP were isolated and the genes 
responsible for this defect identified. These genes are ygbP, ychB, ygbB and gcpE. The genes 
ygbP, ychB, and ygbB are all essential in E. coli and the enzymatic steps catalyzed by their gene 
products belong to the trunk line of the MEP pathway (Campos et al., 2001a). 
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ygbP (ispD) was shown to encode MEP cytidylyltransferase converting MEP into 4-
diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) in the presence of CTP (Rohdich et al., 
1999; Kuzuyama et al., 2000a). Its activity is also substantially lower compared to DXP synthase 
activity.  
In the presence of ATP, CDP-ME is converted to 2-phospho-4-diphosphocytidyl-2-C-methyl-D-
erythritol (CDP-ME2P) by the CDP-ME kinase encoded by ispE (Lüttgen et al., 2000; 
Kuzuyama et al., 2000b). On the basis of sequence comparisons, CDP-ME kinase was 
recognized as a member of the GHMP kinase family which initially included galactose kinase, 
homoserine kinase, mevalonate kinase and phosphomevalonate kinase and more recently 
mevalonate 5-diphosphate decarboxylase and the archaeal shikimate kinase (Miallau et al., 
2003). 
2-C-methyl-D-erythritol 2,4-cyclodiphosphate (MECDP) synthase, encoded by ygbB (ispF), was 
demonstrated to catalyze the formation of MECDP from CDP-ME2P with concomitant 
elimination of cytidine monophosphate (CMP) (Takagi et al., 2000b; Herz et al., 2000). ispF has 
been shown to be essential (Campos et al., 2001a; Freiberg et al., 2001) and conditional mutation 
of ispF in E. coli or of its ortholog yacN in B. subtilis led to a decrease in growth rate and altered 
cell morphology (Campbell and Brown, 2002). In contrast to the dispersed nature of genes 
belonging to the MEP pathway, ispD and ispF are transcriptionally coupled or, in some cases, 
fused into one coding region leading to a bifunctional enzyme. IspDF coupling is highly unusual 
as these enzymes catalyze non consecutive steps of the MEP pathway. Interactions have been 
observed between the bifunctional IspDF and IspE protein. Monofunctional IspD, IspF and IspE 
proteins have also demonstrated a close interaction suggesting a multienzymatic complex maybe 
responsible for the metabolic flux control through the MEP pathway (Gabrielsen et al., 2004). 
In contrast to the mevalonate pathway, in which DMAPP is synthesized from IPP by the 
essential IPP:DMAPP isomerase activity, the finding that IPP:DMAPP isomerase was functional 
but non-essential for growth of E. coli indicated that the MEP pathway was branched i.e. 
DMAPP and IPP are synthesized by two different routes splitting at late stages of the pathway 
(Rodríguez-Concepción et al., 2000).  
The last two steps of the pathway were recently solved by Hintz et al. (2001) who reported the 
accumulation of the formerly unknown intermediate 1-hydroxy-2-methyl-2-(E)-butenyl 4-
diphosphate (HMBPP) in a lytB (ispH) disrupted E. coli strain. Several studies aimed at 
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demonstrating the essential nature of gcpE (ispG) and/or lytB (Altincicek et al., 2001a; 
Altincicek et al., 2001b), their necessity for DXP conversion to IPP and DMAPP (Hecht et al., 
2001; Steinbacher et al., 2002; Campos et al., 2001b) and the efficiency of their gene products in 
converting MECDP into HMBPP (Seemann et al., 2002) and HMBPP into IPP and DMAPP 
(Altincicek et al., 2002). An important feature of both GcpE and LytB is a [4Fe-4S] cluster as 
prosthetic group underlying their high sensitivity towards oxygen. This property, common to 
both enzymes, may explain why the investigations of the terminal reactions of the MEP pathway 
have been hampered for so long (Seemann et al., 2002; Eberl et al., 2003; Wolff et al., 2003).  
The finding that a single enzyme is responsible for the formation of both IPP and DMAPP 
contrasts with the mevalonate pathway where DMAPP is successively formed from IPP by IPP 
isomerase. As a consequence of these findings, the role of IPP isomerase in microorganisms 
expressing the MEP pathway comes into question. The non-essential and non-limiting roles of 
the Idi interconversion are currently being investigated as on one hand the E. coli Idi enzyme 
was reported to have 20-fold less activity than its yeast counterpart (Hahn et al., 1999), idi from 
E. coli is dispensable (Rodríguez-Concepción et al., 2000) and idi homologs have not been found 
in genomes of many bacteria using the MEP pathway sequenced so far (Cunningham et al., 
2000). On the other hand, structurally and mechanistically different IPP isomerases, referred to 
as class II IPP isomerases, have been identified in Streptomyces sp. strain CL190 and also in a 
variety of Gram-positive bacteria, cyanobacteria and archaebacteria (Hamano et al., 2001). 
Furthermore, the overexpression of idi genes from different origins in E. coli engineered for the 
production of lycopene has always led to carotenoid overproduction (Cunningham et al., 2000; 
Kajiwara et al., 1997; Wang et al., 1999), these findings keep going the debate about the non-
essentiality and non-limiting role of IDI reaction (Hoeffler et al., 2002b). 
 
 
1.4 Metabolic engineering of microorganisms for isoprenoid production 
In the last decade there have been a number of investigations on the construction of engineered 
microorganisms with the ability to produce different isoprenoids. Figure 1.5 schematically shows 
the different steps for constructing industrial isoprenoid producing microorganisms. As it will be 
seen in the next sections, a common feature for most of the conducted studies for microbial 
isoprenoid production is that they include expression of heterologous genes for converting 
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isoprenoid precursors of the host microorganism into the desired isoprenoid, and deregulation of 
metabolic pathways in order to increase the metabolic flux to isoprenoid precursors. 
 
Figure 1.5. Summary of different steps for establishing industrial cell factories capable of 
isoprenoid production 
 
Tetraterpenoid carotenoids (C40) have been the most interesting group of isoprenoids for 
metabolic engineering studies because of their easy color screening (Marshall and Wilmoth, 
1981) and their industrial importance as feed supplements in the poultry and fish farming 
(Johnson and Schroeder, 1996). Carotenoid biosynthetic pathway in Erwinia uredovora was first 
elucidated by Misawa et al (1990), and the corresponding genes were subsequently used in 
several studies for production of heterologous carotenoids in non-carotenogenic microorganisms. 
However, isolation and characterization of more than 150 carotenogenic genes involved in the 
synthesis of 27 different enzymes in the carotenoid biosynthesis pathways in several organisms 
(Lee and Schmidt-Dannert, 2002; Schmidt-Dannert, 2000) has opened the door for the 
heterologous production of a broad range of carotenoids. 
Ergosterol (the main sterol in yeasts), found in large amounts in the yeast membranes, plays a 
key role in regulating the membrane fluidity and permeability (Arthington-Skaggs et al., 1996) 
and is produced through the mevalonate pathway. Although E. coli has been the main host for 
metabolic engineering of isoprenoids, in several cases yeasts (which have high capacity for 
ergosterol production) have been subject to metabolic engineering studies (Yamano et al., 1994; 
Miura et al., 1998a; Miura et al., 1998b; Shimada et al., 1998; Jackson et al., 2003; Verwaal et 
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al., 2007, Takahashi et al., 2007; Lindahl et al., 2006; Ro et al., 2006; Shiba et al., 2007; DeJong 
et al., 2005; Oswald et al., 2007). 
 
1.4.1 Metabolic engineering of the MEP pathway 
Amongst the different enzymes in the MEP pathway, DXP synthase (encoded by dxs), IPP 
isomerase (encoded by idi) and DXP isomeroreductase (encoded by dxr) have been the main 
targets for the metabolic engineering investigations. Overexpression of dxs has been achieved in 
several studies in order to improve the intracellular pool of precursors for isoprenoid 
biosynthesis (Huang et al., 2001; Reiling et al., 2004; Martin et al., 2001; Martin et al., 2003; 
Wang and Liao, 2000; Matthews and Wurtzel, 2000; Harker and Bramley, 1999; Kim and 
Keasling, 2001; Albrecht et al., 1999; Yuan et al., 2006; Yoon et al., 2007; Alper et al., 2005c). 
For example, overexpression of dxs in E. coli strains harboring the carotenogenic genes resulted 
in up to 10.8- and 3.9-fold increase in the accumulated levels of lycopene and zeaxanthin, 
respectively (Matthews and Wurtzel, 2000). Overproduction of DXP synthase also had a great 
impact on the biosynthesis of taxadiene (Huang et al., 2001) as the required intermediate for the 
synthesis of paclitaxel (Taxol), and lycopene in E. coli (Harker and Bramley, 1999). 
Chromosomal replacement of native dxs promoter with a strong bacteriophage T5 promoter 
improved β-carotene production 2- to 3.3-fold in E. coli (Yuan et al., 2006). The strength of 
promoter and plasmid copy number are important in balancing expression of dxs with overall 
metabolism (Kim and Keasling, 2001).  
The second step in the MEP pathway, which is catalyzed by DXP isomeroreductase, has been 
shown to control the flux to isoprenoid precursors in E. coli (Kim and Keasling, 2001; Albrecht 
et al., 1999). Co-overexpression of dxr and dxs was concomitant with a 1.4- to 2-fold increase in 
lycopene level compared to the strains overexpressing only dxs (Kim and Keasling, 2001). 
However, overexpression of dxs had a greater impact on lycopene production than 
overexpression of dxr. In another study (Albrecht et al., 1999), simultaneous overexpression of 
dxs and dxr in the ß-carotene and zeaxanthin producing E. coli strains was lethal for the cells, 
probably due to restricted storage capacity for lipophilic carotenoids, which causes membrane 
overload and loss of its functionality. This problem implies the need for host microorganisms 
with higher storage capacity for heterologous production of carotenoids (Sandmann et al., 1999; 
Sandmann, 2001; Ruther et al., 1997). However, in contrast to the previous study (Albrecht et al., 
CHAPTER 1                                                                                                                   Introduction 
 20 
1999) that showed 1.6 mg/g DW as the maximum membrane capacity of E. coli for ß-carotene 
and zeaxanthin storage, Yoon et al. (2006) did not observe any toxicity effect in the E. coli 
strains accumulating 49.3 mg ß-carotene/g DW.  
Isomerization of IPP to DMAPP has been another target for improving isoprenoid biosynthesis 
in the MEP pathway, and several studies have shown the enhancing effect of IPP isomerase 
overproduction (Kajiwara et al., 1997; Wang et al., 1999; Huang et al., 2001; Reiling et al., 2004; 
Martin et al., 2003; Albrecht et al., 1999; Yuan et al., 2006). Overexpression of idi genes from 
different organisms in the recombinant E. coli showed 1.5- to 4.5-fold increase in the lycopene, 
ß-carotene, and phytoene levels compared to the control strains (Kajiwara et al., 1997). Positive 
effects of idi or dxs overexpression on ß-carotene and zeaxanthin accumulation in E. coli have 
also been shown. Amplification of idi or/and dxs resulted in approximately 2- to 3.5-fold more 
carotenoid accumulation in the recombinant strains than the control (Albrecht et al., 1999; Yuan 
et al., 2006). Engineered lycopene producing E. coli overexpressing dxs, idi, and ispA 
(responsible for FPP synthase activity in E. coli) produced 6-fold more lycopene than the control 
strain (Reiling et al., 2004). Simultaneous amplification of idi and GGPP synthase gene (gps) in 
astaxanthin producing E. coli strains increased the astaxanthin level from 33 µg/g dry weight in 
the control strain to 1419 µg/g dry weight in the recombinant strain (Wang et al., 1999). In the 
same laboratory, subjecting gps gene to directed evolution resulted in 2-fold increase in the 
lycopene level and subsequent co-overexpressions of dxs gene further enhanced the lycopene 
accumulation (Wang et al., 2000). 
The MEP pathway is initiated with combining pyruvate and GAP in equal amounts catalyzed by 
DXP synthase. Hence, balanced pools of pyruvate and GAP would be an important factor in 
efficient directing of central carbon metabolism to the isoprenoid pathway. Pyruvate is required 
as a precursor in many cellular pathways and presumably it is more available than GAP for 
isoprenoid biosynthesis. It was shown that overproduction or inactivation of enzymes that leads 
to redirection of flux from pyruvate to GAP results in higher lycopene production in E. coli 
(Farmer and Liao, 2001). Thus, overproduction of phosphoenolpyruvate (PEP) synthase (Pps) 
and PEP carboxykinase (Pck) or inactivation of pyruvate kinase isozymes (Pyk-I and Pyk-II) 
were shown to enhance lycopene production in E. coli. 
Effect of manipulating central carbon metabolism on lycopene production in E. coli by 
inactivating the competing pathways at acetyl-CoA and pyruvate nodes has been studied (Vadali, 
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et al., 2005). Deletion of acetate production pathway at pyruvate node improved lycopene 
production by 45% but further deletion of acetate production pathway at acetyl-CoA node and 
lactate production pathway did not have any more effect.   
Poor expression of plant genes and inadequate amounts of enzymes could be another limiting 
factor for the production of plant isoprenoids in the engineered hosts (Martin et al., 2001). To 
circumvent the problems of low sesquiterpene yield arisen from the poor expression of plant 
genes, in one study (Martin et al., 2003), a codon-optimized variant of amorphadiene synthase 
gene (ADS) was synthesized and expressed in E. coli. This improved the enzyme synthesis and 
production yield of amorphadiene and changed the flux control in the biosynthesis of 
sesquiterpenes from the step catalyzed by the heterologous plant genes to the supply of precursor 
(FPP) provided by the MEP pathway. The expression of this synthetic ADS gene in E. coli 
resulted in a 10- to 300-fold increase in sesquiterpene accumulation compared to the previous 
study (Martin et al., 2001) in which the native plant sesquiterpene synthase genes were 
expressed. Further overexpression of genes responsible for the synthesis of DXP synthase, IPP 
isomerase and FPP synthase, with the synthetic ADS led to a 3.6-fold increase in the 
concentration of amorphadiene indicating the supply of precursor is limiting the sesquiterpene 
production. However, considering the fact that overexpression of three flux controlling enzymes 
of the pathway only resulted in a 3.6-fold increase in amorphadiene concentration, this approach 
to increase the flux to FPP seems to be limited by some other native control mechanisms in E. 
coli. Introduction of the mevalonate pathway from S. cerevisiae to E. coli has been shown to be 
an alternative approach to increase the intracellular concentration of isoprenoid precursors, 
thereby circumventing the as yet unidentified regulations of the native MEP pathway and also 
minimizing the complicated regulatory network of the mevalonate pathway observed in yeast. 
The mevalonate pathway from S. cerevisiae was divided into two synthetic operons, referred to 
as top (MevT) and bottom (MBIS) section of the pathway and was expressed in the E. coli strain 
harboring the engineered MEP pathway and synthetic ADS. MevT contains three genes for the 
conversion of acetyl-CoA to mevalonate, whereas MBIS is responsible for the conversion of 
mevalonate to FPP. Importing the heterologous mevalonate pathway into E. coli resulted in 10-
fold further increase in the amorphadiene concentration (Martin et al., 2003). This engineered 
strain produced 480 mg/L amorphadiene in a fed-batch bioreactor supplemented with increased 
carbon and complex nutrients (Newman et al., 2006). Growing the above strain in a medium 
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supplemented with increasing concentration of exogenous mevalonate led to higher 
amorphadiene production which indicates limited supply of mevalonate by the MevT operon. 
However, increasing expression of the MevT genes inhibited cell growth due to accumulation of 
HMG-CoA. Introduction of an additional copy of tHMG1 for conversion of the toxic HMG-CoA 
to non-toxic mevalonate, restored the growth of cells, reduced the accumulation of intracellular 
HMG-CoA and improved mevalonate production 2-fold (Pitera et al., 2007). To remedy the 
imbalanced gene expression in the MevT genes, expression of the three genes in the operon was 
tuned by generating libraries of tunable intergenic regions (TIGRs) and resulted in a 7-fold 
increase in mevalonate production (Pfleger et al., 2006). 
Heterologous expression of the mevalonate pathway from Streptomyces sp. Strain CL190 into 
lycopene producing E. coli improved lycopene biosynthesis only if acetate production pathway 
had been inactivated (Vadali et al., 2005). In another study (Yoon et al., 2006), the lower 
mevalonate pathway from the Gram-positive bacterium Streptococcus pneumoniae was imported 
into lycopene producing E. coli. Supplementation of 3.3 mM mevalonate for the mevalonate 
lower pathway improved lycopene production more than 3-fold. Cultivation of this strain in 2YT 
medium containing 2(w/v)% glycerol, 6.6 mM mevalonate and 0.5(w/v)% Tween 80 to prevent 
clump formation due to high amounts of lycopene resulted in 102 mg/L lycopene which is about 
5-fold higher than the lycopene obtained through metabolic engineering of the MEP pathway by 
the same group (Kim and Keasling, 2001). The above engineered E. coli strain harboring the 
lower mevalonate pathway from S. pneumoniae was also studied for β-carotene production by 
introducing crtY gene from Pantoea ananatis and a 4-fold increase in β-carotene production was 
observed due to expression of the lower mevalonate pathway and mevalonate supplementation. 
Addition of 16.5 mM mevalonate and 2.5(w/v)% glycerol resulted in 503 mg/L (49.3 mg/g DW) 
β-carotene which is the highest reported microbial carotenoid production to date. In contrast to 
lycopene, β-carotene had no effect on cell growth and addition of Tween 80 was not necessary 
for preventing clump formation (Yoon et al., 2007).   
Most of the metabolic engineering efforts on microbial isoprenoid production were focused on 
the genes that are directly involved in the isoprenoid biosynthesis pathway, genes from central 
carbon metabolism or introduction of heterologous mevalonate pathway. However, there have 
been some attempts to identify new target genes from other pathways that can affect isoprenoid 
biosynthesis. In one study (Alper et al., 2005a), genome-wide stoichiometric flux balance 
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analysis using a genome-scale model for E. coli and minimization of metabolic adjustment 
(MOMA) requirement between wild type and single gene knockout mutant as an objective 
function was performed to identify the genes whose deletions could enhance lycopene 
production in E. coli. Using this systematic (model-based) approach a triple knockout construct 
(∆gdhA ∆aceE ∆fdhF) was identified that resulted in approximately 40% more lycopene 
production compared to the engineered parental strain. In a further improvement, the same group 
(Alper et al., 2005b) identified additional knockout targets by applying a global transposon 
library search (combinatorial method) in the parental strain. By combining the identified target 
genes from both systematic and combinatorial approaches, they found two globally optimum 
mutants each producing the same amounts of lycopene. One of the mutants (∆gdhA ∆aceE 
∆fdhF) was obtained using pure systematic approach and the other (∆gdhA ∆aceE ∆PyjiD) was a 
result of combination of targets from both approaches. Detailed characterization of these two 
mutants in a fed-batch fermenter running under optimized operating parameters revealed 
significant increase in the volumetric productivity and specific productivity for both engineered 
strains compared to the parental strain (Alper et al., 2006a).  
Metabolic engineering of microbial hosts for constructing overproducers of a certain compound 
in many cases needs overexpression of genes to enhance the flux towards the product of interest. 
In one study (Kang et al., 2005), a colorimetric screening of shot-gun library clones with E. coli 
genomic library was used to identify target genes whose overexpressions could enhance 
lycopene production in E. coli lycopene producing strains. After analyzing 6 overproducer 
clones, 4 genes were identified to be involved in improved lycopene production. Among these 4 
genes, 3 genes were not directly involved in lycopene biosynthesis and 2 of them were new 
target genes not identified by others.   
Metabolic engineering of microorganisms for improving a certain phenotype often needs 
simultaneous alterations in the expression of many genes. This, in many cases is unachievable 
due to both difficulties in identifying all target genes using conventional pathway analysis 
methods and experimental limitations. Global transcription machinery engineering (gTME) 
approach (Alper et al., 2006b) as a means to induce multiple genetic perturbations through 
altering key proteins regulating the global transcriptome was applied to improve several 
phenotypes including lycopene production in E. coli (Alper and Stephanopoulos, 2007). 
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1.4.2 Metabolic engineering of the mevalonate pathway 
Engineering of industrially important yeasts, S. cerevisiae and Candida utilis, for carotenoid 
production by introducing the carotenoid biosynthetic genes of E. uredovora has been reported 
(Yamano et al., 1994; Miura et al., 1998a; Miura et al., 1998b; Shimada et al., 1998; Verwaal et 
al., 2007). Modification of carotenogenic genes based on the codon usage of the C. utilis GAP 
dehydrogenase gene, increased the phytoene and lycopene contents of the strains 1.5- and 4-fold, 
respectively, compared to those of the strains carrying non-modified genes (Miura et al., 1998b). 
HMG-CoA reductase is believed to be the key enzyme in the mevalonate pathway and 
overexpression of both full length and truncated versions of the gene responsible for HMG-CoA 
reductase synthesis increased the lycopene production in C. utilis but the truncated version had 
greater impact. Subsequent disruption of ERG9 gene also improved lycopene production 
(Shimada et al., 1998). Stimulating effect of HMG-CoA reductase overproduction on the 
lycopene and neurosporaxanthin content in a naturally carotenoid producing fungus, Neurospora 
crassa (Wang and Keasling, 2002), on β-carotene (Verwaal et al., 2007), epi-cedrol (Jackson et 
al., 2003) and amorphadiene (Ro et al., 2006) production in S. cerevisiae have also been shown.  
Transformation of S. cerevisiae with carotenogenic genes from E. uredovora led to low levels of 
lycopene and β-carotene (Yamano et al., 1994), whereas S. cerevisiae transformed with the 
carotenogenic genes from Xanthophyllomyces dendrorhous (formerly known as Phaffia 
rhodozyma) produced higher levels of carotenoids (Verwaal et al., 2007). Overexpression of 
tHMG1 enhanced carotenoid production 7-fold but phytoene was the main produced carotenoid 
suggesting existence of a bottleneck at the phytoene desaturation step. Overexpression of crtI 
changed the composition of carotenoids in the favor of β-carotene and led to reduced 
accumulation of phytoene (Verwaal et al., 2007). 
Heterologous production of several sesquiterpenes including epi-cedrol (Jackson et al., 2003), 5-
epi-aristolochene, premnaspirodiene, valencene, capsidiol (Takahashi et al., 2007), 
amorphadiene (Lindahl et al., 2006; Ro et al., 2006), and artemisinic acid (Ro et al., 2006) in S. 
cerevisiae have been successfully reported. In one study (Ro et al., 2006), S. cerevisiae was 
exploited as a platform for the biosynthesis of artemisinic acid, which can readily be converted to 
the antimalarial drug artemisinin by semisynthetic routes (Ro et al., 2006). To this end, first the 
mevalonate pathway in S. cerevisiae was deregulated by several modifications including 
overexpression of a truncated HMG-CoA reductase, down-regulation of ERG9, overexpression 
CHAPTER 1                                                                                                                   Introduction 
 25 
of upc2-1, a semi-dominant allele that enhances the activity of a global transcription factor 
regulating sterol biosynthesis in yeast encoded by UPC2, and overexpression of ERG20. 
Combining all these alterations resulted in an engineered yeast strain capable of producing 153 
mg/L amorphadiene. This engineered strain was subsequently transformed with a novel 
cytochrome P450 monooxygenase (CYP71AV1) from Artemisia annua that converts 
amorphadiene to artemisinic acid through a three-step oxidation and was able to produce up to 
100 mg/L artemisinic acid (Ro et al., 2006). Engineering of pyruvate dehydrogenase bypass by 
overproduction of acetaldehyde dehydrogenase (encoded by ALD6) and a variant of acetyl-CoA 
synthetase from Salmonella enterica enhanced amorphadiene biosynthesis in S. cerevisiae (Shiba 
et al., 2007).  
S. cerevisiae has been examined as a microbial host for the biosynthesis of Taxol intermediates 
as well (DeJong et al., 2005). Total biosynthesis of Taxol from GGPP takes place in 19 steps. 
Eight genes of the pathway were functionally expressed in the yeast. Co-expression of GGPP 
synthase and taxadiene synthase resulted in a yeast strain producing 1 mg/L taxadiene but further 
modification of this terpene backbone was limited by the first cytochrome P450 hydroxylation 
step and produced only 25 µg/L of taxadien-5α-ol. 
GPP serves as the sole precursor for the biosynthesis of monoterpenes. The level of GPP in yeast 
seems to be very low due to its tight binding to the farnesyl diphosphate synthase catalytic site 
and also the fact that no cellular function for GPP has been described in yeast. However, 
expression of geraniol synthase of Ocimum basilicum in yeast gave rise to the biosynthesis of 
geraniol and linalool in yeast. A 10-fold increase in geraniol production was observed upon 
expression of geraniol synthase in a yeast mutant bearing an erg20-2 mutation (Oswald et al., 
2007). 
Table 1.3 summarizes the examples of metabolically engineered microorganisms for production 
of different isoprenoids. 
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Table 1.3 Examples of different isoprenoids produced by metabolically engineered microorganisms 
Class Isoprenoid 
Host 
microorganism 
Yield/ 
concentration  
Ref. 
     Monoterpenoids Limonene E. coli ~ 5000 µg/L Carter et al., 2003 
 3-Carene E. coli 3 µg/L/OD600 Reiling et al., 2004 
 Geraniol S. cerevisiae 989 µg/L/OD600 Oswald et al., 2007 
     
Diterpenoids Taxadiene E. coli  1300 µg/L Huang et al., 2001 
 Taxadiene S. cerevisiae  1000 µg/L DeJong et al., 2005 
 Taxadien-5α-ol S. cerevisiae 25 µg/L DeJong et al., 2005 
 Casbene E. coli 30 µg/L/OD600 Reiling et al., 2004  
     Sesquiterpenoids (+)-δ-Cadinene E. coli 10.3 µg/L Martin et al., 2001 
 5-Epi-aristolochene E. coli 0.24 µg/L Martin et al., 2001 
 Vetispiradiene E. coli 6.4 µg/L Martin et al., 2001 
 Amorphadiene E. coli 24000 µg/L a  Martin et al., 2003 
 Amorphadiene E. coli 480000 µg/L   Newman et al., 2006 
 Amorphadiene S. cerevisiae 153000 µg/L   Ro et al., 2006 
 Amorphadiene S. cerevisiae 120000 µg/L   Shiba et al., 2007 
 Amorphadiene S. cerevisiae 600 µg/L   Lindahl et al., 2006 
 Artemisinic acid S. cerevisiae 100000 µg/L   Ro et al., 2006 
 Epi-cedrol S. cerevisiae 370 µg/L Jackson et al., 2003 
 5-Epi-aristolochene S. cerevisiae 90000 µg/L Takahashi et al., 2007 
 Premnaspirodiene S. cerevisiae 90000 µg/L Takahashi et al., 2007 
 Valencene S. cerevisiae 20000 µg/L Takahashi et al., 2007 
 Capsidiol S. cerevisiae 50000 µg/L Takahashi et al., 2007 
     Carotenoids Lycopene E. coli 25000 µg/g DW Farmer and Liao, 2001 
 
Lycopene E. coli 1333 µg/g DW 
Matthews and Wurtzel, 
2000 
 
Lycopene E. coli ~ 1000 µg/g DW 
Harker and Bramley, 
1999 
 Lycopene E. coli 22000 µg/L 
Kim and Keasling, 
2001 
 Lycopene E. coli 45000 µg/g DW Wang et al., 2000 
 Lycopene E. coli 1029 µg/g DW Kajiwara et al., 1997 
 Lycopene E. coli 1210 µg/L Reiling et al., 2004 
 Lycopene E. coli 4280 µg/L Vadali et al., 2005 
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 Lycopene E. coli 
102000 µg/L, 22000 
µg/g DW 
Yoon et al., 2006 
 Lycopene E. coli 6600 µg/g DW Alper et al., 2005a 
 Lycopene E. coli 18000 µg/g DW Alper et al., 2005b 
 Lycopene E. coli 220000 µg/L Alper et al., 2006a 
 Lycopene E. coli 4700 µg/g DW Kang et al., 2005 
 Lycopene E. coli 7700 µg/L 
Alper and 
Stephanopoulos, 2007 
 Lycopene S. cerevisiae 113 µg/g DW Yamano et al., 1994 
 Lycopene C. utilis 758 µg/g DW Miura et al., 1998a 
 Lycopene C. utilis 1100 µg/g DW Miura et al., 1998b 
 Lycopene C. utilis 7800 µg/g DW Shimada et al., 1998 
 Lycopene N. crassa 17.9 µg/g DW 
Wang and Keasling, 
2002 
 β-Carotene E. coli 1310 µg/g DW Kajiwara et al., 1997 
 β-Carotene E. coli 1533 µg/g DW Albrecht et al., 1999 
 β-Carotene E. coli 6000 µg/g DW Yuan et al., 2006 
 β-Carotene E. coli 
503000 µg/L ,49300 
µg/g DW 
Yoon et al., 2007 
 β-Carotene E. coli 
390000 µg/L, 4800 
µg/L h 
Kim et al., 2006 
 β-Carotene S. cerevisiae 103 µg/g DW Yamano et al., 1994 
 β-Carotene S. cerevisiae 5918 µg/g DW Verwaal et al., 2007 
 β-Carotene C. utilis 400 µg/g DW Miura et al., 1998b 
 β-Carotene Z. mobilis 220 µg/g DW Misawa et al., 1991 
 β-Carotene A. tumefaciens 350 µg/g DW Misawa et al., 1991 
 Astaxanthin E. coli 1419 µg/g DW Wang et al., 1999 
 Astaxanthin C. utilis 400 µg/g DW Miura et al., 1998b 
 Zeaxanthin E. coli 289 µg/g DW Ruther et al., 1997 
 Zeaxanthin E. coli 592 µg/g DW 
Matthews and Wurtzel, 
2000 
 Zeaxanthin E. coli 1570 µg/g DW Albrecht et al., 1999 
 Neurosporaxanthin N. crassa 63.4 µg/g DW 
Wang and Keasling, 
2002 
     a:
 112200 µg/L expected if evaporation is taken into account. 
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1.4.3 Metabolic engineering for heterologous production of novel isoprenoids 
Metabolic engineering can also be applied for heterologous microbial production of novel 
isoprenoids. In the past few years, production of uncommon and non-commercially available 
carotenoids has drawn much attention because of the increasingly scientific documents 
indicating their potential applications in preventing cancer and cardiovascular diseases as well as 
their anti-tumor properties (Cooper et al., 1999). However, production of these complex 
carotenoids by chemical synthesis is impractical and natural sources are containing only trace 
amounts of these carotenoids. Hence, microbial production is the method of choice for their 
commercial production. Expression or combination of carotenogenic genes from different 
bacteria in E. coli was successfully applied for the production of a number of novel 
hydroxycarotenoids (Albrecht et al., 1997; Albrecht et al., 2000). In another example (Yokoyama 
et al., 1998), E. coli transformants were developed by introducing seven carotenoid biosynthetic 
genes from E. uredovora and A. aurantiacum for production of new astaxanthin glucosides. 
Production of two other uncommon acyclic carotenoids has been achieved in E. coli by 
introducing the crtC and crtD genes from Rhodobacter and Rubrivivax (Steiger et al., 2002). 
Schmidt-Dannert et al. (2000) shuffled phytoene desaturases (encoded by crtI) and lycopene 
cyclases (encoded by crtY) from different bacterial species to evolve new enzyme functions and 
produce a library of carotenoids. 
 
1.5 The choice of microbial host 
During the development of novel bioprocesses (or the improvement of existing bioprocesses), 
the value added element is primarily in the design of efficient cell factories. There are several 
large research groups and companies focusing on the development of cell factories for novel 
and/or improved bioprocesses worldwide. Traditionally, biotech processes have been developed 
based on screening for a microorganism with interesting properties (for example, it produces an 
interesting compound), whereas in recent years there has been a paradigm shift towards the use 
of a few well-chosen cell factories. Good examples of this are: 1) the use of a few selected 
microorganisms to produce a wide range of different enzymes (the Danish company Novozymes 
has expressed a large number of different enzymes in the filamentous fungus Aspergillus 
oryzae), 2) the use of the penicillin-producing fungus Penicillium chrysogenum by the Dutch 
company DSM for the production of adipoyl-7-aminodeacetoxycephalosporanic acid (adipoyl-7-
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ADCA) (Robin et al., 2001), a precursor for the production of semi-synthetic cephalosporins, 
and 3) the production of the chemical 1,3-propanediol by the American company Dupont by a 
recombinant E. coli, an organism that is already used for the production of many other 
chemicals, such as phenylalanine. There are several drivers for this development, including:  
• Scale-up of bioprocesses can be intensified; when a cell factory has already been used for the 
production of different products there is extensive empirical knowledge on how a new process 
based on this cell factory can be scaled-up. 
• Fundamental research on the cell factory pays off, as it may impact several different processes. 
Furthermore, deeper insight into the function of the cell factory is gained through fundamental 
research, and this enables even wider use of the cell factory for industrial production. 
• It may be easier to obtain process (and product) approval when cell factories that are already 
well implemented are applied. 
So far in most of the metabolic engineering studies for microbial production of isoprenoids, E. 
coli or the yeast S. cerevisiae have been exploited as the host cells and both of them 
demonstrated suitability as host platform for the biosynthesis of isoprenoid precursors. These 
two organisms exhibit several advantages including availability of sequences of their genomes, a 
plenty of molecular biology tools for the genetic manipulation of cells, and extensive 
physiological studies on these organisms. Although metabolic engineering tools are available for 
both organisms, E. coli still remains more amenable for genetic modifications. Faster growth of 
E. coli is another advantage compared to S. cerevisiae which makes it more economical in 
industrial fermentation. On the other hand, yeast is generally regarded as safe which is a benefit 
with regards to social concerns and also makes the approval of both product and process easier 
and faster.  
However, the final choice of microbial host will depend mainly on the type of product and the 
downstream reactions for the complete biosynthesis of the desired compound. Modifying 
reactions of the terpene scaffold, such as hydroxylation, lactonization, epoxidation, oxidation and 
reduction, halogenation, acetylation, and glucosylation are of crucial importance for imparting 
chemical properties that correlate with biological activities of the final isoprenoid products 
(Takahashi et al., 2007). Thus, biosynthesis of many of the commercial isoprenoids such as 
Taxol and artemisinin requires several modifications in the structure of their precursors through 
one or several of the mentioned downstream reactions. Therefore, for the biosynthesis of plant 
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isoprenoids, S. cerevisiae is considered as a superior host as it provides the biosynthetic 
machinery for the proper functioning of the downstream modifying enzymes and also has less 
natural codon bias (Takahashi et al., 2007; Chang and Keasling, 2006). 
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Chapter 2 
Analytical platform for characterization of sesquiterpene 
producing yeast strains 
 
2.1 Introduction 
Metabolic engineering is a systematic and rational approach for improving cellular phenotypes 
using directed application of recombinant DNA technology tools for strain improvement 
(Stephanopulos et al., 1998). Metabolic engineering is a continuous process in which the 
phenotype of interest is improved in several rounds of modifications until the desired phenotype 
is obtained. Therefore, metabolic engineering can be considered as a cycle including three main 
steps (synthesis, analysis, and design) as illustrated in Figure 2.1 (Nielsen, 2001). 
Depending on the phenotype of interest, the cycle can be started from different steps. As such, 
for heterologous production of a metabolite in a microbial host, as it is the case for our study 
(heterologous production of sesquiterpenes in yeast), it is necessary to start from the synthesis 
step. However, in order to improve the cell factory for higher productivity or yield of the 
product, the strains and the pathways involved in the biosynthesis of the product need to be 
analyzed (Nielsen, 2001). Therefore, developing an analytical platform for characterizing strains 
and analyzing the products is of crucial importance. 
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Figure 2.1. The cycle of metabolic engineering (Adopted from Nielsen, 2001) 
 
In this study, we have developed an experimental set up for the characterization of sesquiterpene 
producing yeast strains. This system is based on a two-phase fermentation where an organic 
solvent forms the secondary phase and the sesquiterpenes excreted into the medium are 
immediately collected in the organic layer.  
 
2.2 Materials and methods 
2.2.1 Strains and plasmids 
The genes encoding valencene synthase (GFTpsD, GenBank accession No. CQ813508) and 
cubebol synthase (GFTpsC, GenBank accession No. CQ813505) were amplified from cloning 
vectors containing these genes. The PCR conditions were in accordance with the Expand High 
Fidelity standard conditions (Roche Applied Science, Mannheim, Germany). Subsequently, the 
PCR fragments were digested by the restriction enzymes EcoRI and NheI. In parallel, pYX212 
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plasmid (Ingenius, Wiesbade, Germany) was digested by the same couple of restriction enzymes. 
The DNA fragments were separated by gel electrophoresis and gel purified using the QIAEX® II 
Gel extraction kit (Qiagen, Hilden, Germany). 
In vitro ligation of the digested plasmid with the digested PCR products was performed as the 
standard procedure given for T4 DNA ligase (Roche Applied Science, Mannheim, Germany). 
The resulting ligation mix was used to transform chemically competent E. coli cells (DH5α) 
(Inoue et al, 1990). Transformants were selected on LB medium supplemented with ampicillin 
(50 mg/L). The constructed plasmids containing GFTpsD and GFTpsC were named pIP031 and 
pIP032, respectively. 
Transformation of the yeast strain CEN.PK113-5D (MATa MAL2-8c SUC2 ura3-52) with either 
pIP031 or pIP032 led to the strains YIP-0V-01 and YIP-0C-01, respectively.  
 
2.2.2 Media for shake flasks 
Baffled, cotton-stopped, 500 ml Erlenmeyer flasks were used for preparing precultures and also 
for investigating the effect of different organic solvents on growth. The shake flasks contained 
100 ml medium with the following composition: 7.5 g/L (NH4)2SO4; 14.4 g/L KH2PO4; 0.5 g/L 
MgSO4.7H2O; 2 ml/L trace metal solution; and 50 µl/L synperonic antifoam (Sigma, St. Louis, 
MO). The pH of mineral medium was adjusted to 6.50 by adding 2M NaOH and autoclaved 
separately from the carbon source solution. Vitamin solution was filter sterilized and aseptically 
added to the medium after autoclaving at the concentration of 1 ml/L. Shake flasks were 
incubated in a shaking incubator at 30 ºC and 150 rpm. Organic solvents were added in a 10% 
(v/v) ratio to the shake flasks. 
 
2.2.3 Media for batch cultivations 
A defined minimal medium as described by Verduyn et al. (1992) containing 20 g/L of either 
glucose or galactose as the sole carbon source was used for all batch fermentations. The medium 
had the following composition: 5 g/L (NH4)2SO4; 3 g/L KH2PO4; 0.5 g/L MgSO4.7H2O; 1 ml/L 
trace metal solution; 1 ml/L vitamin solution and 50 µl/L synperonic antifoam.  
Glucose and galactose were autoclaved separately from the medium and subsequently added to 
the fermenter, as was the case for the vitamin solution that was added after filter sterilization.  
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2.2.4 Batch fermentations 
Batch fermentations were carried out in well-controlled 5 L in-house manufactured glass 
bioreactors with a working volume of 4 L. The bioreactors were equipped with two disk-turbine 
impellers and 4 baffles to ensure proper mixing. The pH was controlled between 4.95 and 5.05 
by automatic addition of 2M NaOH. The temperature was kept constant at 30 ºC.  The air flow 
was 4 L/min (1 vvm) and was sterilized by filtration and the off gas passed through a condenser.  
 
2.2.5 Liquid-liquid extraction (LLE) 
Valencene and cubebol from culture aliquots of 1 ml were extracted with an equal volume of 
hexane. Extraction was performed in glass vials and mixture was vortexed for 2 min. After 
equilibration and phase separation, the hexane extract was analyzed using GC-MS. The hexane 
extract was concentrated under a gentle nitrogen
 
stream prior to GC-MS analysis. 
 
2.2.6 Collection of sesquiterpenes from off-gas using adsorbent tubes 
Sesquiterpenes from the fermenter off-gas were collected either in glass tubes containing coconut 
charcoal as adsorbent (SKC, 8 × 110 mm, 2-section, 200/400 mg sorbent) or in stainless steel 
Perkin Elmer (PE) tubes filled with 200 mg of Tenax-TA adsorbent material. PE tubes were 
conditioned before use by heating to 300 ºC for 1 h while being purged with approximately 10 
ml/min nitrogen (purity > 99.999%).  
In order to collect sesquiterpenes carried with the off-gas, adsorbent tubes were connected to the 
outlet gas tube from fermenter (with both ends open). A gas drier tube (W.A. Hammond Drierite, 
Xenia, OH) was placed before the adsorbent tubes to remove trace humidity in the outlet air. 
Adsorbent tubes were replaced with new tubes and analyzed every two hours. Thus, the total 
amounts of sesquiterpenes carried with the off-gas were the sum of all analyses.  
Sesquiterpenes trapped on the SKC tubes were extracted with 2 ml hexane and allowed to stand 
with occasional shaking for 30 min. The sesquiterpenes in the hexane extract were detected and 
analyzed with GC-MS.  
Sesquiterpenes trapped on PE tubes were thermally desorbed on a Perkin-Elmer ATD 400 
coupled to a Hewlett-Packard 5890 gas chromatograph further coupled to a HP 5972 mass 
spectrometer. Sesquiterpenes were separated on a VB-5 ValcoBond capillary column (SIS, 
Ringoes, NJ) using He as carrier gas. Initial pressure was 13 psi, and the He flow rate was 1 
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ml/min. The system was run in a split (75:1) mode and the injection temperature was set to 250 
ºC. The initial oven temperature was 35 ºC. After 1 min, the oven temperature was raised to 175 
ºC at the ramp of 4 ºC/min and then to 260 ºC at the ramp of 10 ºC/min. Mass spectra were 
recorded at 70 eV, scanning from m/z 33 to 330. 
 
2.2.7 Analysis of sesquiterpenes by solid phase microextraction (SPME) method 
Identification of sesquiterpenes produced by the yeast strains transformed with heterologous 
sesquiterpene synthases was performed by extracting volatile compounds from the head-space of 
the samples on 100 µm polydimethyl siloxane (PDMS) fibers (Supelco, Bellefonte, PA, USA). 
Fibers were conditioned according to the suppliers’ instruction. Two ml samples from the culture 
media were immediately frozen and stored in 4 ml screw cap glass vials at -20 ºC until analysis. 
The contents of vials were thawed on ice and allowed to equilibrate at room temperature. 
Extraction was performed for 25 min at 60 ºC while mixing the sample with a small magnet. 
After extraction, the analytes were thermally desorbed at 250 ºC from SPME fiber into the 
injector of gas chromatogram in the splitless mode. The oven temperature was held initially at 45 
ºC for 1 min, then raised to 130 ºC by a ramp of 10 ºC/min followed by a ramp of 3 ºC/min to 
160 ºC. The oven temperature was further raised to 250 ºC at 10 ºC/min and maintained at this 
temperature for 5 min to equilibrate.  
 
2.2.8 Analysis of sesquiterpenes in the organic phase  
Samples from organic layer (obtained either from LLE of culture aliquots or from two-phase 
fermentations) were analyzed by GC-MS to determine the level of sesquiterpenes. GC-MS 
analyses were run on a Thermo Finnigan Focus GC coupled to a Focus DSQ quadrupole mass 
spectrometer. Analytes from 1 µl samples were separated on a SLB-5ms capillary column (30 m 
× 0.25 mm i.d., 0.25 µm film thickness; Supelco, Bellefonte, PA, USA) using He as carrier gas at 
the flow rate of 1.2 ml/min. A split/splitless injector was used in the splitless mode. The initial 
oven temperature was 80 ºC (50 ºC for samples obtained from LLE), and injector temperature 
was 250 ºC. After 1 min, the oven temperature was increased to 120 ºC at the rate of 10 ºC/min 
and subsequently increased to 160 ºC at the rate of 3 ºC/min. The oven temperature was finally 
increased to 270 ºC at the rate of 10 ºC/min and held for 5 min at this temperature. When 
necessary, to increase the sensitivity, the MS was run in selected ion monitoring (SIM) mode 
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using ions of m/z 133, 161, and 204 (for valencene) and 161, 207, and 222 (for cubebol) which 
represent the molecular ions and two abundant ions for these sesquiterpenes. 
Quantification of compounds was carried out using standard curves generated after each analysis 
run.    
 
2.2.9 Analysis of glucose and ethanol 
To determine the concentration of glucose and ethanol in the culture media, 2 ml samples were 
withdrawn from the fermenter and immediately filtered through a 0.45 µm pore-size cellulose 
acetate filter (Sartorius AG, Göttingen, Germany).  The filtrate was stored at -20 ºC until HPLC 
analysis. Glucose and ethanol concentrations were determined in a Waters 717 plus Autosampler 
HPLC system equipped with a Bio-Rad Aminex HPX-87H reverse phase column (Biorad, 
Hercules, CA) at 60 ºC using 5 mM H2SO4 as mobile phase at a flow rate of 0.6 ml/min. Glucose 
and ethanol were detected refractometrically (Waters 410 Differential Refractometer Detector, 
Millipore Corp., Milford, MA).  
 
2.3 Results 
2.3.1 Extraction of sesquiterpenes by LLE 
Sesquiterpenes are very hydrophobic compounds and therefore extraction of the excreted 
sesquiterpenes from the culture by an organic solvent like hexane seemed to be the method of 
choice. However, it was very difficult to detect peaks for valencene and cubebol in the hexane 
extracts and the extracts needed to be upconcentrated several-fold. Low concentration of 
sesquiterpenes produced by the yeast strains could be due to poor expression of plant 
sesquiterpene synthases (Martin et al., 2001).  
 
2.3.2 SPME is a more powerful method for extraction and concentration of sesquiterpenes 
The low concentration of sesquiterpenes in the culture made it necessary to use more sensitive 
techniques for their analysis. SPME, introduced in the early 1990s (Arthur and Pawliszyn, 1990; 
Zhang and Pawliszyn, 1993), was used as a powerful alternative method to the traditional LLE.  
In this study, we used 100 µm PDMS fibers for extraction of sesquiterpenes from the culture. 
The optimum extraction temperature and exposure time were found by extraction of valencene 
and cubebol standards spiked into water at different time periods and temperatures. Thus, the 
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optimum temperature and exposure time were found to be 60 ºC and 25 min, respectively. 
Addition of salt did not improve the extraction efficiency as these two compounds are already 
highly hydrophobic.  
Extraction of sesquiterpenes from the fermentation medium using SPME and their analysis with 
GC-MS gave rise to very nice peaks and large peak areas compared to those obtained with the 
LLE method proving the capability and sensitivity of the SPME method for sample preparation. 
However, we noticed that the sesquiterpene concentration in the fermentation medium increased 
as cells grew and reached to a maximum but afterwards a drastic drop in the concentration was 
observed (Figure 2.2). This rapid decrease in the sesquiterpene concentration could be due to loss 
of these compounds through the off-gas. Martin et al. (2003) also observed loss of amorphadiene 
to the headspace in cultures inoculated with engineered amorphadiene producing E. coli strains. 
To assess if the loss of sesquiterpenes was a consequence of evaporation into the gas phase, a 
fermenter containing distilled water was spiked with standard valencene and the valencene 
concentration in the water phase was measured as a function of time in the presence or absence 
of agitation and aeration using SPME-GC-MS (Figure 2.3). The results clearly show that 
valencene has a high partitioning into the gas phase which is greatly accelerated by agitation and 
aeration. 
 
0.E+00
2.E+08
4.E+08
6.E+08
8.E+08
0 10 20 30 40 50
Time (h)
Cu
be
bo
l (P
ea
k 
Ar
ea
)
 
Figure 2.2. Sesquiterpene concentrations measured by SPME-GC-MS as a function of time for 
(a) YIP-0V-01 and (b) YIP-0C-01  
Cells were grown on 4 L ml minimal medium containing 20 g/L glucose in 5 L batch fermenters. 
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Figure 2.3. The ratio of valencene concentration at different time points to its initial 
concentration in the fermenters containing distilled water spiked with standard valencene (a) No 
aeration and no agitation (b) No aeration, agitation: 700 rpm (c) Aeration: 1 vvm, no agitation (d) 
Aeration: 1 vvm, Agitation: 700 rpm 
 
2.3.3 Trapping sesquiterpenes from the off-gas 
Substantial loss of valencene and cubebol through the off-gas is a major problem for 
characterization of engineered sesquiterpene producing yeast strains. Characterization of strains 
for sesquiterpene production requires measurement of total produced sesquiterpenes and 
therefore the lost sesquiterpenes in the off-gas need to be somehow collected and analyzed. We 
examined different methods for collecting sesquiterpenes from the off-gas.  
The fermenter off-gas was first passed through the PE tubes filled with Tenax-TA adsorbent. By 
desorbing the trapped compounds using an automatic thermal desorber coupled to a GC-MS, it 
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was possible to detect the sesquiterpenes peaks. However, quantification of the lost compounds 
required making suitable standard curves which was very difficult as sampling was done from 
gas phase and no solvent was used for desorbing the collected compounds.  Therefore we tested 
the glass tubes filled with coconut charcoal in two separate zones to ensure complete collection 
of all compounds in the gas phase. By extracting the desorbed compounds from each zone into 
hexane and making standard curve it was possible to quantify the lost sesquiterpenes. However, 
the collected sesquiterpenes on the adsorbent was only a fraction of the lost compounds and the 
adsorbent was not able to collect all the sesquiterpenes. This could be because the trace humidity 
in the air flow made the adsorbent matrix wet and sticky and prevented total adsorption onto the 
adsorbent. Although this problem was circumvented by using gas drier tubes before the 
adsorbent tubes, there was a risk that the sesquiterpenes were retained on the drying material. 
Hence, instead of passing the off-gas through adsorbent tubes, we decided to pass it through an 
organic solvent and analyze the organic solvent for the presence of sesquiterpenes. The organic 
solvent was upconcentrated and analyzed by GC-MS. This method also allowed detection and 
quantification of the sesquiterpenes in the gas phase but again the trapped sesquiterpene in the 
organic solvent was only a fraction of the total lost sesquiterpene. Since sesquiterpenes are very 
hydrophobic and they have to pass through the condenser, outlet air filter and silicon tubes 
before entering the adsorbent tubes or organic solvent, we speculated that most of the 
sesquiterpenes were bound to the air filter, silicon tubes or other parts of the fermenter before 
getting to the collection units.  
 
2.3.4 In situ separation of sesquiterpenes from the culture media 
Considering all the practical problems faced for collection of the lost sesquiterpenes from the 
off-gas, the best solution for quantification of the produced sesquiterpenes would be to use in situ 
separation from the fermentation medium before they are evaporated into the gas phase. This can 
be achieved by two different methods: addition of adsorbent resins directly to the culture for 
separation of hydrophobic compounds or trapping the sesquiterpenes into a secondary organic 
phase which is added to the fermenter.  
Synthetic adsorbent resins are highly porous spherical crosslinked polymer particles with no ion-
exchange or functional groups that adsorb organic compounds on the surface due to hydrophobic 
interactions. These resins were successfully used for separation of pigments (Bae et al., 2001) 
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and epi-cedrol (Jackson et al., 2003) from culture media. However, desorption of compounds 
from resins is time consuming and involves several steps of extraction and concentration before 
they can be analyzed. Furthermore, utilizing these resins only allows measurement of final 
sesquiterpene titer and it is not possible to follow the concentration profile throughout a 
fermentation process. In situ separation of sesquiterpenes can alternatively be achieved using a 
two-phase fermentation where the secondary phase is an organic phase that traps the released 
sesquiterpenes quickly. Selection of an appropriate solvent is the key driver for successful 
operation of a two-phase fermentation. We first identified three different organic solvents 
(diisononyl phthalate, oleyl alcohol, and dodecane) which seemed to have suitable characteristics 
(biocompatibility, immiscibility, and low volatility) and investigated their applicability in two-
phase fermentations in shake flasks with S. cerevisiae. None of these solvents had significantly 
detrimental effects on the specific growth rate (Figure 2.4). However, phase separation was faster 
and clearer when dodecane was the organic solvent, and this solvent was therefore chosen for the 
subsequent experiments. The effect of dodecane on the growth was further examined in a 5 L 
batch fermenter, and it was found not to have any negative effects on cell growth (Figure 2.5). 
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Figure 2.4. Growth pattern of YIP-0V-01 strain in the presence of 10% (v/v) different organic 
solvents; No solvent: ●; Diisononyl phthalate: ; Dodecane: ○; Oleyl alcohol:   
Cells were cultivated in shake flasks containing 100 ml minimal medium and 15 g/L glucose. 
Organic solvent was added aseptically at OD=1 ± 0.1. 
CHAPTER 2      Analytical platform for characterization of sesquiterpene producing yeast strains 
 55 
Time (h)
0 30 35 40 45 50 55 60 65
O
D
60
0 
n
m
0
5
10
15
20
25
30
35
40
 
Figure 2.5. Growth pattern of YIP-0V-01 with () and without (▲) dodecane. 
Cells were grown on 4 L ml minimal medium containing 20 g/L galactose in 5 L batch 
fermenters. 300 ml dodecane was added aseptically at OD=1 ± 0.1. 
 
YIP-0C-01 strain was then characterized in two-phase 5 L batch fermenters containing 4 L 
minimal medium and 20 g/L glucose. Samples were taken from the organic phase and culture 
medium at different times and were analyzed for sesquiterpene, biomass, glucose and ethanol. 
Time-course analysis (Figure 2.6) showed collectively accumulation of sesquiterpenes in the 
dodecane phase as cells were growing and proved the potential of this system for capturing the 
hydrophobic sesquiterpenes. No drop in sesquiterpene concentration was observed even after 
depletion of all the carbon sources. At the end of fermentation a sample from the aqueous phase 
was analyzed by SPME-GC-MS to check the presence of sesquiterpenes in the aqueous phase. 
However no sesquiterpenes were detectable reflecting the high partition coefficient of these 
compounds into the dodecane phase. It was therefore concluded that two-phase fermentations 
using dodecane as organic phase presents a suitable platform for characterization of 
sesquiterpene producing yeast strains.  
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Figure 2.6. Cubebol, glucose, ethanol and OD600 as a function of time for YIP-0C-01 strain. 
Cells were grown on 4 L ml minimal medium containing 20 g/L glucose in 5 L batch fermenters. 
300 ml dodecane was added aseptically at OD=1 ± 0.1. 
 
 
2.4 Discussion 
Towards establishment of yeast as a platform for production of sesquiterpenes, yeast strains were 
transformed with valencene synthase and cubebol synthase and were shown to produce these two 
sesquiterpenes by their extraction from culture media with hexane followed by GC-MS analysis. 
However, the sesquiterpene concentration in the culture was very low and the hexane extract had 
to be upconcentrated many folds. SPME is a solvent-free sample preparation technique in which 
a fine silica fiber coated with a thin layer of a selective coating is exposed either into the 
headspace above the sample or directly into the sample to extract and concentrate organic 
compounds. After equilibration has reached between the fiber and analytes, the SPME fiber is 
readily introduced into the injection port of the GC instrument for thermal desorption. Thus, 
SPME integrates extraction, concentration and sample introduction steps into a single step. 
Although SPME is not based on exhaustive extraction of compounds, all the extracted analytes 
are transferred to the analytical instrument which improves the sensitivity compared to the 
traditional LLE method where only a small portion of the analyte is injected. Extraction of 
sesquiterpenes from fermentation media by SPME followed by GC-MS presented a suitable 
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method for detection of even trace amounts of sesquiterpenes. Nonetheless, this method was not 
chosen for characterization of strains since a dramatic decrease in the sesquiterpene 
concentration was observed during fermentation. Analysis of water spiked with standard 
valencene in a fermenter confirmed the rapid loss of valencene through the gas phase. However, 
with the high boiling point of valencene which is 274 ºC at atmospheric pressure the question 
arises how valencene can behave as a volatile compound. Since valencene is highly hydrophobic, 
it is sparingly soluble in water and therefore its partial pressure in the gas phase is calculated 
from Henry’s law equation for dilute solutions:  
valvalval cHp =
∗
 
where ∗valp is the partial pressure of valencene in the gas phase, valH is Henry’s law constant for 
valencene, and valc  is the valencene concentration in the aqueous phase.  
The partial pressure of valencene in the gas phase is therefore highly dependent on its Henry’s 
law constant. This constant has not been reported for valencene in the literature but isoprene and 
monoterpenes have very high Henry’s law constant (Niinemets and Reichstein, 2003). For 
instance, the reported values for isoprene and α-pinene are 7780 and 10840 Pa m3 mol-1, 
respectively, whereas it is only 3.88 Pa m3 mol-1 for acetone (boiling point 56.3 ºC). Humulene 
which is a sesquiterpene has a Henry’s law constant of 16500 Pa m3 mol-1 (Jürgens et al., 2007). 
These large Henry’s law constants indicate big deviations from ideal solution behavior and 
presence of a high partial pressure in the gas phase for these compounds despite their high 
boiling points and low concentrations in the water phase. This could explain why valencene 
molecules partition into the gas phase at a high rate. It is noteworthy that this partitioning is only 
due to interaction of valencene with water molecules which makes their mixture a very non-ideal 
solution. Therefore volatility is not the correct word to describe the reason for loss of valencene 
from the water phase, even though valencene (Lücker et al., 2004) and generally sesquiterpenes 
(Tamogami et al., 2007) are commonly referred to as volatiles in the literature. This mechanism 
of moving valencene molecules from the liquid phase to the gas phase holds true if the valencene 
concentration in water is below its solubility limit. If valencene concentration exceeds this limit 
then the extra valencene forms a new phase and other mechanisms could also contribute to its 
loss to the gas phase as well. In this case, if there is no mixing and aeration, since valencene has 
lower density than water, it forms a layer on top of the mixture and evaporation mainly occurs 
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from this pure layer of valencene which would be very low compared to its loss when it is 
dissolved in water. If the mixture is disturbed by aeration or agitation, besides evaporation of 
valencene from solution, the undissolved valencene which is now dispersed in water would also 
be stripped into the gas phase in the form of aerosols.  
To evaluate total sesquiterpene production by these strains, we next sought to analyze the loss of 
sesquiterpenes in the gas phase by trapping them in either adsorbent tubes (Tenax-TA or coconut 
charcoal) or in an organic solvent. Even though we were able to detect sesquiterpenes by both 
methods, practical problems such as difficulties in making a good standard curve (for the case of 
PE tubes containing Tenax-TA), adhesion of adsorbents because of humidity in the outlet air, 
and adsorption of sesquiterpenes onto different parts of the fermenter before entering the 
collection unit, none of these methods were chosen for further experiments.  
In a further attempt, we tested in situ separation of sesquiterpenes in a two-phase fermentation 
and showed that this method can be used for analyzing the total produced sesquiterpenes and 
therefore is suitable for characterization of strains. Two-phase fermentation has been 
successfully used for in situ separation of products (Frenz et al., 1989; Sim et al., 2001) and also 
for controlled substrate delivery for biodegradation of toxic substrates where high concentration 
of substrate could kill or inhibit the microorganisms (Collins and Daugulis, 1999). All three 
tested solvents were appropriate for using in a two-phase fermentation with yeast but dodecane 
was chosen as its phase separation was faster and more distinct and also because it has been used 
as an oxygen vector for improving oxygen transfer in fermenters (Rols et al., 1990). Two-phase 
fermentation using dodecane as the organic phase demonstrated a suitable platform for 
characterization of sesquiterpene producing yeast strains and enabled collection and analysis of 
all the produced sesquiterpenes. No loss of sesquiterpenes was observed even after depletion of 
all the carbon sources and cessation of growth. This proposes that the loss of sesquiterpenes did 
not occur because of their degradation in the culture medium. Moreover, constant level of 
sesquiterpenes at the end of fermentation suggests a low Henry’s law constant for these 
compounds in dodecane and further proves that these compounds are not volatile and their loss 
through the gas phase was mainly due to their interaction with water molecules at low 
concentration.  
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Chapter 3 
Effect of ERG9 repression on sesquiterpene biosynthesis in 
yeast 
 
3.1 Introduction 
Tens of thousands of metabolites including isoprenoids, alkaloids, phenylpropanoids and all 
allied phenylic compounds are synthesized by plants (Croteau et al., 2000). The isoprenoids with 
more than 40,000 described examples (Withers and Keasling, 2007) comprise the largest and 
most structurally diverse group of plant metabolites. Sesquiterpenes are the most diverse class of 
isoprenoids with more than 300 identified carbon skeletons (Cane, 1999) and more than 7,000 
characterized compounds (Connolly and Hill, 1991). Sesquiterpenes play numerous important 
ecological roles in plants e.g. in pollinator attraction, as phytoalexins and antifeedants (Harborne, 
1991).  
From an industrial point of view, sesquiterpenes are interesting compounds because of their 
potent anticancer, antitumor, cytotoxic, antiviral and antibiotic properties as well as their 
characteristic flavors and aromas. Most sesquiterpenes are constituents of plant essential oils, but 
extraction from plants is not a suitable method for large scale production of many sesquiterpenes. 
Furthermore, using plants as resources for industrial production of sesquiterpenes include slow 
growth, varying composition and concentration depending on the geographical position and 
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climate conditions. There is therefore much interest in using microorganisms as cell factories for 
the production of isoprenoids. The intracellular pools of isoprenoid precursors in microorganisms 
appear, to be however, not enough to provide high level production. It may therefore be 
necessary to deregulate the pathways involved in the biosynthesis of isoprenoid precursors in 
order to improve production (Kim and Keasling, 2001, Martin et al., 2003; Pitera et al., 2007). In 
the last decade numerous studies have been conducted with regard to engineer microorganisms 
for the production of different isoprenoids (for review see Maury et al., 2005).  In most studies, 
E. coli has been used as the microbial platform for metabolic engineering of isoprenoid 
production (Alper et al., 2005; Carter et al., 2003; Martin et al., 2001). However, in some cases 
the mevalonate pathway in yeasts has been deregulated to improve the biosynthesis of different 
isoprenoids (DeJong et al., 2006; Jackson et al., 2003; Miura et al., 1998a; Miura et al., 1998b; 
Shimada et al., 1998; Yamano et al., 1994; Verwaal et al., 2007; Takahashi et al., 2007; Ro et al., 
2006). In S. cerevisiae the mevalonate pathway is the only pathway involved in the biosynthesis 
of isoprenoid precursors. This pathway leads to the formation of ergosterol as the end product of 
the pathway, the content of which in S. cerevisiae can reach 5% of the dry weight (Lamačka and 
Šajbidor, 1997). Yeast therefore has a high inherent capacity for the biosynthesis of isoprenoid 
precursors that may be directed to the production of heterologous compounds.  
In this study, we chose S. cerevisiae as a host cell for heterologous production of three different 
plant sesquiterpenes namely valencene, cubebol and patchoulol. These three compounds are 
derived directly in a single enzymatic step from FPP, the biological precursor for all 
sesquiterpenes. In the case of ergosterol, FPP is converted to squalene by squalene synthase, 
which is encoded by the ERG9 gene. In order to increase the level of FPP and direct flux towards 
sesquiterpenes an obvious strategy is to attenuate the expression of the ERG9 gene. Since 
ergosterol is vital for yeast growth and yeast is unable to assimilate exogenous ergosterol during 
aerobic growth conditions, this gene can not be completely deleted. We therefore controlled the 
ERG9 expression by using the MET3 promoter (Gardner and Hampton, 1999; Mountain et al., 
1991) to drive the expression of ERG9. This strategy has been successfully reported to increase 
2-fold the final titer of amorphadiene in an engineered yeast strain (Ro et al., 2006). 
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Characterization of engineered yeast strains was performed in two-phase batch fermenters using 
dodecane as the secondary phase. This allowed in situ separation of released sesquiterpenes 
before they are lost through the off-gas. 
 
3.2 Materials and methods 
3.2.1 Cloning of MET3 promoter 
The MET3 promoter was amplified from genomic DNA of S. cerevisiae CEN.PK 113-7D using 
the primers Met3pf_bis and Met3pr_bis (Table 3.1). The PCR conditions were in accordance 
with the Expand High Fidelity standard conditions (Roche Applied Science, Mannheim, 
Germany). Subsequently, the PCR fragments were digested by the restriction enzymes SpeI and 
SacII. In parallel, pUG6 plasmid (Güldener et al., 1996) was digested by the same couple of 
restriction enzymes. The DNA fragments were separated by gel electrophoresis and gel purified 
using the QIAEX® II Gel extraction kit (Qiagen, Hilden, Germany). 
In vitro ligation of the digested plasmid with the digested PCR products was performed as the 
standard procedure given for T4 DNA ligase (Roche Applied Science, Mannheim, Germany). 
The resulting ligation mix was used to transform chemically competent E. coli cells (DH5α) 
(Inoue et al., 1990). Transformants were selected on LB medium supplemented with ampicillin 
(50 mg/L). The plasmid obtained was named pIP007. 
 
3.2.2 ERG9 promoter replacement by MET3 promoter 
In order to replace the ERG9 promoter by the MET3 promoter, fusion PCR and a bipartite gene 
targeting method (Erdeniz et al., 1997) were applied. Four fragments were separately amplified 
before fusing them together in pairs. First, two fragments containing the MET3 promoter and the 
KanMX selection cassette were amplified from pIP007 in two separate, but overlapping, 
fragments using the two couples of primers (Table 3.1):  pUG6met3f/ KanMXr (Fragment A) 
and  KanMXf/ pUG6met3r (Fragment B). Furthermore, 500 bp upstream of the ERG9 promoter 
in the genome of S. cerevisiae were amplified using the primers ERG9_up_f and ERG9_up_r 
(Fragment C). The first 500 bp of the ERG9 ORF were as well amplified using the primers 
ERG9f and ERG9r (Fragment D). 
The resulting four PCR fragments were gel purified using the High Pure PCR Product 
Purification kit (Roche Applied Science) and subsequently fused together in pairs using fusion 
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PCR. Fused fragments A and C were obtained after a fusion PCR using the primers ERG9_up_f 
and KanMXr while fused fragments B and D were obtained after a fusion PCR using the primers 
KanMXf and ERG9r (Table 3.1). The two final fusion PCR fragments were gel purified with the 
High Pure PCR Product Purification kit (Roche Applied Science). 
 
3.2.3 Strain construction 
Strain S. cerevisiae YIP-0V-01, obtained by transformation of strain YIP-00-03 with the plasmid 
pIP031 (plasmid obtained by cloning GFTpsD in pYX212 using EcoRI and NheI restriction 
sites) was transformed with the obtained fusion PCR fragments to result in strain YIP-MV-02. 
Strain YIP-M0-04 was obtained after exclusion of plasmid pIP031 from strain YIP-MV-02 by 
selection on plates containing 5-fluoroorotic acid (5-FOA). Strains YIP-MC-02, YIP-MV-01 and 
YIP-MP-01 were obtained after transformation of strain YIP-M0-04 with either pIP032 
(obtained by cloning GFTpsC into pYX212 using EcoRI and NheI restriction sites), pIP027 
(obtained by cloning GFTpsD into pESC-URA using AgeI and SacII restriction sites) or pIP029 
(obtained by cloning PatTps177 into pESC-URA using BamHI and XhoI restriction sites), 
respectively. 
Transformation of strain YIP-00-03 with either pIP032, pIP013 (obtained by cloning of GFTpsC 
into pESC-TRP by gap repair using the two primers Gap_Trp_f and Gap_Trp_r (Table 3.1)), 
pIP027 or pIP029 led to the strains YIP-0C-01, YIP-0C-02, YIP-0V-02 and YIP-0P-02, 
respectively. Table 3.2 demonstrates the strains used in this study. 
Sequences of the genes GFTpsD (valencene synthase), GFTpsC (cubebol synthase) and 
PatTps177 (patchoulol synthase) can be obtained from GenBank: accession numbers CQ813508, 
CQ813505 and AY508730, respectively. 
 
3.2.4 Media for shake flasks 
Baffled, cotton-stopped, 500 ml Erlenmeyer flasks were used for preparing precultures and also 
for preparing samples for ergosterol measurement. The shake flasks were containing 100 ml 
medium with the following compositions: 7.5 g/L (NH4)2SO4; 14.4 g/L KH2PO4; 0.5 g/L 
MgSO4.7H2O; 2 ml/L trace metal solution; 1 ml/L vitamin solution and 50 µl/L synperonic 
antifoam (Sigma® A-5551). The pH of mineral medium was adjusted to 6.50 by adding 2M 
NaOH and autoclaved separately from carbon source solution. Vitamin solution was filter 
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sterilized and aseptically added to the medium after autoclavation. Shake flasks were incubated 
in a shaking incubator at 30 ºC and 150 rpm. 
 
3.2.5 Media for batch cultivations 
A defined minimal medium as described by Verduyn et al. (1992) containing 20 g/L of either 
glucose or galactose as the sole carbon source was used for all batch fermentations. The media 
had the following compositions: 5 g/L (NH4)2SO4; 3 g/L KH2PO4; 0.5 g/L MgSO4.7H2O; 1 ml/L 
trace metal solution; 1 ml/L vitamin solution and 50 µl/L synperonic antifoam. Expression of 
ERG9 was repressed by supplementing media with 2 mM filter sterilized methionine. 
Glucose and galactose were autoclaved separately from the medium and subsequently added to 
the fermenter, as was the case for the vitamin solution that was added after filter sterilization. 
 
Table 3.1. Primers used in this study  
Primer Sequence 
Met3pf_bis ggactagtcctTGGTATAAGGTGAGGGGGTCCACAG 
Met3pr_bis tccccgcggggaGAATACCACCGTGAGGAGCAGGCATG 
pUG6met3f gatccccgggaattgccatgACGCTGCAGGTCGACAACCC 
pUG6met3r caatgccaattgtaatagcttcccatGTTAATTATACTTTATTCTTGTTATTATTATAC 
KanMXf CTATCGATTGTATGGGAAGCCCG 
KanMXr CCATGAGTGACGACTGAATCCGG 
ERG9_up_f AGCCTCAGTACGCTGGTACCCG 
ERG9_up_r catggcaattcccggggatcTGGGCTATGAAATGTACTGAGTCAG 
ERG9f ATGGGAAAGCTATTACAATTGGCATTG 
ERG9r GTCGTAGTCGTGGACGGTTTGC 
Gap_Trp_f ATACTTTAACGTCAAGGAGAAAAAACCCCGGATCCCGTTatggcacttcaagattcaga 
Gap_Trp_r TCTTCTTCGGAAATCAACTTCTGTTCCATGTCGACGCTtcaaaagggaacaggcttct 
 
  
 
    
Table 3.2. Strains used in this study 
    Strain Genotype Plasmid Plasmid description 
    YIP-00-03 (CEN.PK113-5D) MATa MAL2-8c SUC2 ura3-52 none  
YIP-0C-01 MATa MAL2-8c SUC2 ura3-52 pIP032 pYX212 2µ URA3 PTPI1-GFTpSC 
YIP-0C-02 MATa MAL2-8c SUC2 trp1-289 pIP013 pESC-TRP 2µ TRP1 PGAL1-GFTpSC 
YIP-0P-02 MATa MAL2-8c SUC2 ura3-52,  pIP029 pESC-URA 2µ URA3 PGAL1- PatTps177 
YIP-0V-01 MATa MAL2-8c SUC2 ura3-52 pIP031 pYX212 2µ URA3 PTPI1-GFTpSD 
YIP-0V-02 MATa MAL2-8c SUC2 ura3-52 pIP027 pESC-URA 2µ URA3 PGAL1- GFTpSD 
YIP-M0-04 
MATa MAL2-8c SUC2 ura3-52, 
erg9 ::PMET3-ERG9 
none  
YIP-MC-02 
MATa MAL2-8c SUC2 ura3-52, 
erg9 ::PMET3-ERG9 
pIP032 pYX212 2µ URA3 PTPI1-GFTpSC 
YIP-MP-01  
MATa MAL2-8c SUC2 ura3-52, 
erg9 ::PMET3-ERG9 
pIP029 pESC-URA 2µ URA3 PGAL1- PatTps177 
YIP-MV-01 
MATa MAL2-8c SUC2 ura3-52, 
erg9 ::PMET3-ERG9 
pIP027 pESC-URA 2µ URA3 PGAL1- GFTpSD 
YIP-MV-02 
MATa MAL2-8c SUC2 ura3-52, 
erg9 ::PMET3-ERG9 
pIP031 pYX212 2µ URA3 PTPI1-GFTpSD 
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3.2.6 Batch fermentations 
Batch fermentations were carried out in well-controlled 5 L in-house manufactured glass 
bioreactors with a working volume of 4 L. The bioreactors were equipped with two disk-turbine 
impellers and 4 baffles to ensure proper mixing. The pH was controlled between 4.95 and 5.05 
by automatic addition of 2M NaOH. The temperature was kept constant at 30 ºC.  The air flow 
was 4 L/min (1 vvm) and was sterilized by filtration and the off gas passed through a condenser. 
Carbon dioxide and oxygen concentrations in the off-gas were determined by a Brüel & Kjær 
acoustic gas analyzer (Brüel & Kjær, Nærum, Denmark). Batch fermenters were inoculated to an 
initial OD600 of 0.02 from a liquid preculture. Three hundred milliliters of dodecane was added 
aseptically to the media at OD600 0f 1 ± 0.1. 
 
3.2.7 OD and dry weight determinations 
The OD of samples was determined at 600 nm by using a Hitachi U-1100 spectrophotometer. 
Dry weight measurement was achieved using 0.45 µm pore-size nitrocellulose filters (Sartorius 
AG, Göttingen, Germany) according to the method described by Dynesen et al. (1998).  
 
3.2.8 Extraction of ergosterol 
Baffled, cotton-stopped, shake flasks containing 100 ml minimal medium and 20 g/L glucose as 
carbon source were inoculated with overnight precultures to an initial OD600 of 0.02 and 
incubated for 24 h in a shaking incubator at 30 ºC and 150 rpm. A certain volume of culture 
medium corresponding to approximately 100 mg of dry cells was harvested by centrifuging at 
5000 rpm for 10 min. The cell pellet was washed with distilled water and the cell suspension was 
centrifuged for another 10 min at 5000 rpm. The cell pellet was resuspended in 4 ml HCl 0.2 N 
and heated in a water bath set at 85 ºC for 1 h and allowed to cool to room temperature. After 
centrifuging for 10 min at 5000 rpm and removing supernatant, the cell pellet was resuspended in 
2 ml methanol containing 0.2% (w/v) pyrogallol and 1 ml KOH 4 N and transferred to a 14 ml 
glass vial sealed with a PTFE lined screw cap, heated again for 2 h in a water bath set at 85 ºC 
for saponification. Following incubation, glass vials were allowed to cool to room temperature. 
Sterols were then extracted by addition of 5 ml heptane followed by vigorous vortex mixing for  
2 min. After 2 h when the heptane layer had clarified, it was transferred to a new glass vial for 
HPLC analysis.  
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 3.2.9 Analysis of ergosterol 
Quantitative determination of ergosterol was carried out by reverse-phase HPLC (Hewlett-
Packard HP 1090 chromatograph series II with built in diode array detector and auto-injector). 
Sterols were separated on a Develosil column (C30-UG-5, Nomura Chemicals, Aichi, Japan) 
with a mobile phase consisting of methanol and acetonitrile. The analysis was performed at  
40 ºC and it was monitored at 280 nm. The amount of ergosterol was determined using absolute 
calibration curves obtained after each analysis run. 
 
3.2.10 Analysis of sugars and extracellular metabolites 
To determine the concentration of sugars and extracellular metabolites in the culture media, 2 ml 
samples were withdrawn from the fermenter and immediately filtered through a 0.45 µm pore-
size cellulose acetate filter (Sartorius AG, Göttingen, Germany).  The filtrate was stored at -20 
ºC until HPLC analysis. Glucose, galactose, glycerol, pyruvate, succinate, acetate, and ethanol 
concentrations were determined in a Waters 717 plus Autosampler HPLC system equipped with 
a Bio-Rad Aminex HPX-87H reverse phase column (Biorad, Hercules, CA) at 60 ºC using 5 mM 
H2SO4 as mobile phase at a flow rate of 0.6 ml/min. Glucose, galactose, glycerol, succinate, and 
ethanol were detected refractometrically (Waters 410 Differential Refractometer Detector, 
Millipore Corp., Milford, MA). Pyruvate and acetate were determined spectrophotometrically 
with a Waters 490E Programmable Multiwavelength Detector set at 210 nm. 
 
3.2.11 Analysis of sesquiterpenes by SPME method 
Identification of sesquiterpenes produced by the yeast strains transformed with heterologous 
sesquiterpene synthases was performed by extracting volatile compounds from the head-space of 
the samples on 100 µm PDMS fibers (Supelco, Bellefonte, PA, USA). Fibers were conditioned 
according to the suppliers’ instruction. Two ml samples from the culture media were 
immediately frozen and stored in 4 ml screw cap glass vials at -20 ºC until analysis. The contents 
of vials were thawed on ice and allowed to equilibrate at room temperature. Extraction was 
performed for 25 min at 60 ºC while mixing the sample with a small magnet. After extraction, 
the analytes were thermally desorbed at 250 ºC from SPME fiber into the injector of gas 
chromatogram in the splitless mode. The oven temperature was held initially at 45 ºC for 1 min, 
then raised to 130 ºC by a ramp of 10 ºC/min followed by a ramp of 3 ºC/min to 160 ºC. The 
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oven temperature was further raised to 250 ºC at 10 ºC/min and maintained at this temperature 
for 5 min to equilibrate.  
 
3.2.12 Analysis of sesquiterpenes in the organic layer  
Samples from organic layer were centrifuged for 5 min at 3500 rpm and subsequently analyzed 
by GC-MS to determine the level of sesquiterpenes during the course of fermentation. GC-MS 
analyses were run on a Thermo Finnigan Focus GC coupled to a Focus DSQ quadrupole mass 
spectrometer. Analytes from 1 µl samples were separated on a SLB-5ms capillary column (30 m 
× 0.25 mm i.d., 0.25 µm film thickness; Supelco, Bellefonte, PA, USA) using helium as carrier 
gas at the flow rate of 1.2 ml/min. A split/splitless injector was used in the splitless mode. The 
initial oven temperature was 80 ºC and injector temperature was 250 ºC. After 1 min the oven 
temperature was increased to 120 ºC at the rate of 10 ºC/min and subsequently increased to  
160 ºC at the rate of 3 ºC/min. The oven temperature was finally increased to 270 ºC at the rate 
of 10 ºC/min and held for 5 min at this temperature. Quantification of compounds was carried 
out using standard curves generated after each analysis run.    
 
3.2.13 Analysis of methionine 
The concentration of methionine in the media was measured by HPLC by the method of 
Barkholt and Jensen (1989).  
 
3.3 Results 
3.3.1 Sesquiterpene synthase genes are functional in the engineered yeast strains 
Yeast strains were transformed with individual plasmids bearing one of the three sesquiterpene 
synthase cDNAs under control of TPI1 or GAL1 promoters: a valencene synthase (GFTpsD) and 
a cubebol synthase (GFTpsC) from grapefruit and a patchoulol synthase (PatTps177) from 
patchouli. To confirm the functionality of these plasmids the transformed strains were grown in 
shake flasks containing 100 ml minimal medium and 20 g/L galactose as carbon source. Volatile 
compounds were adsorbed on SPME fibers and analyzed by GC-MS. All the transformed strains 
were able to synthesize sesquiterpenes. In the case of valencene synthase, valencene was clearly 
the major product (Figure 3.1-a) in accordance with the relative high product specificity 
observed with this enzyme in in-vitro assay (data not shown). However, the patchoulol synthase 
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and the cubebol synthase are multiple product enzymes. The patchoulol synthase produces, in in-
vitro assays, 14 different sesquiterpenes with patchoulol as major product (Deguerry et al, 2006). 
Similarly, the cubebol synthase produces mainly cubebol besides at least 14 additional products. 
Analysis of the volatiles produced by yeast cells transformed with either the patchoulol or 
cubebol synthase cDNA revealed the same sesquiterpene profile as observed in the in-vitro 
assays. Figures 3.1-b and 3.1-c illustrate the range of sesquiterpene products produced by the 
cubebol synthase from grapefruit and patchoulol synthase from patchouli, respectively.  
 
 
Figure 3.1. GC profile of the sesquiterpenes produced by yeast strains expressing (a) valencene 
synthase (YIP-0V-02) (b) cubebol synthase (YIP-0C-02) (c) patchoulol synthase (YIP-0P-02) 
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3.3.2 Minimum methionine concentration for ERG9 repression 
The minimum methionine concentration for adjusting the expression of ERG9 was determined 
by growing the ERG9 repressed yeast cells in shake flasks supplemented with varying amounts 
of methionine (Figure 3.2).  
Repression of ERG9 led to lower specific growth rates compared to the wild type strain and also 
reduced the final concentration of biomass in the medium presumably as a result of decreased 
flux towards ergosterol. Increasing the methionine concentration to 1 mM resulted in an 
elongation of the lag phase and a lower final biomass concentration. However, there was no 
further effect on growth profile at concentrations of methionine above 1 mM (Figure 3.2). So the 
minimum required level of methionine should be 1 mM. However, to maintain the concentration 
of methionine at the minimum required level for ERG9 repression during the course of 
fermentation, 2 mM methionine was chosen for running fermentations.  
Repression of ERG9 resulted in the reduced ergosterol content of yeast strains. For the wild type 
the ergosterol content was found to be 9.37 ± 0.96 mg ergosterol/g DW, whereas it was found to 
be 7.48 ± 1.55 mg ergosterol/g DW for YIP-MV-02 when there was no methionine added to the 
medium and 1.66 ± 0.02 mg ergosterol/g DW when 2 mM methionine was added to the medium.   
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Figure 3.2. Effect of methionine on growth pattern of ERG9 repressed yeast strain (YIP-MV-02) 
cultivated in shake flasks containing minimal medium and 20 g/L glucose. (Without methionine: 
□; 0.25 mM methionine: ■; 0.50 mM methionine: ▲; 1.0 mM methionine: ; 1.5 mM 
methionine: ; 2 mM methionine: ) 
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3.3.3 Characterization of strains expressing synthases on plasmid 
Yeast strains transformed with plasmids harboring each of the three sesquiterpene synthase genes 
under control of either TPI1 or GAL1 promoters were characterized in two-phase 5 L batch 
fermenters containing 4 L minimal medium and 20 g/L galactose. Dodecane was added to 
fermenters as secondary phase. Samples were taken from the organic phase at different times and 
were analyzed for sesquiterpene content. Figure 3.3 illustrates the profile of sesquiterpene 
accumulation for the yeast strains expressing sesquiterpene synthases on plasmid.  
 
. 
Figure 3.3. Sesquiterpene concentration as a function of time for yeast strains expressing 
sesquiterpene synthases (a) YIP-0C-01 (b) YIP-0C-02 (c) YIP-0V-02 (d) YIP-0P-02 
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Table 3.3 summarizes the final concentrations and yields of the sesquiterpenes for the yeast 
strains harboring synthase genes. However patchoulol constitutes only 37% of the total 
sesquiterpenes synthesized by the patchoulol synthase (Deguerry et al., 2006) and the total 
concentration and yields of this sesquiterpene (strain YIP-0P-02) are significantly higher than for 
the other strains indicating higher activity of patchoulol synthase than valencene and cubebol 
synthases. In the same way, cubebol represents only 28% of sesquiterpenes produced by the 
cubebol synthase (unpublished data) and the total quantities of sesquiterpenes produced by 
strains expressing this enzyme are higher than for strains expressing the valencene synthase 
indicating that cubebol synthase is also more active than valencene synthase. Total sesquiterpene 
concentrations were estimated based on the known percentage of the target sesquiterpenes 
produced by the different sesquiterpene synthases (28% and 37% for cubebol and patchoulol, 
respectively).  
Replacement of GAL1 promoter with TPI1 promoter for controlling the expression of cubebol 
synthase gene reduced the efficiency of sesquiterpene production both in terms of final 
concentration and yield when galactose was the carbon source (Table 3.3; YIP-0C-01 vs.  
YIP-0C-02). 
 
Table 3.3. Final concentrations of target sesquiterpenes and total sesquiterpenes and yields of 
target sesquiterpenes (mg sesquiterpene per gram dry weight or gram consumed galactose in the 
galactose consumption phase) for yeast strains expressing sesquiterpene synthases.  
Cells were grown in 5 L batch fermenters containing 4 L minimal medium and 20 g/L galactose 
as carbon source. 
Yeast strain Promoter 
Valencene 
(mg/L) 
Cubebol 
(mg/L) 
Patchoulol 
(mg/L) 
Total 
sesquiterpenes 
(mg/L) 
YXP 
(mg/g 
DW) 
YSP 
(mg/g 
galactose) 
YIP-0V-02 GAL1 2.0   2.0 0.33 0.08 
YIP-0C-02 GAL1  2.0  7.1 0.33 0.07 
YIP-0C-01 TPI1  1.5  5.4 0.21 0.04 
YIP-0P-02 GAL1   6.7 18.1 1.21 0.31 
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3.3.4 ERG9 repression diverts FPP towards farnesol  
Analysis of dodecane layer from two-phase batch fermentation of the ERG9 repressed strain 
without any sesquiterpene synthase (YIP-M0-04) revealed formation of farnesol as an FPP-
derived compound during fermentation.  
The yield of farnesol when cells were assimilating galactose as carbon source was 10.90 mg/g 
DW and the final titer was 22.6 mg/L. The concentration and yield of the compounds directly 
derived from FPP are higher when ERG9 is repressed. Taken together with the reduced 
ergosterol content of the ERG9 repressed strains, this confirms the possibility of using this 
strategy for enhancing FPP availability for the sesquiterpene synthases.  
 
3.3.5 Combination of ERG9 repression and sesquiterpene synthase expression 
ERG9 repression was shown to result in formation of FPP derived by-products and therefore it is 
likely that FPP availability for sesquiterpene synthases was improved. Hence, combination of 
ERG9 repression and sesquiterpene synthase expression was expected to give rise to higher 
accumulation of sesquiterpenes. To investigate this hypothesis the YIP-M0-04 strain was 
transformed with plasmids each bearing one of the three sesquiterpene synthase genes and the 
constructed strains were characterized in 5 L batch fermenters. None of the sesquiterpene 
synthase genes were able to convert all the available FPP to the target sesquiterpenes and again 
farnesol was observed as FPP derived by-product (Figure 3.4).  
Comparing the final concentrations of desired sesquiterpenes and farnesol produced by ERG9 
repressed strains and the corresponding strains where ERG9 is under control of the endogenous 
promoter (Table 3.3 and Table 3.4) indicate that except for the patchoulol synthase, repression of 
ERG9 did not lead to significantly higher amounts of sesquiterpenes but mainly resulted in the 
diverting of FPP to farnesol. This again shows that patchoulol synthase activity in the yeast cells 
is higher than the activities of the other two sesquiterpene synthases. 
Replacing the GAL1 promoter in the YIP-MV-01 strain with TPI1 promoter (YIP-MV-02) 
resulted in lower amount of valencene and higher yield and concentration of farnesol.  
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Figure 3.4. Target sesquiterpenes and farnesol concentrations as a function of time for ERG9 
repressed yeast strains expressing sesquiterpene synthases (a) YIP-MC-02 (b) YIP-MV-01 (c) 
YIP-MV-02 (d) YIP-MP-01; Valencene (♦) Cubebol (●) Patchoulol (■) Farnesol () 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Table 3.4. Final concentrations and yields of sesquiterpenes for the ERG9 repressed yeast strains. Cells were grown in 5 L batch 
fermenters containing 4 L minimal medium and 20 g/L galactose. 
Yeast strain 
Sesquiterpene 
synthase 
Promoter 
Final titer of 
target 
sesquiterpene 
(mg/L) 
Total 
sesquiterpenes 
(excluding 
farnesol) (mg/L) 
Farnesol 
(mg/L) 
Yield of 
target 
sesquiterpene 
on biomass 
(mg/g DW) 
Yield of target 
sesquiterpene 
on galactose 
(mg/g 
galactose) 
Yield of 
farnesol on 
biomass 
(mg/g DW) 
Yield of 
farnesol on 
galactose 
(mg/g 
galactose) 
YIP-MC-02 Cubebol TPI1 1.6 5.7 29.9 0.39 0.23 13.15 5.30 
YIP-MV-01 Valencene GAL1 3.0 3.0 19.6 3.13 0.67 9.05 3.77 
YIP-MV-02 Valencene TPI1 0.6 0.6 34.6 0.38 0.14 14.93 5.99 
YIP-MP-01 Patchoulol GAL1 11.5 31.1 11.1 6.25 2.13 4.98 2.06 
YIP-M0-04 ---- ---- ---- 0 22.6 0 0 10.90 1.76 
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3.3.6 Regulating methionine concentration alters the flux towards sesquiterpenes  
ERG9 down-regulation was not concomitant with substantial improvement in the final 
concentrations of the target sesquiterpenes, but comparing the yields (Table 3.3 and Table 3.4) 
demonstrates that there was some increase in the yields. Plotting the sesquiterpene concentration 
versus dry weight of biomass or galactose concentration allowed calculation of yields and this 
revealed two different linear phases during  the galactose consumption phase (Figure 3.5) 
suggesting that the rate of sesquiterpene accumulation in the organic phase dropped at one time 
during the fermentation. It was speculated that methionine was metabolized by the cells and the 
subsequent reduced levels of methionine would relieve a true repression of the ERG9 gene and 
consequently lowered the accumulation rate of sesquiterpenes. Analyzing the methionine 
concentration in the culture media confirmed that there was a total consumption of methionine 
(data not shown). To examine the effect of methionine concentration on the level of products we 
therefore ran fermentations with the YIP-MP-01 strain using higher amounts of methionine 
added to the medium at different times during fermentation. Maintaining the methionine 
concentration at higher level during the fermentation resulted in a 47% increase in the final 
patchoulol titer and a 82% increase in the final farnesol titer. Thus, the final concentrations of 
patchoulol and farnesol reached to 16.9 and 20.2 mg/L, respectively. 
 
3.3.7 Farnesol is converted to other by-products at the end of fermentation 
It was noticed that there is a drastic drop in the farnesol concentration for the ERG9 repressed 
strains when all carbon sources had been depleted. This decrease could not be a result of 
evaporation of farnesol from the organic phase since the same pattern was not observed for other 
compounds. We speculated that at the end of fermentation and after depletion of all carbon 
sources, farnesol is further converted to other related compounds and appearance of a second 
peak during GC-MS analysis for FPP-derived compounds at the end of the fermentations 
supported this hypothesis (Figure 3.6).  
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Figure 3.5. Target sesquiterpenes and farnesol concentrations as a function of galactose 
concentration for calculating yields on galactose. (a) YIP-MV-01 (b) YIP-MC-02 (c) YIP-MP-
01; Valencene (♦)Cubebol (●)  Patchoulol (■) Farnesol () 
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Figure 3.6. Farnesol degradation at the end of fermentation and appearance of an unknown 
compound. (a) YIP-MV-01 (b) YIP-MC-02; Farnesol () Unknown compound (●) 
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3.3.8 Galactose is preferred carbon source for biosynthesis of sesquiterpenes  
Galactose is an expensive carbon source and S. cerevisiae exhibits a lower specific growth rate 
on this carbon source. Therefore for industrial fermentation it would be desirable to use glucose 
as carbon source. We investigated the possibility of using glucose in the media by growing yeast 
cells expressing cubebol and valencene synthases under control of the TPI1 promoter using 
glucose rather than galactose as carbon source. However, the results showed that both the final 
titer and the yield were lower when cells were grown on glucose (Table 3.4 and Table 3.5).  
 
Table 3.5. Final concentrations and yields of sesquiterpenes and farnesol for the ERG9 repressed 
yeast strains expressing sesquiterpene synthases under control of TPI1 promoter. Cells were 
grown in 5 L batch fermenters containing 4 L minimal medium and 20 g/L glucose. 
Yeast strain 
Valencene 
(mg/L) 
Cubebol 
(mg/L) 
Farnesol 
(mg/L) 
Yield of corresponding 
sesquiterpene on glucose 
(mg/g glucose) 
Yield of 
farnesol on 
glucose (mg/g 
glucose)  
YIP-0C-01  0.7  0.03  
YIP-MC-02  1.5 20.0 0.08 0.82 
YIP-MV-02 0.2  15.7 0.01 0.84 
 
3.4 Discussion 
In this study we report heterologous production of three different plant sesquiterpenes in the 
yeast S. cerevisiae. The corresponding sesquiterpene genes for cubebol, valencene and 
patchoulol were expressed in yeast and were shown to be functional, and this is the first instance 
of a cubebol synthase being expressed for heterologous production of cubebol.  
Patchoulol and cubebol synthases produced several products besides their main products, i.e. 
patchoulol and cubebol, respectively. The ability of sesquiterpene synthases to make multiple 
products has been well documented and is probably a consequence of premature quenching of 
the highly unstable carbocationic intermediates that are generated from FPP (Davis and Croteau, 
2000). This could also represent adaptation of these enzymes through evolutionary mechanisms 
to generate the maximum number of products using the minimum genetic and enzymatic 
machinery (Steele et al., 1998). Indeed, ability of certain enzymes to catalyze secondary 
reactions besides their primary reactions on a single active site is not a rare phenomenon and has 
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been termed catalytic promiscuity (Copley, 2003) and multiple product formation by 
sesquiterpene synthases could also be an example for this feature. 
The availability of FPP which is the precursor for all sesquiterpene synthases was enhanced by 
replacement of the native ERG9 promoter with a regulatable MET3 promoter and repressing the 
promoter with the presence of 2 mM methionine. The ergosterol content was drastically reduced 
as a consequence of this repression. Nevertheless, this strategy did not improve appreciably the 
production of the target sesquiterpenes but resulted in further production of farnesol as an FPP-
derived by-product. Consistent with this finding are accumulation of farnesol in Candida 
albicans (Buurman et al., 2004; Hornby et al., 2003) as a consequence of treatment with 
zaragozic acid, which is potent inhibitor of squalene synthase. Furthermore, deletion of ERG9 
gene in S. cerevisiae was reported to lead to accumulation of farnesol in S. cerevisiae (Song, 
2003). Poor expression of the plant sesquiterpene genes and also low catalytic activity of 
sesquiterpene synthases may explain why sesquiterpene synthesis was not improved significantly 
after repression of ERG9. The use of codon optimized sesquiterpene synthases may help in 
diverting more FPP towards the desired sesquiterpenes. The production of amorphadiene in yeast 
was significantly enhanced when the codon usage of the amorphadiene synthase was optimized 
(Martin et al., 2001; Martin et al., 2003). 
Metabolism of methionine during the growth phase relieved the repression of ERG9, which was 
accompanied by a reduction in the rate of sesquiterpene synthesis. Further experiments showed 
that it was possible to improve the target sesquiterpene production by supplying more 
methionine during fermentation. Under these conditions the final titer of patchoulol and farnesol 
reached to 16.9 and 20.2 mg/L, respectively. More precise regulation of methionine should 
improve further the efficiency of sesquiterpene biosynthesis.  
The effect of replacing galactose as an expensive carbon source with glucose, which is less 
expensive and is faster metabolized by cells, on the sesquiterpene biosynthesis was investigated.  
However, higher final titer and yield were observed when cells were grown on galactose.  
Considering that the reported titers and yields have been achieved only by down-regulating one 
gene in the pathway, this work demonstrates the capacity of yeast as a cell factory for the 
production of sesquiterpenes. 
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Chapter 4 
Overexpression of tHMG1 enhances heterologous 
production of sesquiterpenes in S. cerevisiae 
 
4.1 Introduction 
The yeast S. cerevisiae has been used in several studies for heterologous production of 
sesquiterpenes (Jackson et al., 2003; Ro et al., 2006; Lindahl et al., 2006; Takahashi et al., 2007; 
Shiba et al., 2007; Asadollahi et al., 2008). Although expression of heterologous sesquiterpene 
synthase genes in yeast allows production of the corresponding sesquiterpenes, the titer is not 
sufficient to support a viable industrial process for the production of sesquiterpenes by yeast. It is 
therefore necessary to increase the supply of the precursor for the production of sesquiterpenes. 
Sesquiterpenes are derived from FPP, which is an intermediate of the sterol pathway. The sterol 
biosynthetic pathway in yeast is initiated with the condensation of two molecules of acetyl-CoA 
and ends with ergosterol as the end product of the pathway after more than 20 steps (Daum et al., 
1998). This pathway is divided into two distinct portions. The first part of the pathway, which is 
also called the mevalonate pathway, leads to the production of FPP but is also responsible for 
providing intermediates required for the biosynthesis of essential constituents of cell such as 
heme A, ubiquinone, dolichols, farnesylated and geranylgeranylated proteins (Maury et al., 2005; 
Kennedy et al., 1999). Regulation of the mevalonate pathway in eukaryotes is very complex, but 
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HMG-CoA reductase and FPP branch-point represent two key regulation sites in the pathway 
(Maury et al., 2005). 
HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate, is a highly 
regulated enzyme that is generally considered to represent the main flux controlling step in the 
pathway. S. cerevisiae possesses two isozymes of HMG-CoA reductase, Hmg1p and Hmg2p, 
encoded by the HMG1 and HMG2 genes, respectively. At aerobic conditions Hmg1p has the 
highest activity (Hampton et al., 1996). Both the yeast isozymes have a C-terminal catalytic 
domain and an N-terminal domain which consists of several transmembrane spans to anchor the 
protein in the endoplasmic reticulum (Hampton and Rine, 1994). Several studies have shown that 
overexpression of the region of gene encoding the catalytic domain of Hmg1p leads to enhanced 
isoprenoid production in yeast (Jackson et al., 2003; Ro et al., 2006; Verwaal et al., 2007).  
The FPP branch-point represents another regulatory site in the mevalonate pathway where 
several enzymes compete for FPP as substrate. However, most of the FPP is required for the 
sterol biosynthesis and hence minimizing the flux towards sterols would provide more FPP for 
the other enzymes of the branch-point including sesquiterpene synthases.  
We have successfully reported production of three plant sesquiterpenes namely valencene, 
cubebol and patchoulol in yeast by expression of the corresponding sesquiterpene synthase 
genes. Minimizing the carbon flux towards sterols through attenuated expression of ERG9, 
which encodes squalene synthase, stimulated sesquiterpene production in yeast. This was done 
by replacing the endogenous ERG9 promoter with a regulatable MET3 promoter that is repressed 
in the presence of methionine (Asadollahi et al., 2008). In this study, we further studied cubebol 
production in yeast. The mevalonate pathway in the cubebol producing yeast strain was 
deregulated by overexpression of the truncated HMG1 (tHMG1) both from the genome and using 
plasmid based expression under control of strong promoters. The overexpression of tHMG1 was 
combined with the down-regulation of ERG9 in order to further improve cubebol production. 
The constructed yeast strains were characterized in batch fermenters and the effect of the 
modifications were studied on cubebol production as well as accumulation of ergosterol and 
squalene.  
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4.2 Materials and methods 
4.2.1 Plasmid construction  
The plasmid pIP025 was constructed by cloning GFTpsC in a pESC-URA vector (Stratagene) 
under control of the GAL1 promoter using BamHI and XhoI restriction sites. Overexpression of 
the catalytic domain of HMG-CoA reductase (tHMG1) was performed using gap repair 
technique taking the advantage of high efficiency homologous recombination in yeast. The 
tHMG1 gene was amplified from the genomic DNA of S. cerevisiae CEN.PK113-7D using the 
primers 5’tctggcgaagaattgttaattaagagctcaTTAGGATTTAATGCAGGTGACGGAC3’ and 
5’cactaaagggcggccgcactagtatcgatgACTATGGACCAATTGGTGAAAACTG3’. The lower case 
letters in the primers show the homologous overhang used for gap repair. The truncated coding 
region has an engineered Met start codon and then continues with the natural coding region from 
codon 531 (Asp) to the natural stop codon. The PCR conditions were in accordance with the 
Phusion™ Hot Start High-Fidelity DNA Polymerase (Finnzymes Oy, Espoo, Finland). pESC-
URA plasmid was digested with ClaI and SacI restriction enzymes. The PCR product and the 
digested expression vector were separated by gel electrophoresis and gel purified using the 
QIAEX® II Gel extraction kit (Qiagen, Hilden, Germany). Homologous recombination of PCR 
product into the digested expression vector after transformation of CEN.PK113-5D with both 
fragments resulted in pIP026 plasmid. 
The plasmid pIP028 was obtained by cloning GFTpsC in pIP026 plasmid under control of the 
GAL1 promoter using BamHI and XhoI restriction sites. The plasmids pIP031 and pIP032 have 
been described previously (Asadollahi et al., 2008). 
Sequences of the genes GFTpsD (valencene synthase) and GFTpsC (cubebol synthase) can be 
obtained from GenBank: accession numbers CQ813508 and CQ813505, respectively. 
 
4.2.2 Integration of tHMG1 into genome 
For genomic integration of tHMG1 under control of TPI1 promoter a plasmid bearing a truncated 
version of HMG1, associated with a selective marker, Kl URA3, was constructed. tHMG1 was 
PCR amplified from CEN.PK 113-7D genomic DNA using primers containing overhangs with 
EcoRI restriction site on one side (5’accggaattcACTATGGACCAATTGGTGAAAACTG3’) and 
NheI restriction site on the other side (5’tctagcttagcCACATGGTGCTGTTGTGCTT3’). After 
digestion with EcoRI and NheI, the PCR fragments were ligated into pYX212 plasmid, in 
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between the two restriction sites EcoRI and NheI. Kl URA3 was further cloned into pYX212 
bearing tHMG1 at the NheI restriction site. Kl URA3 flanked by two direct repeats was first PCR 
amplified from the plasmid pWJ1042 (Reid et al., 2002) using the couple of primers 
5’tctagctagcTTCGGCTTCATGGCAATTCCCG3’ and 
5’tctagctagcTAACGCCAGGGTTTTCCCAGTCAC3’. After digestion with NheI, Kl URA3 
flanked by the two direct repeats was ligated into the NheI restriction site of pYX212 bearing 
tHMG1. This plasmid was named pTTU. 
In order to integrate the TPIp-tHMG1-Kl URA3 construct into the URA3 locus, fusion PCR and 
the bipartite gene targeting method (Erdeniz et al., 1997) was used. TPIp-tHMG1-Kl URA3 was 
amplified from the plasmid pTTU in two separate, but overlapping, fragments (Figure 4.1) using 
the primers listed in Table 4.1. Furthermore, 500 bp upstream and downstream of URA3 on the 
genome of S. cerevisiae were amplified. The four resulting PCR fragments were gel-purified and 
fused together in pairs by fusion PCR (Figure 4.1). The primers URA3sl500 and 3’int KL URA3 
were used for fusion of the “left fragment”; primers 5’int KL URA3 and URA3rr500 were used 
for fusion of the “right fragment”. The resulting two fusion PCR fragments were purified after 
gel electrophoresis. S. cerevisiae strain CEN.PK 113-5D was subsequently transformed with the 
fusion PCR fragments. Transformants were selected on SC-ura medium after incubation at 30 °C 
for 2-4 days. Several transformants were selected and their genomic DNA was isolated. Correct 
integrants were identified by PCR using both external primers (URA3sl500 and URA3rr500) and 
a combination of external and internal primers (5’int KL URA3 and URA3rr500).  
Subsequently, correct transformants were restreaked on a medium containing 5-FOA for the loop 
out of the Kl URA3 marker and the reuse of uracil auxotrophy. 
 
4.2.3 Strain construction 
The native promoter of ERG9 gene was replaced with a regulatable MET3 promoter and thus the 
strain YIP-M0-04 was obtained (Asadollahi et al., 2008).  
Strains YIP-MV-07 and YIP-MC-13 were obtained by transforming YIP-M0-03 with the pIP031 
and pIP032 plasmids, respectively. Strains YIP-0C-04, YIP-MC-05, YIP-MC-07, YIP-MC-08, 
YIP-MC-09, and YIP-MC-10 were constructed by transforming their corresponding backgrounds 
with either pIP025 or pIP028 plasmids. Table 4.2 lists the strains used in this study. 
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Figure 4.1. Insertion of TPIp-tHMG1-Kl URA3 into the URA3 locus of S. cerevisiae. The TPIp-
tHMG1-KL URA3 construct is amplified from pTTU in two separate, but overlapping, reactions 
using primers at the extremities with adaptamers homologous to the insertion site. 500 bp up- 
and downstream from the insertion site are amplified as well. After a second round of PCR 
where the four resulting fragments are fused together in pairs the two fusion fragments are 
transformed into S. cerevisiae. 
 
Table 4.1. Primers for amplification of fusion PCR fragments.  
Primer Sequence 
URA-tHMG1s atgtcgaaagctacatataaggaacgtgctgctactcatcctagtcctgtGAAAAGTGCCACCTGACGTC 
URA-tHMG1r ttgctggccgcatcttctcaaatatgcttcccagcctgcttttctgtaacgTGTAAAACGACGGCCAGTGAG 
5’int KL URA3 CTTGACGTTCGTTCGACTGATGAGC 
3’int KL URA3 GAGCAATGAACCCAATAACGAAATC 
URA3sl500 AAACGACGTTGAAATTGAGGCTACTGCG 
URA3rl500 GGACTAGGATGAGTAGCAGCACGTTCC 
URA3sr500 GGGAAGCATATTTGAGAAGATGCGGC 
URA3rr500 GGAAACGCTGCCCTACACGTTCGC 
 The sequence of the primer used for amplification of the DNA fragments is given in capital 
letters, while the overhangs used in fusion PCR are in small letters. 
 
  
   Table 4.2. Strains used in this study 
     
Strain Genotype Plasmid Plasmid description Reference 
YIP-00-03 
(CEN.PK113-5D) 
MATa MAL2-8c SUC2 ura3-52 none  Peter Köttera 
YIP-M0-04 
MATa MAL2-8c SUC2 ura3-52, 
erg9 ::PMET3-ERG9 
none  
Asadollahi et 
al., 2008 
YIP-0V-01 MATa MAL2-8c SUC2 ura3-52 pIP031 pYX212 2µ URA3 PTPI1-GFTpsD Asadollahi et 
al., 2008 
YIP-0C-01 MATa MAL2-8c SUC2 ura3-52 pIP032 pYX212 2µ URA3 PTPI1-GFTpsC Asadollahi et 
al., 2008 
YIP-M0-03 MATa MAL2-8c SUC2, ura3 ::PTPI1-tHMG1 none  This study 
YIP-MV-07 MATa MAL2-8c SUC2, ura3 ::PTPI1-tHMG1 pIP031 pYX212 2µ URA3 PTPI1-GFTpsD This study 
YIP-MC-13 MATa MAL2-8c SUC2, ura3 ::PTPI1-tHMG1 pIP032 pYX212 2µ URA3 PTPI1-GFTpsC This study 
YIP-0C-04 MATa MAL2-8c SUC2 ura3-52 pIP025 pESC-URA 2µ URA3 PGAL1- GFTpsC This study 
YIP-MC-05 MATa MAL2-8c SUC2 ura3-52 pIP028 
pESC-URA 2µ URA3 PGAL1-GFTpsC 
PGAL10-tHMG1 
This study 
YIP-MC-07 
MATa MAL2-8c SUC2 ura3-52, 
erg9 ::PMET3-ERG9 
pIP025 pESC-URA 2µ URA3 PGAL1- GFTpsC This study 
YIP-MC-08 
MATa MAL2-8c SUC2 ura3-52, 
erg9 ::PMET3-ERG9 
pIP028 
pESC-URA 2µ URA3 PGAL1-GFTpsC 
PGAL10-tHMG1 
This study 
YIP-MC-09 MATa MAL2-8c SUC2, ura3 ::PTPI1-tHMG1 pIP025 pESC-URA 2µ URA3 PGAL1- GFTpsC This study 
YIP-MC-10 MATa MAL2-8c SUC2, ura3 ::PTPI1-tHMG1 pIP028 
pESC-URA 2µ URA3 PGAL1-GFTpsC 
PGAL10-tHMG1 
This study 
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4.2.4 Media for Shake flasks 
Baffled, cotton-stopped, 500 ml Erlenmeyer flasks were used for preparing precultures and also 
for preparing samples for ergosterol measurement and HMG-CoA reductase assays. The shake 
flasks were containing 100 ml medium with the following compositions: 7.5 g/L (NH4)2SO4; 
14.4 g/L KH2PO4; 0.5 g/L MgSO4.7H2O; 2 ml/L trace metal solution; 1 ml/L vitamin solution 
and 50 µl/L synperonic antifoam (Sigma, St. Louis, MO). The pH of the mineral medium was 
adjusted to 6.50 by adding 2M NaOH and autoclaved separately from carbon source solution. 
Vitamin solution was filter sterilized and aseptically added to the medium after autoclavation. 
Shake flasks were incubated in a shaking incubator at 30 ºC and 150 rpm. 
 
4.2.5 Media for batch cultivations 
A defined minimal medium as described by Verduyn et al. (1992) containing 20 g/L of 
galactose as the sole carbon source was used for all batch fermentations. The media had the 
following compositions: 5 g/L (NH4)2SO4; 3 g/L KH2PO4; 0.5 g/L MgSO4.7H2O; 1 ml/L trace 
metal solution; 1 ml/L vitamin solution and 50 µl/L synperonic antifoam. Expression of ERG9 
was repressed by supplementing media with 2 mM filter sterilized methionine. 
Galactose was autoclaved separately from the medium and subsequently added to the 
fermenter, as was the case for the vitamin solution that was added after filter sterilization. 
 
4.2.6 Batch fermentations 
Batch fermentations were carried out in well-controlled 5 L in-house manufactured glass 
bioreactors with a working volume of 4 L. The bioreactors were equipped with two disk-
turbine impellers and 4 baffles to ensure proper mixing. The pH was controlled between 4.95 
and 5.05 by automatic addition of 2M NaOH. The temperature was kept constant at 30 ºC.  The 
air flow was 4 L/min (1 vvm) and was sterilized by filtration and the off gas passed through a 
condenser. Carbon dioxide and oxygen concentrations in the off-gas were determined by a 
Brüel & Kjær acoustic gas analyzer (Brüel & Kjær, Nærum, Denmark). Batch fermenters were 
inoculated to an initial OD600 of 0.02 from a liquid preculture. Three hundred milliliters of 
dodecane was added aseptically to the media at OD600 0f 1 ± 0.1. 
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4.2.7 OD and dry weight determinations 
The OD of samples was determined at 600 nm in duplicate by using a Hitachi U-1100 
spectrophotometer. Dry weight measurement was achieved by using 0.45 µm pore-size 
nitrocellulose filters (Sartorius AG, Göttingen, Germany) according to the method described by 
Dynesen et al. (1998).  
 
4.2.8 Analysis of galactose and ethanol 
To determine the concentration of sugars and extracellular metabolites in the culture media, 2 
ml samples were withdrawn from the fermenter and immediately filtered through a 0.45 µm 
pore-size cellulose acetate filter (Sartorius AG, Göttingen, Germany).  The filtrate was stored at 
-20 ºC until HPLC analysis. Analysis was performed in a Waters 717 plus Autosampler HPLC 
system equipped with a Bio-Rad Aminex HPX-87H reverse phase column (Biorad, Hercules, 
CA) at 60 ºC using 5 mM H2SO4 as mobile phase at a flow rate of 0.6 ml/min. Galactose and 
ethanol were detected refractometrically (Waters 410 Differential Refractometer Detector, 
Millipore Corp., Milford, MA).  
 
4.2.9 Analysis of sesquiterpenes in the organic layer  
Samples from organic layer were centrifuged for 5 min at 3500 rpm and subsequently analyzed 
by GC-MS to determine the level of sesquiterpenes during the course of fermentation. GC-MS 
analyses were run on a Thermo Finnigan Focus GC coupled to a Focus DSQ quadrupole mass 
spectrometer. Analytes from 1 µl samples were separated on a SLB-5ms capillary column (30 
m × 0.25 mm i.d., 0.25 µm film thickness; Supelco, Bellefonte, PA, USA) using helium as 
carrier gas at the flow rate of 1.2 ml/min. A split/splitless injector was used in the splitless 
mode. The initial oven temperature was 80 ºC and injector temperature was 250 ºC. After 1 min 
the oven temperature was increased to 120 ºC at the rate of 10 ºC/min and subsequently 
increased to 160 ºC at the rate of 3 ºC/min. The oven temperature was finally increased to  
270 ºC at the rate of 10 ºC/min and held for 5 min at this temperature.  
Quantification of compounds was carried out using standard curves generated after each 
analysis run.    
 
 
CHAPTER 4     Overexpression of tHMG1 enhances heterologous production of sesquiterpenes                                                                                                                   
 93 
4.2.10 Extraction of sterols 
Baffled, cotton-stopped, shake flasks containing 100 ml minimal medium and 20 g/L of 
glucose or galactose as carbon source were inoculated with overnight precultures to an initial 
OD600 of 0.05 and incubated for 24 h in a shaking incubator at 30 ºC and 150 rpm. A certain 
volume of culture media corresponding to approximately 100 mg of dry cells was harvested by 
centrifuging at 5000 rpm for 10 min. The cell pellet was washed with distilled water and the 
cell suspension was centrifuged for another 10 min at 5000 rpm. The cell pellet was 
resuspended in 4 ml HCl 0.2 N and heated in a water bath set at 85 ºC for 1 h and then allowed 
to cool to room temperature. After centrifuging for 10 min at 5000 rpm and removing 
supernatant, the cell pellet was resuspended in 2 ml methanol containing 0.2% (w/v) pyrogallol 
and 1 ml KOH 4 N and transferred to a 14 ml glass vial sealed with a PTFE lined screw cap, 
heated again for 2 h in a water bath set at 85 ºC for saponification. Following incubation, glass 
vials were allowed to cool to room temperature. Sterols were then extracted by addition of 5 ml 
heptane followed by vigorous vortex mixing for 2 min. After 2 h when the heptane layer had 
clarified, it was transferred to a new glass vial for HPLC and GC-MS analyses.  
 
 4.2.11 Analysis of ergosterol 
Quantitative determination of ergosterol was carried out by reverse-phase HPLC (Hewlett-
Packard HP 1090 chromatograph series II with built in diode array detector and auto-injector). 
Sterols were separated on a Develosil column (C30-UG-5, Nomura Chemicals, Aichi, Japan) 
with a mobile phase consisting of methanol and acetonitrile. The analysis was performed at 40 
ºC and it was monitored at 280 nm. The amount of ergosterol was determined using absolute 
calibration curves obtained after each analysis run. 
 
4.2.12 Analysis of squalene 
Samples from sterol extraction were injected into a Thermo Finnigan Focus GC coupled to a 
Focus DSQ quadrupole mass spectrometer for squalene analysis and determination. Sterols 
were separated on a SLB-5ms capillary column (30 m × 0.25 mm i.d., 0.25 µm film thickness; 
Supelco, Bellefonte, PA, USA) using helium as carrier gas at the flow rate of 1.2 ml/min. A 
split/splitless injector was used in the splitless mode. The initial oven temperature was 80 ºC 
and injector temperature was 250 ºC. After 1 min the oven temperature was increased to 270 ºC 
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at the rate of 10 ºC/min. The oven temperature was then held for 20 min at this temperature to 
equilibrate. 
 
4.2.13 HMG-CoA reductase activity 
Baffled, cotton-stopped, shake flasks containing 100 ml minimal medium and 20 g/L of 
glucose as carbon source were inoculated with overnight precultures to an initial OD600 of 0.02 
and incubated for 24 h in a shaking incubator at 30 ºC and 150 rpm. Fifty milliliters of culture 
medium was harvested by centrifuging at 5000 rpm for 10 min. The cell pellets were washed 
twice with 25 ml of 50 mM phosphate buffer (pH 7.0). After removing the supernatant, cells 
were resuspended in 300 µl of lysis buffer (100 mM phosphate buffer, pH 7.0; 1 mM 
Na2EDTA, pH 8.0; 5mM DTT). The suspension was then transferred to a 2 ml FastPrep® tube 
and precooled glass beads (0.25-0.50 mm) were added to reach the meniscus. The cells were 
broken by vortexing in FastPrep® instrument (FP 120, BIO 101, Savant, Holbrook, NY) at the 
speed set to 5.0 m/sec for 3×20 sec separated by periods of cooling on ice. An additional 300 µl 
of lysis buffer was added to assist the recovery of the extract. The extract was transferred to a 
new Eppendorf tube and Nonidet P-40 was added to 0.5% (w/v) and incubated on ice for 1 h. 
The extract was centrifuged at 10000 g for 2 min at 4 ºC. Activity assays were modified from 
the procedure of Quain and Haslam (1979). For the assay a reaction buffer containing 100 mM 
KPO4 buffer, pH 7.0, 0.5% (w/v) Nonidet P-40, 5 mM DTT was prepared. Stock solutions of 
NADPH and HMG-CoA in KPO4 buffer, 3mM, pH 7.0, were prepared in separate tubes. 
Assays were done in 1 ml (1 cm path length) quartz cuvettes by adding reaction buffer and  
150 µM NADPH. The cuvette temperature was kept constant at 30 ºC by circulating water. The 
cuvette was put in the place at 30 ºC for 10 min to equilibrate. Then different amounts of cell 
extract (50, 100, and 150 µl) were added to the cuvette. After 5 min of incubation at 30 °C to 
stabilize the endogenous oxidation of NADPH, 150 µM HMG-CoA was added to the cuvette as 
substrate. The initial change in absorbance at 340 nm due to oxidation of NADPH was 
recorded. 
The protein content of cell extract was determined using the Lowry method (Lowry et al., 
1951) using BSA as standard. 
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4.3 Results 
4.3.1 Overexpression of tHMG1 by integrating it into genome 
Enzymatic activity of HMG-CoA reductase was assayed for CEN.PK113-7D and YIP-M0-03. 
Since HMG-CoA reductase consumes NADPH as a cofactor for reduction of HMG-CoA to 
mevalonate, the enzyme activities were tested based on the ability of cell extracts to oxidize 
NADPH in the presence of HMG-CoA as substrate. Overexpression of tHMG1 increased the 
activity of this enzyme from 4.04 ± 0.49 in CEN.PK113-7D to 5.82 ± 0.29 U/(mg protein) in 
the YIP-M0-03 strain where U is defined as the nmol NADPH oxidized min-1. 
The effect of tHMG1 overexpression on sesquiterpene biosynthesis was examined by 
measuring sesquiterpenes produced by the strains YIP-MV-07 and YIP-MC-13 in shake flask. 
These two strains produced approximately 40% more sesquiterpene compared to their 
corresponding control strains, YIP-0V-01 and YIP-0C-01, respectively (data not shown). 
Similar ratios for increase in the accumulation of both valencene and cubebol and increase in 
the enzyme activity of HMG-CoA reductase after tHMG1 overexpression propose a flux 
controlling role and using the method of large deviations (Stephanopoulos et al., 1998) for 
calculation of the flux control coefficient a value of almost 1 is found for this enzyme in the 
mevalonate pathway.  
 
4.3.2 Overexpression of tHMG1 from plasmid 
Since single copy integration of tHMG1 in the genome led to only a 45% increase in the HMG-
CoA reductase activity, we decided to further enhance the enzyme activity by expressing the 
tHMG1 gene under control of a strong promoter in a high copy number plasmid. Therefore 
tHMG1 and GFTpsC were cloned together into a pESC-URA plasmid under control of the 
strong inducible GAL promoters to make the plasmid pIP028. The plasmid pIP025 was also 
constructed as a control by cloning only GFTpsC into the pESC-URA plasmid. By 
transforming the YIP-M0-03 strain with the pIP028 plasmid it was possible to overexpress 
tHMG1 both from the genome and a high copy number plasmid. The strains overexpressing 
tHMG1 were characterized in 5 L batch two-phase fermentations for both growth (Figure 4.2) 
and cubebol production (Figure 4.3). For all the strains overexpression of tHMG1 resulted in a 
decrease in the specific growth rate (Figure 4.2) probably as a consequence of squalene 
accumulation which could be toxic for cells at high concentrations (Donald et al., 1997). 
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Figure 4.2. Effect of tHMG1 overexpression on the maximum specific growth rate of yeast 
strains. Cells were grown in 5 L batch fermenters containing 4 L minimal medium and 20 g/L 
galactose. 
 
Overexpression of tHMG1 led to increased final titers and yields of cubebol compared to the 
control strain, YIP-0C-04 (Table 4.3 and Figure 4.3). In Table 4.3 the total sesquiterpene 
concentration was calculated using the known percentage of cubebol in the mixture produced 
by the multi-product enzyme, cubebol synthase (Asadollahi et al., 2008). Overexpression of 
tHMG1 from the genome or plasmid enhanced the cubebol production, but plasmid 
overexpression had a greater impact. However, simultaneous overexpression of tHMG1 both 
from the plasmid and the genome in a single strain (YIP-MC-10) did not further improve 
cubebol production.  
Comparison of the yield of cubebol on galactose and on ethanol showed that ethanol was a 
more efficient carbon source for cubebol production as the yields were higher on ethanol (Table 
4.3). 
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Table 4.3. Final concentrations and yields of sesquiterpenes for the different yeast strains 
Yeast strain 
Cubebol 
(mg/L) 
Total 
sesquiterpenes 
(excluding 
farnesol) (mg/L) 
Farnesol 
(mg/L) 
Yield of 
cubebol on 
biomass (mg/g 
DW) 
Yield of 
cubebol on 
galactose 
(mg/g 
galactose) 
Yield of 
cubebol on 
ethanol 
(mg/g 
ethanol) 
YIP-0C-04 3.2 11.3  0.43 0.15 0.22 
YIP-MC-09 5.1 18.2  0.52 0.17 0.55 
YIP-MC-05 6.7 23.9  0.60 0.22 0.72 
YIP-MC-10 5.3 18.9  0.58 0.17 0.46 
YIP-MC-07 9.9 35.3 16.3 1.59 0.54 1.18 
YIP-MC-08 9.0 32.1 18.4 1.44 0.54 1.06 
Cells were grown in 5 L batch fermenters containing 4 L minimal medium and 20 g/L galactose 
 
4.3.3 Combining tHMG1 overexpression and ERG9 down-regulation 
In an earlier study (Asadollahi et al., 2008) it was found that repression of ERG9 in 
sesquiterpene producing yeast strains led to accumulation of the FPP derived compound, 
farnesol, indicating an increase in the intracellular pool of FPP. Besides farnesol, this strategy 
also improved the target sesquiterpene production with a more profound effect on patchoulol 
biosynthesis presumably because of higher activity of patchoulol synthase compared to 
valencene and cubebol synthases. Here we combined down-regulation of ERG9 and 
overexpression of tHMG1 in a cubebol producing yeast strain. Down-regulation of ERG9 alone 
in a cubebol producing strain led to a 3-fold increase in cubebol titer but combination of ERG9 
down-regulation and tHMG1 overexpression did not further improve cubebol production (Table 
4.3 and Figure 4.3).  
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Figure 4.3. Cubebol, galactose and OD600 profiles as a function of time for the cubebol 
producing yeast strains (a) YIP-0C-04; (b) YIP-MC-09; (c) YIP-MC-05; (d) YIP-MC-10; (e) 
YIP-MC-07;  (f) YIP-MC-08. Cells were grown in 5 L batch fermenters containing 4 L 
minimal medium and 20 g/L galactose 
 
a) b) 
c) d) 
e) f) 
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4.3.4 Effect of tHMG1 overexpression on ergosterol content of the cells 
To assess the effect of tHMG1 overexpression on ergosterol which is the end product of the 
pathway, the ergosterol content of tHMG1 overexpressed strains were determined and 
compared with the control (YIP-0C-04) and WT (CEN.PK113-7D) strains (Figure 4.4). The 
increase in the ergosterol content of cells is not proportionally correlated with the increase in 
the HMG-CoA reductase activity and increase in the cubebol titer meaning that conversion of 
HMG-CoA to mevalonate is not the only rate controlling step in the complete ergosterol 
pathway and there are other regulatory sites downstream in the pathway towards ergosterol 
(Polakowski et al., 1998). 
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Figure 4.4. Influence of tHMG1 overexpression on ergosterol content of yeast strains. 
Cells were grown in shake flasks containing 100 ml medium and 20 g/L galactose. 
 
4.3.5 Ergosterol content of cells in the ERG9 down-regulated strains 
We previously observed reduced ergosterol content of cells upon down-regulation of ERG9 by 
replacing its endogenous promoter with a regulated MET3 promoter in the presence of 
methionine (Asadollahi et al., 2008). In this study, we also determined the ergosterol content of 
all ERG9 down-regulated strains harboring the cubebol synthase gene or no sesquiterpene 
synthase (Figure 4.5). Surprisingly, we observed that ergosterol biosynthesis in the ERG9 
repressed strains is restored when cubebol synthase is expressed in this background strain both 
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on galactose and glucose whereas the YIP-M0-04 strain had lower ergosterol content as it was 
expected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Influence of ERG9 down-regulation and the combination of ERG9 repression and 
tHMG1 overexpression on ergosterol content of yeast strains. Cells were grown in shake flasks 
containing 100 ml medium and 20 g/L of either galactose (GAL) or glucose (GLC) as carbon 
sources. Repression of ERG9 was induced by supplementing media with 2 mM methionine. 
YIP-M0-04 strain was also supplemented with 100 mg/L uracil as it had auxotrophy towards 
uracil. 
 
4.3.6 Influence of tHMG1 overexpression on squalene accumulation 
Overexpression of tHMG1 did not lead to a substantial increase in the ergosterol content 
indicating the existence of other regulatory steps in the pathway. One of these regulatory steps 
is conversion of squalene to squalene epoxide catalyzed by squalene epoxidase and therefore 
accumulation of squalene in the strains with higher activity of HMG-CoA reductase is expected 
(Polakowski et al., 1998). Extraction and measurement of squalene in the tHMG1 
overexpressed strains also revealed a dramatic change in squalene concentration from trace 
amounts in the WT and control strains to several milligrams per gram of biomass for the 
mutants (Figure 4.6).  
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Figure 4.6. Influence of tHMG1 overexpression on squalene accumulation in the yeast strains. 
Cells were grown in shake flasks containing 100 ml medium and 20 g/L galactose. 
 
4.3.7 Effect of ERG9 down-regulation on squalene accumulation 
Quantification of ergosterol for the ERG9 down-regulated strains showed unexpectedly high 
levels of ergosterol for these strains whenever cubebol synthase was also expressed. Therefore 
it would be interesting to see if expression of cubebol synthase in an ERG9 repressed strain 
leads to accumulation of squalene as well. Figure 4.7 presents the squalene levels for the ERG9 
repressed strains. Again, to our surprise, we observed high squalene levels for the ERG9 
repressed strains upon expression of cubebol synthase but in contrary to the results from the 
ergosterol analysis, the squalene level was very low when the YIP-MC-07 strain was grown on 
glucose as carbon source (Figure 4.7). 
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Figure 4.7. Influence of ERG9 down-regulation and the combination of ERG9 down-regulation 
and tHMG1 overexpression on squalene accumulation in the different yeast strains. Cells were 
grown in shake flasks containing 100 ml medium and 20 g/L of either galactose (GAL) or 
glucose (GLC) as carbon sources. Repression of ERG9 was induced by supplementing media 
with 2 mM methionine. YIP-M0-04 strain was also supplemented with 100 mg/L uracil since it 
had auxotrophy towards uracil. 
 
4.4 Discussion 
In this study, we deregulated the mevalonate pathway in the yeast S. cerevisiae in order to 
enhance the biosynthesis and also availability of FPP which is precursor for the biosynthesis of 
sesquiterpenes. Deregulation of the mevalonate pathway was accomplished by constructing 
strains overproducing HMG-CoA reductase which is responsible for the catalysis of the main 
flux controlling step in the mevalonate pathway. Overexpression of the truncated HMG1 
encoding the catalytic domain of HMG-CoA reductase was first done by integrating tHMG1 
into the genome under control of the strong constitutive TPI1 promoter. This modification 
enhanced the activity of the enzyme by approximately 45% and increased the biosynthesis of 
valencene and cubebol by roughly 40% in shake flask experiments. The tHMG1 gene was 
further overexpressed by cloning it into a high copy number plasmid under control of the strong 
inducible GAL10 promoter. Overexpression of tHMG1 from plasmid was more efficient and 
the final concentration of cubebol in batch fermenter reached to 6.7 mg/L whereas the cubebol 
concentration was 5.1 mg/L when tHMG1 was overexpressed by genomic integration. 
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However, simultaneous overexpression of tHMG1 from both the genome and high copy 
number plasmid did not further improve cubebol production.  
In addition to enhancing sesquiterpene production, overexpression of tHMG1 resulted in 
accumulation of squalene in the cells. Squalene accumulating organisms are scarce in the 
nature and the liver oil of deep-sea shark, which is traditionally used for squalene production 
(Donald et al., 1997), is one of the few exceptions with up to 60% squalene (Pietsch and Jaeger, 
2007). Although the wild type strain contained trace amounts of squalene, the tHMG1 
overexpressed strains were able to accumulate up to 9 mg squalene/g DW. Accumulation of 
squalene as a result of tHMG1 overexpression has been reported by other investigators as well 
(Donald et al., 1997; Polakowski et al., 1998) and proposes the reaction catalyzed by squalene 
epoxidase as a flux controlling step in the ergosterol biosynthetic pathway (Polakowski et al., 
1998; Veen et al., 2003). Comparison of kinetic parameters of the enzymes squalene synthase 
and squalene epoxidase may explain why squalene expoxidase is a flux controlling step in the 
ergosterol pathway. The yeast squalene synthase has a Km value of 2.5 µM for its substrate FPP 
(LoGrasso et al., 1993) and the wild type specific activity for this enzyme was found to be 460 
pmol min-1 mg-1 (Jennings et al., 1991) whereas the reported numbers for the yeast squalene 
epoxidase are 13.5 µM and 32.1 pmol min-1 mg-1, respectively (Satoh et al., 1993). The higher 
Km value of squalene epoxidase for its substrate and lower specific activity of this enzyme 
suggest that squalene epoxidase has lower capacity than squalene synthase and this could lead 
to accumulation of squalene if the flux through the pathway exceeds a certain limit e.g. when 
HMG-CoA reductase is overproduced. Expression of cubebol synthase does not result in a 
sufficiently high drain of FPP from the sterol pathway to avoid squalene build up. Typical Km 
values of sesquiterpene synthases for FPP are in the range of 0.4-10 µM (Picaud et al., 2005) 
which is comparable with that of yeast squalene synthase. However, the reported catalytic 
activities for sesquiterpene synthases are much smaller than the kcat for the yeast squalene 
synthase. For instance, the kcat values for amorpha-4,11-diene synthase from Artemisia annua 
L. vary from 3.4 × 10-4 to 15.4 × 10-3 s-1 depending on pH and the divalent metal ions (Picaud et 
al., 2005) and germacrene D synthase from Zingiber officinale has a kcat value of 3.34 × 10-3 s-1 
(Picaud et al., 2006) whereas squalene synthase has a kcat value of 0.53 s-1 (LoGrasso et al., 
1993). These low values indicate that the conversion of FPP to sesquiterpenes by sesquiterpene 
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synthases is less efficient than the condensation of two FPP molecules to squalene by squalene 
synthase.  
Polakowski and coworkers (1998) noticed that the squalene content of HMG-CoA reductase 
overproduced yeast strains is not proportionally correlated with the activity of the enzyme since 
similar levels of squalene were produced for two strains that differed in the HMG-CoA 
reductase activity by a 16-fold factor. Since YIP-MC-05 and YIP-MC-10 strains accumulated 
close amounts of squalene it is likely that the squalene content is at inhibitory level and the 
strain YIP-MC-10 cannot support more flux through the pathway and this may explain why the 
strain YIP-MC-10 did not produce more cubebol than the strain YIP-MC-05.  
Overexpression of tHMG1 resulted in a reduction in the specific growth rate of yeast strains. 
This could be due to accumulation of squalene and its cytotoxic effects at high concentrations 
(Donald et al., 1997). Treatment of fungi with squalene epoxidase inhibitors such as terbinafine 
results in ergosterol depletion of fungal cell membrane and also high intracellular concentration 
of squalene which is believed to interfere with normal fungal membrane function and cell wall 
synthesis (Mukherjee et al., 2003; Liu et al., 2004). In contrary to the lower specific growth rate 
of squalene accumulating yeast strains observed by us and Donald et al. (1997), Veen et al. 
(2003) did not observe any adverse effect of squalene accumulation on cell growth.  
FPP is a branch-point intermediate of the mevalonate pathway that serves as a substrate for 
several important enzymes. However most of the FPP is used for the biosynthesis of sterols and 
therefore minimizing the flux of FPP towards sterols would enhance available FPP for other 
enzymes of the branch-point including sesquiterpene synthases. We previously (Asadollahi et 
al., 2008) reduced the FPP utilization for sterols by replacing the endogenous ERG9 promoter 
with a repressible MET3 promoter. This strategy led to reduced ergosterol content of cells and 
enhanced sesquiterpene biosynthesis, but we also found that there was accumulation of farnesol 
as a major FPP derived by-product. Here, we combined overexpression of tHMG1 and down-
regulation of ERG9 to both enhance the flux through the pathway and improve the availability 
of FPP for sesquiterpene synthases. Down-regulation of ERG9 alone increased the cubebol titer 
more than 3-fold and farnesol was also accumulated. However, overexpression of tHMG1 in 
this background did not further improve cubebol production. This does not accord with the 
results obtained by Ro and coworkers (2006) who reported a 2-fold increase in amorphadiene 
titer after down-regulation of ERG9 in a tHMG1 overexpressed yeast strain and a further 50% 
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increase after integration of a second copy of tHMG1 in this background. Also for lycopene 
production in C. utilis it was shown that disruption of one of the copies of ERG9 and 
overexpression of tHMG1 resulted in improved lycopene production (Shimada et al., 1998).  
Examination of the YIP-MC-07 and YIP-MC-08 strains for their sterol content revealed that 
these two strains were able to build up the same levels of ergosterol as the wild type strain 
during growth on both galactose and glucose as carbon source whereas the YIP-M0-04 strain 
had a lower ergosterol content. This means that expression of cubebol synthase restored the 
ergosterol biosynthesis in these strains. Surprisingly, these strains also accumulated a 
substantial amount of squalene comparable to the amounts accumulated by the tHMG1 
overexpressed strains, but only when they were grown on galactose as carbon source where the 
cubebol synthase is expressed. Since down-regulation of ERG9 is expected to minimize the 
flux towards ergosterol and it was confirmed by determination of ergosterol content in the  
YIP-M0-04 strain, our findings arise the question whether this change is only a result of 
expressing cubebol synthase. We speculate that since ergosterol is vital for cell growth and 
there is a tight regulation in the pathway to maintain a certain amount of ergosterol in the cell 
one of the intermediates in the cubebol biosynthetic pathway is somehow able to react with 
FPP and make squalene thereby bypassing the native pathway for squalene and ergosterol 
biosyntheses. Since ergosterol has priority for the cell over sesquiterpenes, the first formed 
intermediates are rerouted to squalene and then to ergosterol. However, the mechanism by 
which squalene can be produced via cubebol synthase still remains to be addressed. The reason 
for the ergosterol level, but not the squalene level, being high on glucose could be due to some 
basal expression of cubebol synthase by the GAL1 promoter in the presence of glucose. The 
expression of cubebol synthase in this case is low and the formed intermediates are channeled 
to ergosterol with no accumulation of squalene. Accumulation of squalene implies that the 
ergosterol content is high and squalene epoxidase is inhibited by feed back regulation triggered 
by ergosterol. This feed back regulation can also inhibit HMG-CoA reductase and thus 
increased expression of tHMG1 cannot enhance the carbon flux towards FPP. In contrast to our 
results, in a very recent study on the production of amorphadiene by ERG9 repressed yeast 
strains, addition of methionine to the medium reduced both ergosterol and squalene as expected 
(Paradise et al., 2008).  
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Comparison of cubebol yields in different phases of growth showed that ethanol was more 
efficient as carbon source than galactose. The higher yield on ethanol could be due to a higher 
cytosolic pool of acetyl-CoA when yeast grows on ethanol as carbon source. Also during 
growth on ethanol, the SNF1 protein kinase is activated, which subsequently inhibits the 
activity of acetyl-CoA carboxylase (Woods et al., 1994; Mitchelhill et al., 1994). This reduces 
the acetyl-CoA consumption for fatty acid biosynthesis and thus more acetyl-CoA can be 
directed to the mevalonate pathway. In addition, ACS1, which encodes acetyl-CoA synthetase 
is less repressed in the presence of ethanol compared to glucose (van den Berg et al., 1996) and 
probably galactose. Furthermore, metabolism of ethanol by its conversion to acetaldehyde and 
then acetate which is subsequently converted to acetyl-CoA is accompanied by generation of 
NADPH which is required as a cofactor for HMG-CoA reductase. Consistent with our finding, 
substantially higher yields of the polyketide 6-MSA has been reported during the yeast growth 
on ethanol (Wattanachaisaereekul et al., 2007). 
In summary, the engineered yeast strains in this study produced up to approximately 10 mg/L 
cubebol or 51.6 mg/L of total sesquiterpenes. Taking into account the accumulated squalene 
and assuming that accumulated squalene originates from one of the intermediates of cubebol 
synthase, the yeast strains were able to produce roughly 110 mg/L sesquiterpene equivalents, 
and the yeast strains hereby represent a good platform for further development of an industrial 
process for production of sesquiterpenes. 
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Chapter 5 
Enhancing sesquiterpene production in S. cerevisiae through 
in silico driven metabolic engineering 
 
5.1 Introduction 
Metabolic engineering emerged over a decade ago as an independent scientific discipline 
following rapid developments in genetic engineering tools. This significantly facilitated rational 
design of cell factories in order to obtain desired cellular phenotypes (Nielsen, 2001). Since then, 
there have been numerous successful examples of metabolic engineering for improved 
production of endogenous or heterologous products, extension of substrate range used by 
microorganism, introduction of new catalytic activities for degradation of toxic compounds and 
manipulation of cell properties (Nielsen, 2001; Stephanopoulos et al., 1998). These remarkable 
accomplishments in most cases were achieved through alteration of gene expressions or 
introduction of new genes by taking the advantage of molecular biology tools.  
Metabolic engineering of cell factories for heterologous production of isoprenoids is a prominent 
example showing how metabolic engineering strategies can be applied for improving a certain 
phenotype (for review see Maury et al., 2005). Application of metabolic engineering strategies 
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has allowed production of up to 480 mg/L amorphadiene (Newman et al., 2006), 102 mg/L 
lycopene (Yoon et al., 2006) and 503 mg/L β-carotene (Yoon et al., 2007) in engineered E. coli 
strains. There are also several studies on the engineering of the mevalonate pathway in yeast 
strains to enhance isoprenoid production (Yamano et al., 1994; Miura et al., 1998a; Miura et al., 
1998b; Shimada et al., 1998; Jackson et al., 2003; Ro et al., 2006; Lindahl et al., 2006; Takahashi 
et al., 2007; Shiba et al., 2007; Asadollahi et al., 2008).  
The metabolic engineering strategies applied to the yeast strains were mainly relying on the 
manipulation of the classical targets in the mevalonate pathway such as overexpression of HMG1 
(Shimada et al., 1998; Verwaal et al., 2007; Jackson et al., 2003; Ro et al., 2006), disruption or 
down-regulation of ERG9 (Asadollahi et al., 2008; Ro et al., 2006; Shimada et al., 1998; 
Takahashi et al., 2007) and overexpression of ERG20 (Ro et al., 2006). There are only a few 
studies on alteration of genes outside the mevalonate pathway e.g. engineering of the pyruvate 
dehydrogenase bypass (Shiba et al., 2007), overexpression of semi-dominant mutant allele of a 
global transcription factor regulating sterol biosynthesis in yeast, upc2-1 (Ro et al., 2006; 
Jackson et al., 2003), and removing a phosphatase activity encoded by DPP1 (Takahashi et al., 
2007). In order to establish yeast as a platform for large scale production of isoprenoids, in 
addition to the genes directly involved in the mevalonate pathway, it is necessary to deregulate 
the pathway through manipulation of genes outside the pathway. However, this is a difficult task 
as it needs a comprehensive knowledge about all pathways and genes functioning in the cell and 
their interactions with each other, which is currently limited due to the immense complexity and 
non-linearity of interactions in the metabolic network and insufficient available information.  
Nevertheless, the explosion of data generated by annotated genome sequences has encountered 
metabolic engineering with new challenges in the post-genomic era mainly concerning 
exploiting the wealth of information for improving cellular phenotypes (Alper and 
Stephanopoulos, 2004). As such, this abundance of data has led to reconstruction of several 
genome-scale metabolic networks (Covert et al., 2001) including E. coli (Edwards and Palsson, 
2000; Reed et al., 2003), Haemophilus influenzae (Edwards and Palsson, 1999), and S. cerevisiae 
(Förster et al., 2003). Current genome scale models are, however, mainly stoichiometric and 
comprise a set of stoichiometric reactions to describe the biochemical reactions in the system 
(Patil et al., 2004). These genome scale models can be used to predict the cell behavior in certain 
conditions e.g. when a gene is disrupted by using constraint-based models such as flux balance 
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analysis (FBA) (Kauffman et al., 2003). This method is used for evaluating the feasible flux 
distributions in a metabolic network at steady-state conditions and assuming maximum growth as 
objective function. Adaptation of metabolic network for optimal growth is logical for wild type 
strains as a consequence of evolutionary pressure during million of years but may not hold for 
the mutant strains artificially constructed in the laboratory. Minimization of metabolic 
adjustments (MOMA) between a wild type and a knockout mutant could therefore be a more 
realistic objective function for assessing the flux distributions in the metabolic networks of 
deletion mutants (Segrè et al., 2002). The prediction power of FBA/MOMA simulations can 
effectively be used for metabolic engineering by formulating a bi-level programming framework 
for suggesting gene deletions leading to overproduction of a certain biochemical compound 
(Burgard et al., 2003). 
In this study, we sought to assess the effect of gene deletions on the flux distributions in the 
stoichiometric model of S. cerevisiae (Förster et al., 2003) in order to identify target genes whose 
deletions can improve sesquiterpene production in yeast. OptGene (Patil et al., 2005) which is an 
extension of OptKnock (Burgard et al., 2003) was used as a modeling framework and MOMA as 
objective function to identify the gene knockouts leading to enhanced sesquiterpene production. 
OptGene uses a genetic algorithm method to search for the global optimal solution and is 
advantageous over OptKnock because it demands less computational time and allows 
optimization of non-linear objective functions (Patil et al., 2005).   
 
5.2 Materials and methods 
5.2.1 In silico computations 
Conversion of FPP to sesquiterpenes catalyzed by sesquiterpene synthases was introduced into 
the stoichiometric model of S. cerevisiae (Förster et al., 2003). This model consisted of 1175 
metabolic reactions and 584 unique metabolites.  
The gene knockouts leading to enhanced sesquiterpene biosynthesis were found by using the 
OptGene algorithm (Patil et al., 2005) and MOMA as objective function. Thus, the knockouts 
leading to higher sesquiterpene yields were selected and further tested experimentally. 
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5.2.2 Strain construction  
The plasmids pIP025 and pIP028 and also the strains YIP-0C-04 and YIP-MC-05 were described 
previously (chapter 4). In order to construct the strains YIP-00-07 and YIP-00-08, the 
CEN.MS1-10C T1 and CEN.PK113-13D were mated together on YPD plates. The next day 
some of the large colonies (the large colonies are more likely to be diploid) were picked and 
placed on an YPD master plate. After growing one day on this plate, the cells were replica plated 
onto a sporulating plate. After 3 days at 30 ºC, a small bit of cells from the sporulation plate was 
taken off with a sterile toothpick and mixed with 10 µl of sterile distilled water. 10 µl of 5 mg/ml 
Zymolyase was added to the mixture and incubated at room temperature for 10 min. The reaction 
was stopped by placing the samples on ice and adding 150 µl of sterile H2O. Spores were 
dissected, separated with a glass needle under microscope, and grown on YPD medium for 3 
days at 30 °C.  
In the next step the tetrads were tested for the desired genotypes. Disruption of URA3 was 
confirmed by growing the strains on SC (synthetic complete medium containing 2% glucose) 
and SC-ura (synthetic complete medium without uracil). Overexpression of GDH2 was also 
verified by growing the strains on YPD plates supplemented with 300 mg/L G418.  
To identify the mating type, the haploid strains on the dissection plate were mated with mating 
tester strains. Those plates were replica plated onto sporulation plates and incubated at 30 ºC for 
3-4 days. The ability of spores to fluoresce under UV lamp at 302nm wavelength, made it 
possible to see which strain was originally MAT a and which was MAT α. 
Deletion of GDH1 in the strains was verified by colony PCR using the primers 
GGTTTGGGCAGGGAAATGTC and GTCCAATCAGCAGAGAGAAG. Thus, the strains YIP-
00-07 and YIP-00-08 were obtained. Transformation of these strains with either pIP025 or 
pIP028 plasmid resulted in YIP-0C-05, YIP-MC-11 and YIP-0C-06 strains. Table 5.1 lists the 
strains used in this study. 
 
5.2.3 Media for batch cultivations 
A defined minimal medium as described by Verduyn et al. (1992) containing 20 g/L of galactose 
as the sole carbon source was used for all batch fermentations. The media had the following 
compositions: 5 g/L (NH4)2SO4; 3 g/L KH2PO4; 0.5 g/L MgSO4.7H2O; 1 ml/L trace metal 
solution; 1 ml/L vitamin solution and 50 µl/L synperonic antifoam.  
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Galactose was autoclaved separately from the medium and subsequently added to the fermenter, 
as was the case for the vitamin solution that was added after filter sterilization. 
 
5.2.4 Batch fermentations 
Batch fermentations were carried out in well-controlled 5 L in-house manufactured glass 
bioreactors with a working volume of 4 L. The bioreactors were equipped with two disk-turbine 
impellers and 4 baffles to ensure proper mixing. The pH was controlled between 4.95 and 5.05 
by automatic addition of 2M NaOH. The temperature was kept constant at 30 ºC.  The air flow 
was 4 L/min (1 vvm) and was sterilized by filtration and the off gas passed through a condenser. 
Carbon dioxide and oxygen concentrations in the off-gas were determined by a Brüel & Kjær 
acoustic gas analyzer (Brüel & Kjær, Nærum, Denmark). Batch fermenters were inoculated to an 
initial OD600 of 0.02 from a liquid preculture. Three hundred milliliters of dodecane was added 
aseptically to the media at OD600 0f 1 ± 0.1. 
 
5.2.5 OD and dry weight determinations 
The OD of samples was determined at 600 nm in duplicate by using a Hitachi U-1100 
spectrophotometer. Dry weight measurement was achieved by using 0.45 µm pore-size 
nitrocellulose filters (Sartorius AG, Göttingen, Germany) according to the method described by 
Dynesen et al. (1998).  
 
5.2.6 Analysis of galactose and extracellular metabolites 
Determination of galactose and extracellular metabolites was performed as described previously 
(Asadollahi et al., 2008).  
 
5.2.7 Analysis of sesquiterpenes in the organic layer  
Samples from organic layer were centrifuged for 5 min at 3500 rpm and subsequently analyzed 
by GC-MS to determine the level of sesquiterpenes during the course of fermentation as 
described (Asadollahi et al., 2008).  
                                              
 
 Table 5.1. Strains used in this study 
Strain Genotype Plasmid Plasmid description Reference 
     YIP-00-03 (CEN.PK113-5D) MATa MAL2-8c SUC2 ura3-52 none  Peter Köttera 
CEN.PK113-13D MATα MAL2-8c SUC2 ura3-52   Peter Köttera 
CEN.MS1-10C T1 
MATa MAL2-8c SUC2 
gdh1(209,1308)::loxP 
gdh2::PPGK-GDH2-KanMX3 
none  
Santos et al., 
2003 
YIP-00-08 
MATa MAL2-8c SUC2 ura3-52 
gdh1(209,1308)::loxP none  This study 
YIP-00-07 
MATa MAL2-8c SUC2 ura3-52 
gdh1(209,1308)::loxP 
gdh2::PPGK-GDH2-KanMX3 
none  This study 
YIP-0C-04 MATa MAL2-8c SUC2 ura3-52 pIP025 pESC-URA 2µ URA3 PGAL1- GFTpsC Chapter 4 
YIP-MC-05 MATa MAL2-8c SUC2 ura3-52 pIP028 
pESC-URA 2µ URA3 PGAL1-GFTpsC 
PGAL10-tHMG1 
Chapter 4 
YIP-0C-06 
MATa MAL2-8c SUC2 ura3-52 
gdh1(209,1308)::loxP pIP025 pESC-URA 2µ URA3 PGAL1- GFTpsC This study 
YIP-0C-05 
MATa MAL2-8c SUC2 ura3-52 
gdh1(209,1308)::loxP 
gdh2::PPGK-GDH2-KanMX3 
pIP025 pESC-URA 2µ URA3 PGAL1- GFTpsC This study 
YIP-MC-11 
MATa MAL2-8c SUC2 ura3-52 
gdh1(209,1308)::loxP 
gdh2::PPGK-GDH2-KanMX3 
pIP028 
pESC-URA 2µ URA3 PGAL1-GFTpsC 
PGAL10-tHMG1 
This study 
     
   a Institut für Mikrobiologie, der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany
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5.3 Results 
5.3.1 In silico metabolic engineering 
The reaction for conversion of the precursor FPP to sesquiterpenes was added to the original 
genome-scale model of S. cerevisiae (Förster et al., 2003) and the intracellular fluxes of the 
resulting model were calculated for the knockout mutants subject to MOMA using OptGene 
(Patil et al., 2005) to find the genes whose deletion could increase the flux towards 
sesquiterpenes. Deletion of GDH1 coding glutamate dehydrogenase turned out to be the best 
target gene for the further experimental work.  
Glutamate dehydrogenase encoded by GDH1 is involved in ammonium metabolism in yeast. 
Once imported in the cell, ammonium is incorporated into amino group of glutamate and amide 
group of glutamine which serve as nitrogen source for 85% and 15% of the total nitrogen 
containing compounds in the cell, respectively (Magasanik and Kaiser, 2002). There are two 
metabolic routes for the biosynthesis of glutamate as the main source of nitrogen in the cell 
(Figure 5.1) (ter Schure et al., 2000). In the first strategy which is the major route in S. cerevisiae, 
ammonium reacts with α-ketoglutarate to form glutamate. This reaction is catalyzed by NADPH-
dependent glutamate dehydrogenase encoded by GDH1 (Moye et al., 1985). The other pathway 
which is a two step process (GS-GOGAT) is mediated by glutamine synthetase (GS) and 
glutamate synthase (GOGAT) encoded by GLN1 and GLT1, respectively (Magasanik, 2003).  
There are two other glutamate dehydrogenases in S. cerevisiae encoded by GDH2 and GDH3. In 
contrary to GDH1, which uses NADPH as cofactor, GDH2 is NADH-dependent. However, 
Gdh2p has much lower activity than Gdh1p in normal cell when ammonium is used as the sole 
nitrogen source (Nissen et al., 1997). GDH3 also codes an NADPH-dependent glutamate 
dehydrogenase activity and it was shown that the cells lacking both GDH1 and GLT1 are still 
able to grow and are not completely glutamate auxotroph whereas the triple GDH1 GDH3 GLT1 
mutants were glutamate auxotroph suggesting a physiological role for GDH3. Nevertheless, 
simultaneous deletion of GDH1 and GDH3 did not affect the cell phenotype compared to the 
single GDH1 deletion which implies NADPH-dependent GDH1 and the GS-GOGAT pathway 
are the major routes for ammonium assimilation (Avendaño et al., 1997). 
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Figure 5.1. Ammonium assimilation pathway in S. cerevisiae 
 
A substantial amount of NADPH in the cell is used as cofactor for the reaction catalyzed by 
NADPH-dependent glutamate dehydrogenase (GDH1) (dos Santos et al., 2003). Therefore, if 
GDH1 is deleted there will be more NADPH available for other NADPH requiring reactions in 
the cell. In the third step of the mevalonate pathway in yeast, HMG-CoA is converted to 
mevalonate by the action of HMG-CoA reductase. This reaction is considered as a major flux 
controlling step in the mevalonate pathway (Veen and Lang, 2004) and requires NADPH as 
cofactor. Deletion of GDH1 could be beneficial for this reaction as there will be more accessible 
NADPH for the HMG-CoA reductase and therefore deletion of GDH1 suggested by in silico 
metabolic engineering makes biologically sense. However, since disruption of GDH1 impairs the 
ammonia utilization, overexpression of the NADH-dependent glutamate dehydrogenase, GDH2, 
was also considered in this study. 
 
5.3.2 Effect of alterations on specific growth rates and yields 
The strains were grown in 5 L batch two phase fermenters. Table 5.2 summarizes the specific 
growth rates and yields of ethanol and glycerol on galactose for the characterized strains. 
Deletion of GDH1 severely affected the specific growth rate of yeast strains. However, 
overexpression of GDH2 restored the growth to some extent.  Overexpression of tHMG1 further 
improved the specific growth rate which is in contrary to our previous observation that 
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overexpression of tHMG1 led to lower specific growth rates (Chapter 4). Manipulation of the 
nitrogen metabolism did not affect the yield of ethanol substantially but there was a marked 
decrease in the yield of glycerol.  
 
Table 5.2. Maximum specific growth rates on galactose (µmax), yields of ethanol on galactose 
(YS/EtOH), and yields of glycerol on galactose (YS/Glycerol) for the characterized strains 
Strain 
µmax 
 
(h-1) 
YS/EtOH 
(g/g) 
YS/Glycerol 
(g/g) 
YIP-0C-04 0.20 0.138 0.015 
YIP-0C-06 0.07 0.133 0.006 
YIP-0C-05 0.13 0.142 0.008 
YIP-MC-11 0.15 0.120 0.013 
 
5.3.3 Sesquiterpene production 
The strains manipulated in the ammonium assimilation pathway were characterized for 
sesquiterpene production in 5 L two phase batch fermenters (Figure 5.2). Table 5.3 lists the final 
titer and yield of sesquiterpenes for the cubebol producing yeast strains. In Table 5.3 total 
sesquiterpenes were calculated using the known percentage of cubebol in the mixture produced 
by the multi-product enzyme, cubebol synthase (Asadollahi et al., 2008). Deletion of GDH1 as 
was predicted by in silico modeling increased cubebol production substantially. Overexpression 
of GDH2 did not further enhance cubebol production but as mentioned above it resulted in an 
increased specific growth rate in the YIP-0C-05 compared to the YIP-0C-06 strain. 
Overproduction of the catalytic domain of HMG-CoA reductase (YIP-MC-11 strain) further 
improved cubebol production as it was expected. 
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Figure 5.2. Cubebol, galactose and OD600 profiles as a function of time for the cubebol 
producing yeast strains (a) YIP-0C-04; (b) YIP-0C-06; (c) YIP-0C-05; (d) YIP-MC-11 
Cells were grown in 5 L batch fermenters containing 4 L minimal medium and 20 g/L galactose. 
 
 
Table 5.3. Final concentrations and yields of sesquiterpenes for the different yeast strains 
Yeast strain 
Cubebol 
(mg/L) 
Total sesquiterpenes 
(mg/L) 
Yield of cubebol on 
biomass  
(mg/g DW) 
Yield of cubebol on 
galactose  
(mg/g galactose) 
YIP-0C-04 3.2 11.3 0.43 0.15 
YIP-0C-06 5.9 20.9 0.83 0.26 
YIP-0C-05 6.0 21.3 0.81 0.28 
YIP-MC-11 8.4 30.1 0.83 0.24 
Cells were grown in 5 L batch fermenters containing 4 L minimal medium and 20 g/L galactose 
 
 
a) b) 
c) d) 
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5.4 Discussion 
Metabolic engineering of cell factories in order to improve a cellular phenotype e.g. 
overproduction of a biochemical compound often requires manipulation of several genes in the 
cell. However, as the metabolic pathways are highly inter-connected, manipulation of a gene will 
often have secondary effects on other pathways and subsequently on the cell behavior. Therefore 
there has been a paradigm shift in metabolic engineering from focusing only on one gene related 
with the pathway of interest to the entire metabolic networks. However, because of the 
complicated regulation, lack of information on the kinetics of enzymes and little information on 
the mechanism of interaction of pathways, it is difficult to predict the minimum genetic 
modifications in order to exploit the maximum capacity of cell for a desired phenotype. Despite 
their limited predictive power (Gombert and Nielsen, 2000), genome scale models that are 
primarily stoichiometric models, can be used to suggest required changes in the genotype for a 
desired phenotype. This strategy has been used with success for identifying new target genes for 
heterologous production of lycopene in E. coli (Alper and Stephanopoulos, 2004; Alper et al., 
2005).  
In this study, we used the genome-scale reconstructed metabolic network of S. cerevisiae (Förster 
et al., 2003) to identify new target genes for improved production of cubebol in yeast. Disruption 
of NADPH-dependent glutamate dehydrogenase encoded by GDH1 was identified as the best 
target. Deletion of this gene will enhance the available NADPH in the cytosol for other NADPH 
requiring reactions, including HMG-CoA reductase. In addition to disruption of GDH1, 
overexpression of the NADH-dependent glutamate dehydrogenase encoded by GDH2 was also 
pursued to restore efficient utilization of ammonium by cells.  Manipulation of the ammonium 
assimilation pathway has been carried out for the purpose of improving ethanol production 
through reducing glycerol formation, the main by-product in anaerobic yeast fermentation. Thus, 
deletion of GDH1 increased the ethanol yield by 8% and reduced the glycerol yield by 38%. The 
increased NADH consumption and ATP formation by the alternative GS-GOGAT pathway was 
the reason for these changes (Nissen et al., 2000). Likewise, this strategy enhanced ethanol 
production on xylose (Roca et al., 2003). Deletion of glutamate dehydrogenase (gdhA) in 
lycopene producing E. coli also led to a 13% improvement in lycopene accumulation (Alper and 
Stephanopoulos, 2004; Alper et al., 2005). 
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Deletion of GDH1 in the current study led to an approximately 85% increase in the final cubebol 
titer. However, deletion of this gene also caused a significant decrease in the maximum specific 
growth rate. This is in consistence with earlier reports on the reduced growth rate of yeast strains 
on glucose as a consequence of GDH1 deletion in both anaerobic (Nissen et al., 2000) and 
aerobic (dos Santos et al., 2003) conditions. Overexpression of GDH2 did not show a further 
effect on the final cubebol titer but the YIP-0C-05 strain had a higher maximum specific growth 
rate compared to the YIP-0C-06 strain. However, the maximum specific growth rate of the YIP-
0C-05 strain was still lower than that of YIP-0C-04 while in other studies overexpression of 
GDH2 completely restored the specific growth rate on glucose to the wild type level (Nissen et 
al., 2000; dos Santos et al., 2003). Although overexpression of GDH2 enables cells to utilize 
ammonium as nitrogen source more efficiently, the modification of ammonium assimilation 
pathway changes the NADPH/NADP+ ratio significantly. This could in turn have secondary 
effects such as channeling isocitrate into the glyoxylate cycle (Satrustegui et al., 1983) or reduced 
flux through the pentose-phosphate pathway (dos Santos et al., 2003).  
The glycerol yields for both YIP-0C-06 and YIP-0C-05 were also significantly lower than that of 
YIP-0C-04 strain but there was not a marked change in ethanol yields. The surplus NADH in the 
cell is reoxidized to NAD+ to avoid imbalances in the NAD+/NADH ratio. Since deletion of 
GDH1 reroutes the formation of glutamate to the other NADH-dependent pathways there will be 
less free NADH and subsequently less glycerol formation (Nissen et al., 2000).  Deletion of 
GDH1 in the YIP-0C-06 strain leads to the formation of glutamate via the GS-GOGAT pathway 
accompanied by higher ATP consumption, which is presumably compensated by more ethanol 
formation (Nissen et al., 2000). However, in aerobic conditions the oxidative phosphorylation 
pathway is active and the slightly higher ATP consumption for growth does therefore not have a 
pronounced effect (dos Santos et al., 2003).   
Formation of 100 g yeast biomass growing on ammonium as nitrogen source requires 931 mmol 
of NADPH (Bruinenberg et al., 1983). In this study, the highest yield of cubebol on biomass was 
0.83 mg/g DW (2.96 mg total sesquiterpenes/ g DW). Assuming the molecular weight of 222 for 
all sesquiterpenes formed by cubebol synthase this yield is equivalent to 0.0133 mmol total 
sesquiterpenes/g DW. Since biosynthesis of each mmol sesquiterpene requires 6 mmol NADPH 
by HMG-CoA reductase as cofactor the highest NADPH requirement is 8 mmol/100 g DW. This 
is less than 1% of total NADPH requirement in the cell and therefore the question arises how 
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enhancing NADPH availability leads to improved sesquiterpene production. We speculate that 
the higher available pool of NADPH would thermodynamically favor the NADPH consuming 
reactions towards NADPH utilization and NADP+ generation to balance NADPH/NADP+ ratio. 
However, if the flux towards the mevalonate pathway is increased, at some point the availability 
of NADPH could also be a limiting factor for HMG-CoA reductase.  
Earlier work showed a lower specific growth rate when tHMG1 was overexpressed, presumably 
caused by accumulation of squalene (Chapter 4). By contrast, in this study the YIP-MC-11 had a 
higher maximum specific growth rate than the YIP-0C-05 strain. We speculate that since 
overexpression of tHMG1 increases the NADPH demand it could be beneficial for the cells with 
the modified ammonium utilization as it may lead to a reduction in the high NADPH/NADP+ 
ratio.  
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Chapter 6 
Metabolic engineering of S. cerevisiae for lycopene 
production 
 
6.1 Introduction 
Carotenoids comprise one of the largest and most diverse groups of naturally occurring pigments 
(Armstrong, 1997) and are responsible for the beautiful colors of many fruits and vegetables such 
as reds of tomatoes and oranges of carrots. Carotenoids are found in all photosynthetic organisms 
as well as in some non-photosynthetic bacteria and fungi (Hirschberg et al., 1997). Carotenoids 
play a variety of essential biological roles including antioxidant defense against photooxidation, 
accessory light harvesting components in photosynthesis, and protection against reactive oxygen 
species. Carotenoids are commercially used as food colorants, feed supplements in poultry and 
fish farming, and nutraceuticals (Lee and Schmidt-Dannert, 2002; Schmidt-Dannert et al., 2006). 
Of about 700 identified carotenoids in various organisms (Hornero-Méndez and Britton, 2002) 
only a few are currently produced in high quantities (Schmidt-Dannert et al., 2006). Although the 
initial large-scale processes for the production of carotenoids were based on native carotenoid 
producing organisms, the cheaper production by chemical synthesis outperformed the biological 
processes (Nicolás-Molina et al., 2008; Ausich, 1997). However, due to new findings about the
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 potential applications of carotenoids in preventing the onset of many diseases (Rao and Rao, 
2007; Fraser and Bramley, 2004) and an increasing demand for carotenoids, there has been a 
renewed attention for biotechnological production of carotenoids. In particular, isolation and 
characterization of more than 150 carotenogenic genes from several organisms (Lee and 
Schmidt-Dannert, 2002; Schmidt-Dannert, 2000) along with the rapid advances in recombinant 
DNA technologies have eased heterologous production of carotenoids in non-carotenogenic 
microorganisms.  
One of the key properties of carotenoids is their ability to quench singlet oxygen which is highly 
dependent on the number of double conjugated bonds in the molecule. Lycopene with 11 double 
conjugated bonds is the most effective carotenoid in this regard and its in vitro quenching rate 
constant is more than 2-fold higher than that of β-carotene (Di Mascio et al., 1989).  
Tomato is one of the most widely used natural sources of lycopene, but the lycopene 
concentration in tomato (10-30 mg/kg) is still not high enough to support a viable industrial 
source for lycopene production (Kerr et al., 2004). Therefore there have been several attempts to 
establish microbial production of lycopene in particular in non-carotenogenic microorganisms 
(Maury et al., 2005). In most of the studies on heterologous biosynthesis of lycopene, E. coli was 
used as the microbial host. However, there are also some reports on heterologous expression of 
carotenogenic genes in S. cerevisiae (Yamano et al., 1994) and C. utilis (Miura et al., 1998a; 
Miura et al., 1998b; Shimada et al., 1998) for lycopene production. In addition to its potential 
applications, lycopene can serve as a tool in metabolic engineering studies for high-throughput 
screening of overproducing mutants due to its strong red color (Alper et al., 2005; Kang et al., 
2005; Klein-Marcuschamer et al., 2007; Alper and Stephanopoulos, 2007). Furthermore, 
lycopene is an intermediate for other carotenoids and hence a mutant overproducer of lycopene 
can be used as a platform for the biosynthesis of other carotenoids as well.  
Previously, we deregulated the mevalonate pathway in S. cerevisiae in order to produce various 
plant sesquiterpenes (Asadollahi et al., 2008; Chapter 4; Chapter 5). Here, we studied 
heterologous production of lycopene in engineered yeast strains. The strains were engineered for 
overproduction of the catalytic domain of the enzyme catalyzing the flux controlling step in the 
mevalonate pathway, HMG-CoA reductase, and down-regulation of ERG9 to minimize the flux 
towards ergosterol.  
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In order to construct lycopene producing yeast strains, we expressed the codon optimized crtE, 
crtB, and crtI genes of the bacterium Erwinia herbicola encoding geranylgeranyl diphosphate 
synthase, phytoene synthase and phytoene desaturase, respectively. The constructed strains were 
characterized in batch fermenters for lycopene production.  
 
6.2 Materials and methods 
6.2.1 Plasmid construction  
The codon optimized crtE, crtB, and crtI genes from E. herbicola were synthesized (Entelechon 
GmbH, Regensburg, Germany) and cloned into pCR®4-TOPO cloning vector (Invitrogen). The 
sequences of original crtE, crtB, and crtI genes from E. herbicola and the codon optimized genes 
are shown in Appendix A. Cloning of crtE, crtB, and crtI genes into pCR®4-TOPO cloning 
vector led to the plasmids pIP033, pIP034, and pIP035, respectively. The plasmid pIP036 was 
constructed by cloning crtE in a pESC-URA vector (Stratagene) under control of GAL10 
promoter using SacI and NotI restriction sites. The plasmid pIP037 was constructed by cloning 
crtI in a pESC-HIS vector (Stratagene) under control of GAL10 promoter using SpeI and SacI 
restriction sites. Cloning of crtB under control of GAL1 promoter in the plasmid pIP037 using 
SalI and XhoI restriction sites resulted in the plasmid pIP038. The plasmid pIP039 was obtained 
by combining the pIP036 and pIP038 plasmids using gap repair technique. The piece of plasmid 
pIP038 containing crtB and crtI genes including their promoters and terminators was amplified 
using pURA_GAP_F and pURA_GAP_R primers (Table 6.1). The PCR conditions were in 
accordance with the Phusion™ Hot Start High-Fidelity DNA Polymerase (Finnzymes Oy, Espoo, 
Finland). The pIP036 plasmid was digested with MfeI restriction enzyme in parallel. The PCR 
product and the digested expression vector were separated by gel electrophoresis and gel purified 
using the QIAEX® II Gel extraction kit (Qiagen, Hilden, Germany). Homologous recombination 
of the PCR product into the digested expression vector after transformation of the strain 
CEN.PK113-5D with both fragments resulted in the plasmid pIP039. 
The plasmid pIP042 was obtained by cloning crtB in the plasmid pIP036 under control of GAL1 
promoter using SalI and XhoI restriction sites.  
Overexpression of the catalytic domain of HMG-CoA reductase (tHMG1) was performed using 
gap repair technique. The tHMG1 gene was amplified from the genomic DNA of S. cerevisiae 
CEN.PK113-7D using the primers GAP_HMG1_F and GAP_HMG1_R (Table 6.1). The 
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truncated coding region has an engineered Met start codon and then continues with the natural 
coding region from codon 531 (Asp) to the natural stop codon. The plasmid pIP037 was digested 
with BamHI and XmaI restriction enzymes. Homologous recombination of the PCR product into 
the digested pIP037 plasmid after transformation of the strain CEN.PK113-11C with both 
fragments resulted in the pIP043 plasmid. 
The plasmid pIP044 was obtained by combining the pIP042 and pIP043 plasmids using gap 
repair technique. The piece of plasmid pIP043 containing tHMG1 and crtI genes including their 
promoters and terminators was amplified using pURA_GAP_F and pURA_GAP_R primers 
(Table 6.1). The pIP042 plasmid was digested with MfeI restriction enzyme in parallel. 
Homologous recombination of the PCR product into the digested expression vector after 
transformation of CEN.PK113-5D with both fragments resulted in the pIP044 plasmid. 
The pIP041 plasmid was constructed using gap repair technique. The red fluorophore used in this 
study was a monomeric version of DsRed (mRFP1) (Campbell et al., 2002) and was amplified 
from the pWJ1350 plasmid (Lisby et al., 2003) using the RFP_crtI_F and RFP_R primers (Table 
6.1). The primers were designed so that after gap repair the stop codon of crtI gene was removed 
and a linker including 3 glycine amino acids was introduced between crtI and mRFP1 (The bold 
underlined sequence in RFP_crtI_F primer). In parallel, the plasmid pIP038 was digested with 
PacI and SacI restriction enzymes. Homologous recombination of the PCR product into the 
digested pIP038 plasmid after transformation of CEN.PK113-11C with both fragments resulted 
in the pIP041 plasmid. 
Table 6.2 and Table 6.3 list the plasmids and strains used in this study, respectively. 
 
Table 6.1. Primers used for constructing the plasmids 
Primer Sequence 
pURA_GAP_F cagcactaccctttagctgttctatatgctgccactcctACGCAAACCGCCTCTCCCCG 
pURA_GAP_R aggaaatgatagcattgaaggatgagactaatccaattaTCGGTGCGGGCCTCTTCGC 
GAP_HMG1_F actttaacgtcaaggagaaaaaaccccggatccACTATGGACCAATTGGTGAAAACTG 
GAP_HMG1_R ttcttcggaaatcaacttctgttccatgtcgacgccTTAGGATTTAATGCAGGTGACGGAC 
RFP_crtI_F tgctagtctgatgatcgaggatttgcaggagctcGGTGGTGGTATGGCCTCCTCCGAGGA 
RFP_R gacaagccgacaaccttgattggagacttgaccaaacctctggcgaagaattgttaattaaTTAGGCGCCGG 
TGGAGT 
Lower case letters are overhangs for homologous recombination. Upper case letters are the actual 
primer sequences. The underlined bold sequence shows the sequence coding for 3 glycine amino 
acid linker between crtI and mRFP1 genes.  
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Table 6.2. Plasmids used in this study 
Plasmid Description Reference 
pIP033 pCR®4-TOPO crtE Entelechon GmbH 
pIP034 pCR®4-TOPO crtB Entelechon GmbH 
pIP035 pCR®4-TOPO crtI Entelechon GmbH 
pIP036 pESC-URA 2µ URA3 PGAL10-crtE This study 
pIP037 pESC-HIS 2µ HIS3 PGAL10-crtI This study 
pIP038 pESC-HIS 2µ HIS3 PGAL1-crtB PGAL10-crtI  This study 
pIP039 pESC-URA 2µ URA3 PGAL10-crtE PGAL1-crtB PGAL10-crtI This study 
pIP041 pESC-HIS 2µ HIS3 PGAL1-crtB PGAL10-crtI-mRFP1 This study 
pIP042 pESC-URA 2µ URA3 PGAL10-crtE PGAL1-crtB This study 
pIP043 pESC-HIS 2µ HIS3 PGAL1-tHMG1 PGAL10-crtI This study 
pIP044 pESC-URA 2µ URA3 PGAL10-crtE PGAL1-crtB PGAL10-crtI PGAL1-tHMG1 This study 
 
 
Table 6.3. Strains used in this study 
Strain Genotype Plasmid Reference 
YIP-00-03 
(CEN.PK113-5D) MATa MAL2-8
c
 SUC2 ura3-52 none Peter Köttera 
CEN.PK113-11C MATa MAL2-8c SUC2 his3-∆1 ura3-52 none Peter Köttera 
YIP-M0-04 MATa MAL2-8c SUC2 ura3-52, erg9 ::PMET3-ERG9 none 
Asadollahi et 
al., 2008 
YIP-M0-03 MATa MAL2-8c SUC2, ura3 ::PTPI1-tHMG1 none Chapter 4 
YIP-0L-02 MATa MAL2-8c SUC2 his3-∆1 ura3-52 
pIP036 & 
pIP038 
This study 
YIP-0L-03 MATa MAL2-8c SUC2 ura3-52 pIP039 This study 
YIP-ML-03 MATa MAL2-8c SUC2 ura3-52, erg9 ::PMET3-ERG9 pIP039 This study 
YIP-ML-04 MATa MAL2-8c SUC2, ura3 ::PTPI1-tHMG1 pIP039 This study 
YIP-0L-05 MATa MAL2-8c SUC2 ura3-52 pIP042 This study 
YIP-ML-05 MATa MAL2-8c SUC2 ura3-52, erg9 ::PMET3-ERG9 pIP042 This study 
YIP-ML-06 MATa MAL2-8c SUC2 ura3-52 pIP044 This study 
YIP-ML-07 MATa MAL2-8c SUC2 ura3-52, erg9 ::PMET3-ERG9 pIP044 This study 
YIP-ML-08 MATa MAL2-8c SUC2, ura3 ::PTPI1-tHMG1 pIP044 This study 
YIP-0L-06 MATa MAL2-8c SUC2 his3-∆1 ura3-52 
pIP036 & 
pIP041 
This study 
a Institut für Mikrobiologie, der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany 
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6.2.2 Media for batch cultivations 
A defined minimal medium as described by Verduyn et al. (1992) containing 20 g/L of galactose 
as the sole carbon source was used for all batch fermentations. The media had the following 
compositions: 5 g/L (NH4)2SO4; 3 g/L KH2PO4; 0.5 g/L MgSO4.7H2O; 1 ml/L trace metal 
solution; 1 ml/L vitamin solution and 50 µl/L synperonic antifoam.  
Galactose was autoclaved separately from the medium and subsequently added to the fermenter, 
as was the case for the vitamin solution that was added after filter sterilization. 
 
6.2.3 Batch fermentations 
Batch fermentations were carried out in well-controlled 5 L in-house manufactured glass 
bioreactors with a working volume of 4 L. The bioreactors were equipped with two disk-turbine 
impellers and 4 baffles to ensure proper mixing. The pH was controlled between 4.95 and 5.05 by 
automatic addition of 2M NaOH. The temperature was kept constant at 30 ºC.  The air flow was 
4 L/min (1 vvm) and was sterilized by filtration and the off gas passed through a condenser. 
Carbon dioxide and oxygen concentrations in the off-gas were determined by a Brüel & Kjær 
acoustic gas analyzer (Brüel & Kjær, Nærum, Denmark). Batch fermenters were inoculated to an 
initial OD600 of 0.02 from a liquid preculture.  
 
6.2.4 OD and dry weight determinations 
The OD of samples was determined at 600 nm in duplicate by using a Hitachi U-1100 
spectrophotometer. Dry weight measurement was achieved by using 0.45 µm pore-size 
nitrocellulose filters (Sartorius AG, Göttingen, Germany) according to the method described by 
Dynesen et al. (1998).  
 
6.2.5 Analysis of galactose and extracellular metabolites 
Determination of galactose and extracellular metabolites was performed as described (Asadollahi 
et al., 2008).  
 
6.2.6 Extraction of carotenoids 
The biomass from a certain volume of culture media was harvested by centrifuging at 5000 rpm 
for 10 min. The cell pellet was washed with distilled water and centrifuged for another 10 min at 
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5000 rpm. The cell pellet was transferred to a 2 ml FastPrep® tube and resuspended in 1 ml 
acetone containing 100 mg/L butylated hydroxytoluene (BHT). Then 200 µl of precooled glass 
beads (0.25-0.50 mm) were added to the tube. The cells were broken by vortexing in FastPrep® 
instrument (FP 120, BIO 101, Savant, Holbrook, NY) at the speed set to 6.5 m/sec for 4×45 sec 
separated by periods of cooling on ice.  
 
6.2.7 Identification and quantification of carotenoids 
In order to identify lycopene and phytoene, the acetone extract was dried in a vacuum centrifuge 
and resuspended in 300 µl acetonitrile. Lycopene and phytoene were identified by reverse-phase 
HPLC (Hewlett-Packard HP 1090 chromatograph series II with built in diode array detector and 
auto-injector). Analytes were separated on a Develosil column (C30-UG-5, Nomura Chemicals, 
Aichi, Japan) with a mobile phase consisting of acetonitrile and methanol. The analysis was 
performed at 40 ºC and it was monitored at 474 nm for lycopene and 286 nm for phytoene. 
In order to quantify lycopene, the acetone extract was centrifuged at 20000 g for 5 min to remove 
the cell debris. The supernatant was filtered using 0.45 µm hydrophobic solvent resistant 
Minisart® filters (Sartorius AG, Göttingen, Germany). The OD of filtrate was measured at 474 
nm. The amount of lycopene was determined using absolute standard curves obtained after each 
analysis run. 
 
6.2.8 Fluorescence microscopy 
Cells were grown in 5 ml of SC-his-ura liquid media containing 20 g/L galactose as carbon 
source. Cultures were grown on a shaker at 150 rpm at 25 ºC to allow the mRFP1 chromophore 
to form efficiently. At OD of 0.3 at 600 nm, cells from 1ml of culture were spun down, washed in 
SC-his-ura media and spun down again. Five microliters of cells were immobilized on a glass 
slide by mixing with a 37 ºC solution of 1.2% (w/v) low melting agarose (Nusieve 3:1 from 
FMC) containing the appropriate medium. Live cell images were captured with a cooled 
Evolution QEi monochrome digital camera (Media Cybernetics Inc., Bethesda, MD, USA) 
mounted on a Nikon Eclipse E1000 automated microscope (Nikon, Japan). Images were captured 
at 100-fold magnification using a Plan-Flour 100x 1.3 NA objective lens. The illumination source 
was a 103 W mercury arc lamp (Osram, Germany). The filter used to visualize crtI-mRFP1 
(excitation 584 nm; emission 607 nm) was from Omega Optical (Brattleboro, VT, USA).  
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6.3 Results 
6.3.1 Identification of lycopene formation in the engineered strains 
The engineered strains harboring the genes for lycopene biosynthesis were grown in 5 L batch 
fermenters on galactose as the sole carbon source. The lycopene producing strains had a reddish 
color which was different from the control strains. This reddish color is an indication of lycopene 
accumulation in these strains but accumulation of lycopene was further confirmed by HPLC and 
comparing the peaks and UV spectra with those of standard lycopene.  
 
6.3.2 Effect of tHMG1 overexpression on lycopene accumulation 
Overproduction of the catalytic domain of HMG-CoA reductase which catalyzes the major flux 
controlling step in the mevalonate pathway was concomitant with higher lycopene production. 
Overexpression of tHMG1 from either the genome or a high copy number plasmid increased the 
lycopene accumulation. Overexpression of tHMG1 from plasmid had a greater impact and the 
YIP-ML-06 strain yielded 0.51 mg/g DW lycopene. However, simultaneous overexpression of 
tHMG1 from both plasmid and genome did not further improve lycopene production (Figure 6.1). 
These results are consistent with the earlier results on the effect of tHMG1 overexpression on 
cubebol production (Chapter 4).  
 
6.3.3 Effect of ERG9 down-regulation on lycopene accumulation 
Repression of ERG9 reduces the carbon flux towards ergosterol and therefore more FPP will be 
available as a precursor for lycopene biosynthesis. In line with our previous results (Asadollahi et 
al., 2008; Chapter 4), squalene synthase down-regulation enhanced lycopene accumulation, but 
when it was combined with tHMG1 overexpression, lycopene production was not further 
improved (Figure 6.1). Down-regulation of squalene synthase resulted in the formation of 
farnesol as an FPP derived by-product in sesquiterpene producing strains presumably as a 
consequence of poor expression of plant sesquiterpene synthase genes and accumulation of FPP 
(Asadollahi et al., 2008; Chapter 4). However, no accumulation of farnesol was observed for the 
YIP-ML-03 and YIP-ML-07 strains suggesting that optimizing codon usage led to diverting all 
the accumulated FPP towards carotenoids.  
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Figure 6.1. Final yields and titers of lycopene for the engineered yeast strains 
 
6.3.4 Phytoene measurement 
The last step in the lycopene biosynthetic pathway is conversion of phytoene, which is a colorless 
carotenoid to lycopene with a strong red color. This step is catalyzed by phytoene desaturase and 
accumulation of phytoene has been reported in the engineered carotenoid producing yeast strains 
(Yamano et al., 1994; Miura et al., 1998b; Verwaal et al., 2007). In order to investigate the 
formation of phytoene as a by-product in the lycopene producing yeast strains, first the peak for 
phytoene was identified for the phytoene producing yeast strains, YIP-0L-05 and YIP-ML-05. 
Phytoene formation for these two strains was confirmed by comparing the UV spectra of the 
phytoene putative peaks with the published UV spectra in the literature (Giuliano et al., 1986). 
The peak for phytoene was observed for both strains, but for the YIP-ML-05 strain an additional 
peak with an UV spectrum similar to that of phytoene was also observed which could be a 
phytoene derivative compound. The phytoene peak was also detected for the lycopene producing 
strains indicating that there is some flux control at the last step in the lycopene biosynthetic 
pathway. However, since we did not have access to commercial standard phytoene it was not 
possible to quantify phytoene level in the strains.  
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6.3.5 Localization of phytoene desaturase  
Phytoene desaturase in the YIP-0L-06 strain was localized by tagging crtI with mRFP1 and 
examining the cells by fluorescence microscopy. YIP-0L-02 was used as a control strain in this 
experiment. Figure 6.2 shows bright field and fluorescence images for both YIP-0L-02 and  
YIP-0L-06 strains. As expected no signal was observed for the YIP-0L-02 strain (Figure 6.2-c), 
whereas a strong signal was observed for the mRFP1 protein in the YIP-0L-06 strain (Figure 6.2-
d). Phytoene desaturase is believed to be a membrane integrated enzyme in natural carotenogenic 
organisms (Fraser et al., 1992). However, it does not seem to be an exclusively membrane 
associated enzyme in the YIP-0L-06 strain as the signal is not restricted to the membrane area.  
 
 
 Figure 6.2. Microscopic images of yeast cells (a & b) Bright field images for the YIP-0L-02 
(control) and YIP-0L-06 strains, respectively; (c & d) Fluorescence images of the YIP-0L-02 
(control) and YIP-0L-06 strains, respectively 
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6.4 Discussion 
The yeast S. cerevisiae was used as a platform for heterologous production of lycopene in this 
study. Expression of the crtE, crtB, and crtI genes allows biosynthesis of lycopene in yeast from 
FPP as precursor. Expression of codon optimized variants of amorphadiene synthase (Martin et 
al., 2003) and carotenogenic genes (Miura et al., 1998b) led to significant improvements in 
amorphadiene and carotenoid biosyntheses, respectively. Therefore the carotenogenic genes from 
E. herbicola were modified based on the optimal codon usage of yeast in the current study. Yeast 
cells transformed with the three crt genes accumulated 0.22 mg lycopene/g DW in a batch 
fermentation. Overproduction of HMG-CoA reductase which catalyzes a highly regulated step in 
the mevalonate pathway, by overexpression of tHMG1 from either genome or a high copy 
number plasmid, increased the production of lycopene by 18% and 130%, respectively. 
Simultaneous overexpression of tHMG1 from both the genome and plasmid did not further 
improve lycopene biosynthesis.  
Earlier reports showed that down-regulation of squalene synthase encoded by ERG9 resulted in a 
lower ergosterol content of yeast cells, increased sesquiterpene production and formation of 
farnesol as an FPP derived by-product (Asadollahi et al., 2008, Chapter 4). Repression of ERG9 
in the YIP-ML-03 strain increased lycopene production by 50% compared to the YIP-0L-03 
strain. However, in line with the previous results (Chapter 4) lycopene production was not further 
improved by combining ERG9 repression and tHMG1 overexpression in the YIP-ML-07 strain.  
Earlier we showed (Asadollahi et al., 2008; Chapter 4) substantially higher sesquiterpene titers 
compared to those obtained for lycopene in the same engineered yeast backgrounds in this study. 
For instance, an ERG9 repressed yeast strain produced 35.3 mg/L total sesquiterpenes and 16.3 
mg/L farnesol (Chapter 4), whereas the YIP-ML-03 strain in this study produced only 2.3 mg/L 
lycopene and did not produce any farnesol suggesting accumulation of other intermediates of the 
pathway. Accumulation of phytoene in the yeast strains engineered for carotenoid production 
(Yamano et al., 1994; Miura et al., 1998b; Verwaal et al., 2007) proposes that there is some flux 
control at the last step where phytoene is desaturated to form lycopene. We were also able to 
detect phytoene accumulation for the lycopene producing strains constructed here. Accumulation 
of phytoene is not due to restricted transcription of crtI as the expression level of crtI was found 
to be equal or even higher than that of other carotenogenic genes in the engineered yeast strains 
(Miura et al., 1998b; Verwaal et al., 2007). Since accumulation of phytoene has not been 
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observed in carotenoid production studies by E. coli the phytoene accumulation does not seem to 
be a consequence of a high Km value of the phytoene desaturase. Conversion of phytoene to 
lycopene is accompanied with the removal of 8 hydrogen atoms from phytoene and formation of 
4 additional conjugated double bonds leading to lycopene. There are contradictory reports on the 
cofactor requirement for this reaction in the literature (Fraser et al., 1992; Sandmann and 
Kowalczyk, 1989; Fraser and Bramley, 1994; Hausmann and Sandmann, 2000). Desaturation of 
phytoene in the daffodil chromoplast was shown to require molecular oxygen as the terminal 
electron acceptor (Beyer et al., 1989). However, the molecular oxygen can be replaced by 
quinones under anaerobic conditions (Mayer et al., 1990). In fact, quinones (plastoquinones in 
higher plants) function as intermediate electron carriers and are converted to hydroquinones 
(plastoquinol in higher plants). Plastoquinol can subsequently be reoxidized via photosynthetic 
electron transport chain or a tissue-specific redox component such as NADPH-dependent 
plastoquinone oxidoreductase in the tissues lacking photosynthetic electron transport chain 
(Norris et al., 1995). Functional expression of plant phytoene desaturase in E. coli (Bartley et al., 
1999), which does not contain plastoquinone but only ubiquinone, implies that ubiquinones can 
take the same electron carrier role as plastoquinone. In prokaryotes the oxidative phosphorylation 
takes place in the inner cell membrane whereas in eukaryotes the protein complexes needed for 
the redox reactions are located in the mitochondria. Hence, it is likely that ubiquinone is more 
available for phytoene desaturase in bacteria than in yeast and this may explain why desaturation 
of phytoene functions more efficiently in bacteria.  
In this study, we expressed the carotenogenic genes from a bacterium in a yeast strain. Therefore 
it is important to make sure that the phytoene desaturase has been localized properly. It was not 
possible to prove that phytoene desaturase is exclusively membrane integrated after examining 
yeast strain harboring crtI tagged with mRFP1 gene under fluorescence microscopy. Lang and 
coworkers (1994) overexpressed crtI from Rhodobacter sphaeroides in E. coli, but they found 
that phytoene desaturase is present in the cytoplasm of E. coli. They argued that this may be due 
to the fact that there is so high expression of phytoene desaturase that targeting to the membrane 
becomes saturated and therefore not all the enzyme becomes membrane associated. As the crtI 
gene used here has a bacterial origin it is possible that it is not targeted properly to the yeast 
membrane.  
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Consistent with our results, expression of carotenogenic genes from E. uredovora in S. cerevisiae 
also led to low levels of lycopene (Yamano et al., 1994). Recently, it was shown that 
transformation of S. cerevisiae with the carotenogenic genes from Xanthophyllomyces 
dendrorhous enables production of considerable amounts of carotenoids in S. cerevisiae but 
expression of the same genes in E. coli resulted in low carotenoid levels (Verwaal et al., 2007). 
Therefore, it seems that for heterologous production of carotenoids in S. cerevisiae it would be 
better to use carotenogenic genes from a yeast species such as X. dendrorhous than from a 
bacterium.  
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Chapter 7 
Conclusions and perspectives 
 
Towards establishment of yeast as a platform for large scale production of sesquiterpenes the 
genes encoding three different sesquiterpene synthases namely valencene synthase, cubebol 
synthase and patchoulol synthase were expressed in S. cerevisiae. Expression of these genes 
resulted in accumulation of target sesquiterpenes in the medium culture. Valencene was the major 
product of valencene synthase but cubebol synthase and patchoulol synthase are multi-product 
enzymes and formed a range of sesquiterpenes with cubebol and patchoulol representing only 
28% and 37% of the total sesquiterpenes, respectively.  
Despite their high boiling points, the partial pressure of sesquiterpenes in the gas phase at low 
concentrations is very high presumably due to very large Henry’s constants law of 
sesquiterpenes. This high partial pressure in the gas phase results in the loss of a significant 
amount of the excreted sesquiterpenes through the off-gas. Therefore the first part of the project 
aimed at developing an analytical platform for the measurement of total sesquiterpenes and 
subsequently characterization and comparison of sesquiterpene producing yeast strains (Chapter 
2). A two-phase fermentation using an organic solvent such as dodecane as the secondary phase 
was shown to be an efficient system for trapping and quantification of total sesquiterpenes. This 
method was therefore used for the characterization of all sesquiterpene producing yeast strains 
throughout the project.   
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Expression of sesquiterpene synthase genes led to accumulation of low amounts of 
sesquiterpenes in a two-phase fermenter. The obtained titers were not sufficient for large scale 
production and therefore the rest of project was dedicated to design and use of metabolic 
engineering strategies to augment the intracellular pool of FPP. In the first attempt (Chapter 3), 
ERG9 expression was attenuated by replacing the native ERG9 promoter with a repressible MET3 
promoter in the presence of methionine. This resulted in reduced ergosterol content of yeast cells, 
increased production of sesquiterpenes and accumulation of farnesol as an FPP derived by-
product. Accumulation of farnesol suggests that the sesquiterpene synthases are unable to divert 
all the available FPP towards the target sesquiterpenes and therefore FPP is converted to farnesol 
probably by the action of general phosphatases in the cell such as lipid phosphate phosphatase 
and diacylglycerol diphosphate phosphatase encoded by LPP1 and DPP1, respectively.  
HMG-CoA reductase catalyzes the main flux controlling step in the mevalonate pathway and 
overproduction of the catalytic domain of this enzyme by overexpression of tHMG1 had a great 
impact on cubebol production. Overexpression of tHMG1 also greatly impacted accumulation of 
squalene from trace amounts in the wild type and control strains to several milligrams per gram 
of biomass for the mutants (Chapter 4). This could be due to higher catalytic efficiency of 
squalene synthase compared to other enzymes at the FPP branch point of the mevalonate pathway 
including sesquiterpene synthases competing for FPP as substrate and therefore most of the FPP 
is converted to squalene. Surprisingly, squalene build up was also observed in the ERG9 down-
regulated strains if cubebol synthase was also expressed. Combination of tHMG1 overexpression 
and ERG9 down-regulation did not further improve cubebol production.  
In silico metabolic engineering using the genome-scale reconstructed metabolic network of S. 
cerevisiae and MOMA approach revealed deletion of NADPH-dependent glutamate 
dehydrogenase encoded by GDH1 as a new target gene for further improvement of sesquiterpene 
biosynthesis in yeast (Chapter 5). Deletion of GDH1 enhanced cubebol titer by 85% but the cells 
had very low specific growth rates probably due to impaired ammonium assimilation. 
Overexpression of NADH-dependent glutamate dehydrogenase encoded by GDH2 restored the 
specific growth rate to some extent.  
The red color of lycopene can be used as a marker for high-throughput screening of lycopene 
overproducer mutants. The lycopene overproducers have most likely enhanced intracellular pools 
of isoprenoid precursors and therefore are probably able to overproduce other isoprenoids as 
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well. Motivated by this idea, in the last step of this project yeast strains capable of lycopene 
accumulation were constructed by expressing of crtE, crtB, and crtI genes from the bacterium E. 
herbicola in yeast (Chapter 6). In line with the results obtained in the previous chapters, both 
down-regulation of ERG9 and overexpression of tHMG1 led to enhanced accumulation of 
lycopene but combination of both modifications did not further improve lycopene biosynthesis. 
However the obtained lycopene titers were significantly lower than the sesquiterpene titers in the 
same background strains. Accumulation of phytoene and also low efficiency of bacterial 
carotenogenic genes in a yeast strain may explain the low lycopene titers.   
One of the best engineered yeast strains in this study produced up to approximately 35.3 mg/L 
total sesquiterpenes, 16.3 mg/L farnesol and nearly 9 mg squalene/g DW. For a viable large scale 
production of sesquiterpene the total sesquiterpene titer should be increased further, and this may 
be accomplished by following some or all of the strategies mentioned below: 
 
• All the characterization studies were carried out in batch fermenters in which the final biomass 
concentration was approximately 6-7 g DW/L. By running a fed-batch fermenter it is possible 
to increase the final biomass by almost 10-fold. This could lead to significantly higher titers of 
sesquiterpenes.  
• A minimal medium was used in all fermentations. Optimization of medium composition can 
improve both specific growth rate and sesquiterpene biosynthesis significantly. 
• Adjustment of methionine concentration in the culture medium of the ERG9 down-regulated 
strains prevents relieved repression of ERG9 during fermentation period and leads to higher 
sesquiterpene production as it was shown for patchoulol (Chapter 3). 
• Accumulation of farnesol in the ERG9 repressed strains may be suppressed by removing the 
phosphatase activities such as the ones encoded by DPP1 and LPP1. 
• Overexpression of ERG20 could also have some enhancing effects on the sesquiterpene 
production. 
• Combination of all the modifications including ERG9 repression, tHMG1 overexpression, 
ERG20 overexpression, DPP1 and LPP1 deletion, GDH1 deletion and GDH2 overexpression 
in a single strain should improve sesquiterpene production. 
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• The sesquiterpene synthase genes used in this study were of a plant origin. Therefore 
optimization of the codon usage of the sesquiterpene synthases for yeast could be another 
strategy to enhance sesquiterpene production. 
• Low catalytic efficiencies of the sesquiterpene synthases was probably one of the reasons for 
farnesol accumulation and squalene build up in the engineered yeast strains. It should be 
possible to improve the catalytic efficiency of these enzymes using protein engineering 
approaches. Although this needs an in-depth knowledge about the protein structure, active site 
and the mechanism of action of the enzyme this could remove one of the major bottlenecks in 
the pathway which is the synthase itself. 
• More detailed experiments are required to gain more insights into the mechanism of squalene 
accumulation in the ERG9 repressed strains in which cubebol synthase is also expressed. 
Understanding the mechanism and removing the cause is of crucial importance as it redirects 
substantial part of the flux from target sesquiterpenes to squalene which may have some 
cytotoxic effects. 
• Heterologous expression of the MEP pathway in S. cerevisiae can be used as an alternative 
strategy to increase the flux towards isoprenoid precursors.  
• High-throughput screening of the lycopene producing yeast mutants eased by the strong color 
of lycopene could be used as a metabolic engineering tool to find the lycopene overproducers 
that are most likely sesquiterpene overproducers as well. Libraries of lycopene overproducer 
yeast strains can be constructed using classical random mutagenesis, deletion libraries, 
transposon libraries etc. The overproducer mutants are then traced back to identify the 
genotypes causing the desired phenotype. This will subsequently lead to new ideas to augment 
intracellular pools of precursors. However, the phytoene accumulation needs to be 
circumvented before this strategy can be applied.  
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Appendix A 
Sequences of natural and codon optimized crtE, crtB, and crtI 
genes from E. herbicola 
 
crtE from E. herbicola 
       1  ATGGTGAGTG GCAGTAAAGC GGGCGTTTCG CCTCATCGCG AAATAGAAGT 
      51  AATGAGACAA TCCATTGACG ATCACCTGGC TGGCCTGTTA CCTGAAACCG 
     101  ACAGCCAGGA TATCGTCAGC CTTGCGATGC GTGAAGGCGT CATGGCACCC 
     151  GGTAAACGGA TCCGTCCGCT GCTGATGCTG CTGGCCGCCC GCGACCTCCG 
     201  CTACCAGGGC AGTATGCCTA CGCTGCTCGA TCTCGCCTGC GCCGTTGAAC 
     251  TGACCCATAC CGCGTCGCTG ATGCTCGACG ACATGCCCTG CATGGACAAC 
     301  GCCGAGCTGC GCCGCGGTCA GCCCACTACC CACAAAAAAT TTGGTGAGAG 
     351  CGTGGCGATC CTTGCCTCCG TTGGGCTGCT CTCTAAAGCC TTTGGTCTGA 
     401  TCGCCGCCAC CGGCGATCTG CCGGGGGAGA GGCGTGCCCA GGCGGTCAAC 
     451  GAGCTCTCTA CCGCCGTGGG CGTGCAGGGC CTGGTACTGG GGCAGTTTCG 
     501  CGATCTTAAC GATGCCGCCC TCGACCGTAC CCCTGACGCT ATCCTCAGCA 
     551  CCAACCACCT CAAGACCGGC ATTCTGTTCA GCGCGATGCT GCAGATCGTC 
     601  GCCATTGCTT CCGCCTCGTC GCCGAGCACG CGAGAGACGC TGCACGCCTT 
     651  CGCCCTCGAC TTCGGCCAGG CGTTTCAACT GCTGGACGAT CTGCGTGACG 
     701  ATCACCCGGA AACCGGTAAA GATCGCAATA AGGACGCGGG AAAATCGACG 
     751  CTGGTCAACC GGCTGGGCGC AGACGCGGCC CGGCAAAAGC TGCGCGAGCA 
     801  TATTGATTCC GCCGACAAAC ACCTCACTTT TGCCTGTCCG CAGGGCGGCG 
     851  CCATCCGACA GTTTATGCAT CTGTGGTTTG GCCATCACCT TGCCGACTGG 
     901  TCACCGGTCA TGAAAATCGC CTGA 
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crtB from E. herbicola 
       1  ATGAGCCAAC CGCCGCTGCT TGACCACGCC ACGCAGACCA TGGCCAACGG 
      51  CTCGAAAAGT TTTGCCACCG CTGCGAAGCT GTTCGACCCG GCCACCCGCC 
     101  GTAGCGTGCT GATGCTCTAC ACCTGGTGCC GCCACTGCGA TGACGTCATT 
     151  GACGACCAGA CCCACGGCTT CGCCAGCGAG GCCGCGGCGG AGGAGGAGGC 
     201  CACCCAGCGC CTGGCCCGGC TGCGCACGCT GACCCTGGCG GCGTTTGAAG 
     251  GGGCCGAGAT GCAGGATCCG GCCTTCGCTG CCTTTCAGGA GGTGGCGCTG 
     301  ACCCACGGTA TTACGCCCCG CATGGCGCTC GATCACCTCG ACGGCTTTGC 
     351  GATGGACGTG GCTCAGACCC GCTATGTCAC CTTTGAGGAT ACGCTGCGCT 
     401  ACTGCTATCA CGTGGCGGGC GTGGTGGGTC TGATGATGGC CAGGGTGATG 
     451  GGCGTGCGGG ATGAGCGGGT GCTGGATCGC GCCTGCGATC TGGGGCTGGC 
     501  CTTCCAGCTG ACGAATATCG CCCGGGATAT TATTGACGAT GCGGCTATTG 
     551  ACCGCTGCTA TCTGCCCGCC GAGTGGCTGC AGGATGCCGG GCTGACCCCG 
     601  GAGAACTATG CCGCGCGGGA GAATCGGGCC GCGCTGGCGC GGGTGGCGGA 
     651  GCGGCTTATT GATGCCGCAG AGCCGTACTA CATCTCCTCC CAGGCCGGGC 
     701  TACACGATCT GCCGCCGCGC TGCGCCTGGG CGATCGCCAC CGCCCGCAGC 
     751  GTCTACCGGG AGATCGGTAT TAAGGTAAAA GCGGCGGGAG GCAGCGCCTG 
     801  GGATCGCCGC CAGCACACCA GCAAAGGTGA AAAAATTGCC ATGCTGATGG 
     851  CGGCACCGGG GCAGGTTATT CGGGCGAAGA CGACGAGGGT GACGCCGCGT 
     901  CCGGCCGGTC TTTGGCAGCG TCCCGTTTAG 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A                                       Sequences of Natural and synthetic crtE, crtB, and crtI genes                                                                                                                    
 151 
crtI from E. herbicola 
       1  ATGAAAAAAA CCGTTGTGAT TGGCGCAGGC TTTGGTGGCC TGGCGCTGGC 
      51  GATTCGCCTG CAGGCGGCAG GGATCCCAAC CGTACTGCTG GAGCAGCGGG 
     101  ACAAGCCCGG CGGTCGGGCC TACGTCTGGC ATGACCAGGG CTTTACCTTT 
     151  GACGCCGGGC CGACGGTGAT CACCGATCCT ACCGCGCTTG AGGCGCTGTT 
     201  CACCCTGGCC GGCAGGCGCA TGGAGGATTA CGTCAGGCTG CTGCCGGTAA 
     251  AACCCTTCTA CCGACTCTGC TGGGAGTCCG GGAAGACCCT CGACTATGCT 
     301  AACGACAGCG CCGAGCTTGA GGCGCAGATT ACCCAGTTCA ACCCCCGCGA 
     351  CGTCGAGGGC TACCGGCGCT TTCTGGCTTA CTCCCAGGCG GTATTCCAGG 
     401  AGGGATATTT GCGCCTCGGC AGCGTGCCGT TCCTCTCTTT TCGCGACATG 
     451  CTGCGCGCCG GGCCGCAGCT GCTTAAGCTC CAGGCGTGGC AGAGCGTCTA 
     501  CCAGTCGGTT TCGCGCTTTA TTGAGGATGA GCATCTGCGG CAGGCCTTCT 
     551  CGTTCCACTC CCTGCTGGTA GGCGGCAACC CCTTCACCAC CTCGTCCATC 
     601  TACACCCTGA TCCACGCCCT TGAGCGGGAG TGGGGGGTCT GGTTCCCTGA 
     651  GGGCGGCACC GGGGCGCTGG TGAACGGCAT GGTGAAGCTG TTTACCGATC 
     701  TGGGCGGGGA GATCGAACTC AACGCCCGGG TCGAAGAGCT GGTGGTGGCC 
     751  GATAACCGCG TAAGCCAGGT CCGGCTGGCG GATGGTCGGA TCTTTGACAC 
     801  CGACGCCGTA GCCTCGAACG CTGACGTGGT GAACACCTAT AAAAAGCTGC 
     851  TCGGCCACCA TCCGGTGGGG CAGAAGCGGG CGGCAGCGCT GGAGCGCAAG 
     901  AGCATGAGCA ACTCGCTGTT TGTGCTCTAC TTCGGCCTGA ACCAGCCTCA 
     951  TTCCCAGCTG GCGCACCATA CCATCTGTTT TGGTCCCCGC TACCGGGAGC 
    1001  TGATCGACGA GATCTTTACC GGCAGCGCGC TGGCGGATGA CTTCTCGCTC 
    1051  TACCTGCACT CGCCCTGCGT GACCGATCCC TCGCTCGCGC CTCCCGGCTG 
    1101  CGCCAGCTTC TACGTGCTGG CCCCGGTGCC GCATCTTGGC AACGCGCCGC 
    1151  TGGACTGGGC GCAGGAGGGG CCGAAGCTGC GCGACCGCAT CTTTGACTAC 
    1201  CTTGAAGAGC GCTATATGCC CGGCCTGCGT AGCCAGCTGG TGACCCAGCG 
    1251  GATCTTTACC CCGGCAGACT TCCACGACAC GCTGGATGCG CATCTGGGAT 
    1301  CGGCCTTCTC CATCGAGCCG CTGCTGACCC AAAGCGCCTG GTTCCGCCCG 
    1351  CACAACCGCG ACAGCGACAT TGCCAACCTC TACCTGGTGG GCGCAGGTAC 
    1401  TCACCCTGGG GCGGGCATTC CTGGCGTAGT GGCCTCGGCG AAAGCCACCG 
    1451  CCAGCCTGAT GATTGAGGAT CTGCAATGA 
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Sequences of synthetic crt genes 
crtE codon optimized 
       1  ATGGTTTCTG GTTCGAAAGC AGGAGTATCA CCTCATAGGG AAATCGAAGT 
      51  CATGAGACAG TCCATTGATG ACCACTTAGC AGGATTGTTG CCAGAAACAG 
     101  ATTCCCAGGA TATCGTTAGC CTTGCTATGA GAGAAGGTGT TATGGCACCT 
     151  GGTAAACGTA TCAGACCTTT GCTGATGTTA CTTGCTGCAA GAGACCTGAG 
     201  ATATCAGGGT TCTATGCCTA CACTACTGGA TCTAGCTTGT GCTGTTGAAC 
     251  TGACACATAC TGCTTCCTTG ATGCTGGATG ACATGCCTTG TATGGACAAT 
     301  GCGGAACTTA GAAGAGGTCA ACCAACAACC CACAAGAAAT TCGGAGAATC 
     351  TGTTGCCATT TTGGCTTCTG TAGGTCTGTT GTCGAAAGCT TTTGGCTTGA 
     401  TTGCTGCAAC TGGTGATCTT CCAGGTGAAA GGAGAGCACA AGCTGTAAAC 
     451  GAGCTATCTA CTGCAGTTGG TGTTCAAGGT CTAGTCTTAG GACAGTTCAG 
     501  AGATTTGAAT GACGCAGCTT TGGACAGAAC TCCTGATGCT ATCCTGTCTA 
     551  CGAACCATCT GAAGACTGGC ATCTTGTTCT CAGCTATGTT GCAAATCGTA 
     601  GCCATTGCTT CTGCTTCTTC ACCATCTACT AGGGAAACGT TACACGCATT 
     651  CGCATTGGAC TTTGGTCAAG CCTTTCAACT GCTAGACGAT TTGAGGGATG 
     701  ATCATCCAGA GACAGGTAAA GACCGTAACA AAGACGCTGG TAAAAGCACT 
     751  CTAGTCAACA GATTGGGTGC TGATGCAGCT AGACAGAAAC TGAGAGAGCA 
     801  CATTGACTCT GCTGACAAAC ACCTGACATT TGCATGTCCA CAAGGAGGTG 
     851  CTATAAGGCA GTTTATGCAC CTATGGTTTG GACACCATCT TGCTGATTGG 
     901  TCTCCAGTGA TGAAGATCGC CTAA 
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crtB codon optimized 
       1  ATGAGTCAAC CACCTTTGTT GGATCATGCT ACTCAAACGA TGGCTAATGG 
      51  TTCCAAGTCC TTTGCTACAG CAGCTAAACT GTTTGACCCA GCTACTAGAA 
     101  GATCAGTGCT TATGCTGTAC ACTTGGTGTA GACACTGTGA TGACGTTATA 
     151  GATGACCAGA CACATGGTTT CGCATCTGAA GCTGCTGCAG AAGAAGAGGC 
     201  TACTCAGAGA TTGGCTAGAT TGAGAACGCT TACACTTGCA GCTTTTGAAG 
     251  GTGCTGAGAT GCAAGATCCT GCTTTTGCTG CATTCCAAGA AGTTGCACTA 
     301  ACACACGGTA TTACGCCAAG AATGGCACTT GATCACTTGG ATGGTTTCGC 
     351  AATGGATGTT GCTCAAACTC GTTACGTGAC CTTTGAAGAC ACCTTGAGAT 
     401  ACTGCTACCA TGTTGCTGGA GTAGTTGGTT TGATGATGGC AAGAGTAATG 
     451  GGTGTAAGAG ACGAAAGGGT TTTGGACAGA GCTTGTGATC TAGGTTTGGC 
     501  TTTTCAGCTG ACAAACATCG CGAGAGATAT TATCGACGAT GCAGCTATTG 
     551  ACAGATGCTA TCTACCTGCT GAATGGTTGC AAGATGCTGG TCTAACTCCT 
     601  GAGAATTACG CTGCAAGAGA GAACAGAGCT GCATTAGCAA GAGTTGCTGA 
     651  AAGGCTGATA GACGCTGCTG AACCCTATTA CATCTCAAGT CAAGCTGGAT 
     701  TGCATGATCT ACCACCTAGA TGTGCTTGGG CTATAGCTAC TGCAAGATCT 
     751  GTCTACAGAG AGATTGGCAT CAAGGTAAAA GCTGCAGGTG GTTCTGCTTG 
     801  GGATAGACGT CAACACACTA GCAAAGGAGA GAAGATTGCG ATGCTTATGG 
     851  CTGCACCAGG ACAAGTCATT CGTGCCAAAA CAACCAGAGT TACACCAAGA 
     901  CCTGCTGGTT TATGGCAAAG ACCTGTCTAA 
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crtI codon optimized 
 
       1  ATGAAGAAAA CCGTAGTGAT TGGTGCAGGT TTTGGTGGTT TAGCTTTGGC 
      51  TATACGTCTA CAAGCTGCAG GTATTCCTAC AGTGCTATTG GAGCAAAGAG 
     101  ACAAACCAGG AGGAAGAGCT TATGTTTGGC ACGATCAAGG CTTTACCTTT 
     151  GATGCTGGTC CTACAGTCAT CACTGATCCT ACTGCATTGG AAGCTTTGTT 
     201  CACCTTAGCT GGTAGAAGAA TGGAAGATTA TGTCCGTCTA TTGCCTGTCA 
     251  AGCCGTTTTA CAGATTGTGT TGGGAATCTG GTAAAACCCT AGATTACGCC 
     301  AATGACAGTG CTGAACTAGA AGCTCAGATT ACGCAGTTTA ATCCCAGAGA 
     351  TGTCGAAGGT TACAGGAGAT TCCTTGCCTA TTCCCAAGCT GTTTTCCAAG 
     401  AGGGTTATCT TCGTTTGGGT TCAGTTCCAT TCCTGTCCTT TAGGGATATG 
     451  CTTAGAGCAG GTCCTCAGTT GTTGAAGCTA CAAGCATGGC AAAGTGTGTA 
     501  TCAGTCTGTT TCGAGATTTA TCGAGGATGA ACATCTGAGA CAAGCATTCT 
     551  CATTCCACAG TCTTCTAGTT GGAGGTAATC CCTTTACCAC ATCGAGCATA 
     601  TATACGTTGA TTCACGCTTT GGAAAGAGAA TGGGGAGTTT GGTTTCCTGA 
     651  AGGTGGAACA GGTGCTTTGG TTAATGGTAT GGTGAAGCTA TTCACGGATT 
     701  TGGGTGGAGA AATAGAGCTG AATGCAAGAG TGGAAGAACT TGTTGTAGCA 
     751  GACAACAGAG TCTCACAAGT TAGACTTGCT GATGGTAGGA TCTTCGATAC 
     801  AGATGCTGTA GCTTCAAACG CAGATGTAGT GAACACTTAT AAAAAGTTGT 
     851  TGGGACATCA TCCTGTTGGA CAAAAGAGAG CAGCTGCTTT GGAGAGGAAA 
     901  TCTATGAGCA ACTCGTTGTT TGTCCTTTAC TTTGGGCTGA ATCAACCACA 
     951  CTCACAACTA GCTCATCACA CAATCTGCTT TGGTCCTAGA TACAGAGAGC 
    1001  TGATAGATGA AATTTTCACT GGATCTGCTT TAGCAGACGA TTTTTCCCTG 
    1051  TACTTGCATT CACCATGTGT TACTGATCCC TCTTTAGCAC CACCTGGTTG 
    1101  TGCTAGCTTC TATGTACTAG CACCTGTACC ACATTTGGGT AATGCTCCAT 
    1151  TAGATTGGGC ACAAGAAGGA CCGAAATTGA GGGATAGGAT CTTCGACTAT 
    1201  TTGGAAGAAC GTTACATGCC AGGTTTGAGA TCTCAGTTGG TTACACAGAG 
    1251  GATATTCACA CCAGCTGATT TTCATGATAC TCTAGATGCG CATTTAGGTA 
    1301  GCGCTTTTTC CATTGAGCCA CTTTTGACGC AAAGTGCTTG GTTTAGACCA 
    1351  CACAACAGAG ATTCTGACAT TGCCAATCTG TACCTAGTAG GTGCAGGAAC 
    1401  TCATCCAGGA GCTGGTATTC CTGGAGTTGT AGCTTCTGCT AAAGCTACTG 
    1451  CTAGTCTGAT GATCGAGGAT TTGCAGTAA 
